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ABSTRACT 
 
The role of ACTH in stimulating or inhibiting growth of adrenal cells has been a 
subject of some controversy. Reports that ACTH may stimulate Erk/MAP kinase in 
Y1 cells have suggested a role for cAMP in this process. In attempting to extend 
this work the ACTH responses in the human H295R cell line have been studied. 
This cell line makes only a very modest cAMP response to ACTH, yet the Erk1/2 
response is highly reproducible and immediate, but not prolonged. It is minimally 
reduced by the protein kinase A inhibitor, H89, but unaffected by PKC and calcium 
inhibitors. Inhibition of EGF receptor or other tyrosine kinase receptor 
transactivation was without effect, as was inhibition of c-Src activity or c-Src 
phosphorylation. The most effective inhibitor of this pathway was dansylcadaverine, 
an inhibitor of receptor internalisation. These findings imply that ACTH-induced 
Erk1/2 activation in H295R cells is dependent on a mechanism distinct from that by 
which most G protein-coupled receptors activate Erk1/2, but which nevertheless 
seems to depend on receptor internalisation. 
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1   INTRODUCTION 
1.1  PRO-OPIOMELANOCORTIN (POMC) 
 
The POMC gene encodes a 32 kDa propeptide molecule that is extensively post-
translationally modified to produce a number of bioactive hormones (Fig. 1.1). The 
major site of expression of POMC is in the corticotroph cells of the anterior 
pituitary however POMC mRNA has been detected in extra-pituitary sites such as 
neurons of the hypothalamic arcuate nucleus as well as in some peripheral tissues. 
Many of the roles of POMC peptides in the brain have been elucidated, however 
their involvement in peripheral tissues is less clear since an alternative, shorter 
transcript is expressed which does not contain the signal sequence required for 
targeting of the peptide to the endoplasmic reticulum and its subsequent processing 
(DeBold et al., 1988). The processing of POMC occurs by proteolytic cleavage in 
secretory granules by a family of serine proteases, the pro-hormone convertases, 
which cleave specifically at dibasic amino acid residues (Cool et al., 1997). 
Processing depends on the tissue specific expression of the prohormone convertase 
enzymes thus yielding different active peptides in different tissues.  
 
In the anterior pituitary, POMC is cleaved by pro-hormone convertase 1 into pro-
adrenocorticotrophic hormone (pro-ACTH) and β-lipotrophin (β-LPH (Fig. 1.1) 
Pro-ACTH is then further cleaved to yield N-pro-opiocortin (N-POC), joining 
peptide (JP) and the 4.5 kDa hormone ACTH (White and Gibson, 1998). ACTH is 
the largest circulating POMC product and its primary role in steroidogenesis is well 
understood  (Haynes, 1958). The role of N-POC is less clear, however it is thought 
to potentiate ACTH-induced steroidogenesis in human and rat adrenocortical cells 
and may have a role in adrenal growth which is discussed in section 1.6.5 (Bicknell 
et al., 2001).  
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Fig. 1.1 Post-translational processing of the POMC peptide. ACTH (adrenocorticotrophic hormone), 
LPH (lipotrophic hormone), N-POC (N-pro-opiocortin), JP (joining peptide),EP (endorphin), CLIP 
(corticotrophin-like intermediary peptide), MSH (melanocyte stimulating hormone), M-EK (met-
enkephalin).  
In extra-pituitary sites however such as the neurons of the hypothalamus, 
expression of pro-hormone convertase 2 results in further processing of ACTH to 
α-melanocyte stimulating hormone (α-MSH) which has a key role in appetite 
control and energy homeostasis (Pritchard et al., 2002). Further processing of N-
POC yields γ-MSH, a hormone thought to have effects on centrally mediated 
cardiovascular control (Li et al., 1996). Other melanocortin peptides in the 
periphery have diverse biological functions such as the control of skin pigmentation 
(Abdel-Malek et al., 1999) and the stimulation of adipocyte lipolysis (Boston, 1999). 
PC1 C1P
PC2
1 13 18 39
PC1
PC2 PC2
1 39
2091
Pro- opiomelanocortin (POMC)
Pro- ACTH β-LPH
N-POC JP ACTH
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β-MSH M-EK
 13 
1.2  THE HYPOTHALMIC-PITUITARY (HPA) AXIS 
 
ACTH, a 39 amino acid peptide was discovered in the 1950’s to be a factor secreted 
from the pituitary gland that was able to regulate steroidogenesis in the adrenal 
gland (Li et al., 1954). ACTH is secreted from the anterior pituitary in an episodic 
manner, with a distinct circadian rhythm. In addition to this it is secreted in 
response to stress.  Its plasma levels peak between 6 and 9 am and fall during the 
day to reach a low point in the evening.   
 
 
 
Fig. 1.2 - The hypothalamic-pituitary-adrenal (HPA) axis. Stress and circadian rhythm induce the 
secretion of CRH from the hypothalamus. CRH then stimulates the secretion of ACTH from corticotroph cells in 
the anterior pituitary and this circulates in the blood. ACTH subsequently stimulates cortisol production and release 
form the adrenal cortex. An inhibitory feedback mechanism exists where cortiosl prevents the release of CRH and 
ACTH. ACTH also negatively regulates its own synthesis in corticotroph cells. 
 
ACTH secretion is stimulated by the release of corticotrophic releasing hormone 
(CRH) from the paraventricular nucleus of the hypothalamus, as well as by arginine 
vasopressin and certain neurotransmitters (Vinson et al., 1992). CRH also acts to 
increase the expression of POMC by stimulating cAMP accumulation through its 
receptor and consequently serine phosphorylation of the cAMP response element 
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binding protein (CREB) transcription factor. ACTH circulates in the blood and acts 
on the adrenal gland through the ACTH receptor, to regulate the synthesis and 
secretion of steroids.  This pathway is referred to as the HPA axis and is under tight 
regulation by a negative feedback loop whereby cortisol inhibits the release of CRH 
from the hypothalamus and also negatively feeds back to the pituitary to prevent 
ACTH release.  
 
1.3  THE ADRENAL GLAND AND STEROIDOGENESIS 
 
The adrenal gland consists of two regions formed from distinct embryological 
origins both of which are involved in coordinating the stress response. The inner 
medulla region is derived from the neural crest, a sympathetic ganglion modified to 
secrete its neurotransmitter, primarily adrenaline into the blood. The adrenal cortex 
develops from the mesoepithelium of the abdominal cavity and during 
embryogenesis, envelops the medulla to form the adrenal gland. The adrenal cortex 
responds to a number of circulating peptides to produce glucocorticoids, androgens 
and mineralocorticoids. 
 
The adrenal cortex itself comprises three histologically distinct functional zones, 
which alternately express various enzyme systems enabling the production of 
different steroids. The outer most zone, the zona glomerulosa (ZG), secretes the 
mineralocorticoid aldosterone which acts to stimulate sodium (and thus water) 
reabsorption in the renal distal tubule in times of hypovolemia and hyponatremia. 
Bordering this zone is the zona fasciculata (ZF) which secretes glucocorticoids such 
as cortisol in response to ACTH. Cortisol functions at times of stress to provide 
substrates for energy production (Wajchenberg et al., 1984). It achieves this in a 
number of ways. Firstly, by inhibiting protein synthesis and at high concentrations 
stimulating protein degradation, thus providing amino acid precursors for glucose 
production. Secondly, it promotes lipolysis thus providing glycerol for 
gluconeogenesis (White and Engel, 1958, Ramachandran and Lee, 1976). Thirdly, 
enzymes critical in reversing glycolysis are upregulated through the action of 
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cortisol on the glucocorticoid receptor (Lucas and Granner, 1992). 
Glucocorticoids are also potent anti-inflammatory agents (Getting, 2002). 
Bordering the ZF is the zona reticularis (ZR) which secretes adrenal androgens. 
These act as pre-cursors which are later released into the circulation and produce 
the sex steroids. Fig. 1.3 depicts the steroidogenic pathways present in the different 
zones of the adrenal cortex where the expression of the enzymes CYP11B1, 
CYP11B2 and 17, 20 lyase are important in determining the types of steroid 
produced (Keegan and Hammer, 2002). 
 
 
 
 
Fig. 1.3 Steroidogenesis in the adrenal cortex (Adapted from Keegan CE, 2002, Trends In 
Endo and Metabolism). DHEA (dehhydroepiandrosterone), DOCS (deoxycorticosterone), HCS 
(hydroxycorticosterone), CS(corticosterone), DOC (deoxycortisol). 
 
1.4 ACTH AND THE ACTH RECEPTOR 
 
ACTH mediates its steroidogenic response through binding to the ACTH receptor 
otherwise known as the Melanocortin 2 receptor (MC2R), which is expressed 
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mainly in the ZF of the adrenal cortex. Early studies looking at the effects of 
ACTH on the adrenal cortex in terms of increasing phosphorylase activity (now 
known as protein kinase A or PKA), found this effect to be mediated through 
cAMP, similar to the stimulation of hepatic phosphorylase by epinephrine (Haynes, 
1958). Later experiments demonstrated specific binding of radiolabelled ACTH 
(I125-ACTH) in adrenal cortex extracts that contained adenylate cyclase (Lefkowitz 
et al., 1970). However it wasn’t until 1992 that the ACTH receptor was isolated. 
The human ACTH receptor was first cloned in parallel with another melanocortin 
receptor, the MC1R. cDNA derived from a human melanoma specimen that was 
known to contain a high number of MSH binding sites, was used in a PCR with 
degenerate primers for conserved transmembrane domains of G-protein coupled 
receptors (GPCRs are discussed in further detail in section 1.5) (Mountjoy et al., 
1992).  The two resultant PCR subclones were found to be expressed in 
melanocytes and the adrenal cortex, the second of which was probably the result of 
genomic DNA contamination of the melanoma specimen. These receptors were 
subsequently named the MC1R and MC2R respectively. In addition to these 
receptors, three further melanocortin receptors have been cloned and named the 
MC3, 4 and 5 receptors (Gantz et al., 1993b, Gantz et al., 1993a, Gantz et al., 1994). 
 
The MC2R is the smallest of all the GPCRs and consists of 297 amino acid residues 
in the mature human protein. In its unmodified state the MC2R is predicted to be 
33 kDa in size, however it has two N-linked glycosylation sites in the N-terminal 
domain and is expressed at the cell surface as a 43 kDa glycoprotein (Hofmann et 
al., 1988). Functional characterisation of the MC2R protein was initially difficult 
because unlike the MC1R which could be readily and functionally expressed in 293 
cells, the MC2R could only be expressed in cells expressing other melanocortin 
receptors (Mountjoy et al., 1992). Recent studies in our laboratory have confirmed 
the requirement of a factor named MRAP that enables functional expression of the 
MC2R in non adrenal cells (Metherell et al., 2005). However, this problem 
complicated earlier binding studies because of the presence of other melanocortin 
receptors capable of binding ACTH. It was later demonstrated that the murine Y1 
cell line (Yasumura et al., 1966) expressed a high affinity ACTH-receptor , with an 
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IC50 of 0.13nM  (see table 1.1) which did not bind to MSH peptides (Schioth et al., 
1996). MSH binding could be restored on expression of the MC1, 3 and 4 receptors 
in these cells. These studies were important in recognising the MC2R as the ACTH 
receptor and the high affinity and ACTH exclusive properties of this receptor were 
consistent with the very specific role of ACTH in regulating steroidogenesis.  
 
1.4.1  The Melanocortin receptors 
 
The melanocortin receptors have affinities for various members of the POMC 
peptides. MC1, 3, 4 and 5 receptors for example bind with the highest affinity to α-
MSH but also with a much lower affinity to ACTH. Conversely, the MC2R binds 
solely, with very high affinity to ACTH (Schioth et al., 1996). Table 1.1 shows the 
affinity of naturally occurring POMC peptides to the melanocortin receptors. 
 
LIGAND RECEPTOR 
 MC1R MC2R MC3R MC4R MC5R 
ACTH (1-39) 3.95 0.13 135 2,170 4,920 
α-MSH 0.12 - 31 660 5,700 
β-MSH 1.2 - 13 380 14,000 
γ-MSH 2.7 - 7.1 29,000 43,000 
TRH 6,400 - - - - 
 
Table 1.1 Melanocortin receptor binding characteristics. Ki values (nm) of natural POMC 
peptides for human melanocortin receptors obtained for ACTH, in competition with I125ACTH and for 
the remainder, in competition with I125NDP-MSH (Schioth et al., 1997, Schioth et al., 1996, Wikberg 
et al., 2000). 
 
The melanocortn receptors are distributed across a large number of different 
tissues. This is in accordance with the wide ranging effects of the melanocortins 
themselves. The MC1R and MC2R are expressed primarily in melanocytes and the 
adrenal gland respectively however, the other melanocortin receptors are more 
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widely distributed where they are expressed in both central and peripheral tissues. 
Table 1.2 summarises the expression pattern of the melanocortin receptors along 
with their reported functions. 
 
RECEPTOR TISSUE EXPRESSION PRIMARY FUNCTION 
MC1R Melanocytes, melanoma, 
macrophages, adipose tissue 
Pigmentation, inflammation 
MC2R Adrenal, adipose tissue, fetal testis, 
pituitary 
Steroidogenesis 
MC3R Brain, placenta, duodenum, pancreas, 
stomach 
Energy homeostasis 
MC4R Brain, spinal cord, muscle, 
sympathetic nervous system 
Energy homeostasis, erectile 
function 
MC5R Brain, skin, adrenal, spleen, thymus, 
testis, ovary, muscle, adipose tissue 
Sebaceous gland secretion 
 
Table 1.2  Properties of the melanocortin receptors (Mountjoy and Wong, 1997, Gantz and Fong, 
2003).  
 
1.4.2  MC2R gene structure and expression 
 
The coding sequence for the human MC2R is contained within a single exon. 
However, the mature mRNA is composed of multiple exons, which are spliced 
together to form the 5’ untranslated region (5’UTR), upstream of the coding 
sequence (Fig. 1.4). The majority of human transcripts contain a single upstream 
exon however in some mRNA species, an alternatively spliced second exon is also 
present (Kubo et al., 2000). The primary site of expression of the MC2R is in the 
adrenal cortex as demonstrated by northern blot and in situ hybridisation 
(Mountjoy et al., 1992). This finding was consistent with the highly conserved role 
of ACTH in adrenal steroidogenesis. ACTH may also play a role in the maintenance 
of growth of the adrenal cortex however this will be discussed in greater detail in 
section 1.6. MC2R mRNA has also been detected in an increasing number of extra-
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adrenal sites. These included the detection of mRNA in sympathetic ganglia, where 
it is upregulated by stress (Nankova et al., 2003) subcutaneous human adipocytes 
have been shown to express MC2R mRNA (Smith et al., 2003). MC2R mRNA has 
also been reported in human skin however it was not clear from which cell type the 
mRNA originated (Slominski et al., 1996). MC2R mRNA was detected in the 
pituitary gland where it may function as part of a short negative feedback loop, 
regulating ACTH secretion from corticotroph cells (Morris et al., 2003).  
 
 
 
 
 
 
 
 
 
Fig. 1.4  Genomic organisation of the human MC2R. Exons are drawn as boxes. Exons 1 
and 2 are constitutively expressed whereas exon 2 is alternatively spliced The sizes of the exons are 
indicated in addition to the approximate length of the intronic sequences. CDS indicates the coding 
sequence. 
 
Much research has also been undertaken in murine cells where significant amounts 
of mRNA have been detected in the murine adipocyte where it may play a 
developmental role (Boston and Cone, 1996). Furthermore, more recently murine 
leydig cells were found to express the MC2R and respond to ACTH stimulation by 
secretion of androgens, a response that is absent in adult testes (O'Shaughnessy et 
al., 2003).   
5’UTR
I
ATG
IIIII
49bp 157bp
6kb 12kb
CDS
3’UTR
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1.5  G-PROTEIN COUPLED RECEPTORS (GPCRS) 
1.5.1  Structure 
 
Bacteriorhodopsin (BR) was the first GPCR to be structurally characterised using 
X-ray crystallography (Muller, 2000) however the elucidation of the structure of 
other GPCRs by this technique has been problematic since GPCRs are difficult to 
purify and dissolve. For this reason, structural modelling of most other GPCRs has 
been based on homology with this receptor. GPCRs are a large and diverse family 
of receptors which have a unique structural conformation within the phospholipid 
bilayer. The peptide chain contains seven regions of alpha-helical transmembrane 
domains rich in hydrophobic residues which allows the receptor to span the 
membrane seven times. All GPCRs have an extracellular amino (N)-terminal 
domain and an intracellular carboxy (C)-terminal domain, in addition to three 
hydrophilic extracellular and intracellular loops. The MC2R belongs to this diverse 
family of receptors and is depicted in fig. 1.5. 
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Fig. 1.5  The human ACTH receptor. The human MC2R is thought to structurally resemble 
that of the GPCR rhodopsin. It comprises an extracellular N-terminal domain, an intracellular C-
terminal tail, three intracellular and three extracellular loops and seven hydrophic transmembrane spanning 
regions.  
 
1.5.2  Signalling 
 
GPCRs are so called because they interact with GTP-binding proteins (G-proteins) 
following agonist stimulation, and this results in the activation or inactivation of an 
enzyme to mediate a signalling response. GPCRs have very conserved signalling 
mechanisms. The signalling pathway that follows the binding of an agonist to a 
GPCR depends on the G-protein with which the receptor interacts. In their inactive 
state G-proteins consist of a heterotrimeric complex made up of α, β and γ 
subunits where the α subunit interacts at the cell membrane with the GPCR and is 
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bound to a GDP molecule. Following agonist binding to the GPCR, a 
conformational change occurs which allows a GDP/GTP exchange on the α 
sunbunit which consequently causes the α subunit to dissociate from the βγ 
subunits. The α subunit, along with the still tightly bound βγ subunits, are then free 
to bind to an effector molecule and induce a cellular response (Fig. 1.6).  
 
Fig 1.6 Agonist stimulation of GPCRs. GPCRs in their inactive state remain bound to the 
heterotrimeric G protein complex consisting of α, β and γ subunits. Binding of the agonist to the GPCR 
causes a conformational change that leads to GDP/GTP exchange on the α subunit. This causes 
dissociation of α and βγ subunits which instigate cell signalling cascades. 
 
There are three major G-protein families which have different second messenger 
actions, these are Gs, Gi/o and Gq/12. Additional specificity is conferred by the 
expression of multiple genes encoding both Gα and βγ subunits (Watson and 
Arkinstall, 1994). α subunits from Gs proteins bind to and activate the enzyme 
adenylate cyclase which catalyzes the synthesis of cyclic adenosine monophosphate 
(cAMP) from ATP. cAMP accumulates in the cell and activates various intracellular 
targets including PKA with a subsequent cascade of events involving cellular targets 
of PKA. It is through the activation of this pathway that ACTH regulates the 
synthesis and release of steroids. This classical signalling pathway is depicted in 
Fig.1.7.  
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Fig. 1.7 Classical Gs coupled signalling pathway. ACTH binding to the MC2R results in 
Gαs mediated activation of the adenylate cyclase (AC) enzyme which catalyses the production of cAMP 
from ATP which accumulates and activates PKA. PKA, in its active state, phosphoylates its cellular 
targets which ultimately result in steroidogenesis. 
Conversely, coupling of a receptor to a Gi protein results in the inactivation of 
adenylate cyclase and therefore has opposing effects within the cell to that of Gs 
signalling. Gq proteins couple to a different enzyme, phospholipase C (PLC). As a 
consequence of PLC activation there is increased production of inositol phosphate 
3 (IP3) which acts on IP3 receptors on the endoplasmic reticulum (ER). Following 
this, Ca2+ is released from the ER leading to an increase in cytosolic Ca2+ 
concentration and the subsequent activation of protein kinase C (PKC) leading to a 
further cascade of events and a cellular effect. The PKC pathway is utilised in many 
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biological systems including endocrine systems such as the synthesis and release of 
gonadotrophins in the reproductive system (Ando et al., 2001).  
Although GPCR signalling mechanisms are highly conserved, the specificity of the 
response is conferred by alternative gene expression in different cell types which 
then act as targets for the effector molecules (PKA and PKC) in these signalling 
pathways. 
 
1.5.3 Targets of cAMP and PKA in adrenocortical cells 
 
The cellular responses to ACTH in an adrenocortical cell are numerous and act at 
both the transcriptional and post-translational level to increase the steroidogenic 
capacity of the cell. One effect of PKA is the activation of CREB. CREB is a 
transcription factor which, when activated, can positively regulate the expression of 
genes containing a cAMP response element (CRE) in the promoter of the gene. In 
addition to later effects brought on by transcriptional activation, PKA also exerts 
more immediate effects through the phosphorylation of other cellular targets. One 
such target is cholesterol ester hydroxylase. This enzyme converts cholesterol esters 
to free cholesterol and therefore increases the availability of the steroid hormone 
substrate (Liscum and Dahl, 1992). The rate-limiting step in the production of all 
steroid hormones is the conversion of cholesterol to pregnenolone, which is 
catalysed by CYP11A1 (cytochrome P450 11A1) in the inner mitochondrial 
membrane. For this reaction to take place, cholesterol must be mobilised from 
intracellular stores and translocated across the mitochondrial membrane by 
steroidogenic acute regulatory protein (StAR). StAR is rapidly upregulated following 
ACTH induced cAMP/PKA signalling thus allowing this process to take place 
(Clark and Combs, 1999). The ACTH induced activation of this second messenger 
signalling pathway also contributes to the upregulation of all steroidogenic CYP 
enzymes which are involved in converting pregnenolone to steroid hormones (John 
et al., 1986). A further level of regulation is in the upregulation of MC2R expression 
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levels which increases the sensitivity of cells to ACTH and thus steroidogenic 
capacity (Penhoat et al., 1989b). 
 
Many of the effects seen in reponse to ACTH are the result of the an increase in 
expression of a transcription factor known as steroidogenic factor 1 (SF1) which 
binds to the promoter regions of many of the steroidogenic CYP genes (Morohashi 
et al., 1992, Clark and Combs, 1999, Naville et al., 1999). However, it is still unclear 
as to what mechanism SF1 is activated although it is thought to be PKA dependent 
and may also involve activation by the mitogen activated protein kinase (MAPK) 
family (Gyles et al., 2001). 
 
1.5.4 Modifying agonist/receptor responses 
 
In every signalling cascade, feedback mechanisms exist whereby in some way a 
response is dampened following continued stimulation of a pathway and 
conversely, a response is amplified in situations where the pathway is under active. 
These mechanisms allows for tight regulation of signalling pathways so that 
appropriate responses are mounted. For GPCRs, these processes include those that 
allow a rapid modification in the magnitude of a response by altering the ability of 
the receptor to signal during continued agonist stimulation, termed 
“desensitisation”; modifying the number of receptors at the cell surface by vesicular 
uptake mechanisms, termed “internalisation”; as well as longer-term mechanisms of 
receptor regulation which may involve receptor degradation or the down-regulation 
of receptor gene expression. Long term regulation of receptor number is illustrated 
in the ACTH-MC2R system, ACTH was shown to positively regulate MC2R cell 
surface expression following ACTH treatment for up to 48 hours of bovine 
fasciculata cells (Penhoat et al., 1989a, Lebrethon et al., 1994, Mountjoy et al., 
1994). 
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1.5.5 Desensitisation 
 
The most common mechanisms of desensitisation of GPCR signalling pathways are 
post-translational modifications to the receptor. Phosphorylation by intracellular 
kinases such as PKA or GRK results in the attenuation of receptor G protein 
coupling which dampens the signalling response. However, additional mechanisms 
exist whereby regulation of the coupling to G proteins is affected which has the 
same result in that the receptor is densenstised. An example of this is in the 
interaction of the regulators of G protein signalling (RGS) family members which 
alter the rate of GTP hydrolysis on G proteins and therefore modulates the 
signalling to effector enzymes (De Vries et al., 2000, Ross and Wilkie, 2000).  
 
1.5.5.1  Second-messenger protein kinase regulation 
 
Second-messenger protein kinases such as PKA and PKC phosphorylate receptors 
on serine and threonine residues within specific amino acid consensus sites. This 
leads to the desensitisation of the response in a classical negative feedback 
mechanism due to the altering of the receptors affinity for its ligand. This method 
of desensitisation is termed heterologous because the activation of one receptor can 
result in the non-specific phosphorylation of agoinst occupied and unoccupied 
receptors of different types (Hausdorff et al., 1989, Lohse et al., 1990).  
 
In addition to altering the receptors affinity for its ligand, PKA mediated 
phosphorylation has also been shown to mediate desenstisation of the cAMP 
response by altering the β2 AR receptors affinity for Gs and cause a switch in 
coupling to Gi. This causes inactivation of adenylate cyclase allowing a more rapid 
dampening of the response (Daaka et al., 1997).  
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1.5.5.2  GRK-mediated regulation 
 
The GRKs are a family of receptor kinases composed of seven members which 
share significant sequence homology and functional organisation. Each have a 
central catalytic domain, an amino terminal domain (which also contains an RGS-
like domain) and a c-terminal domain that allows plasma membrane targeting. 
GRK1 and 7 are specifically expressed in the retina and are farnesylated on their c-
terminal domains; GRK2 and 3 share added similarity in their c-terminus each 
containing a βγ-subunit binding domain with homology to PH domains (Pitcher et 
al., 1992); GRK5 has a c-terminal region thought to mediate plasma membrane 
interactions (Kunapuli et al., 1994, Kunapuli and Benovic, 1993); GRK4 and 6 are 
palmitoylated at cysteine residues which is also thought to allow their localization at 
the plasma membrane (Stoffel et al., 1994, Stoffel et al., 1998).  
 
The GRKs mediate homologous desensitisation whereby agonist-occupied 
receptors are phosphorylated leading to desensitisation of only activated receptors 
(Krupnick and Benovic, 1998). GRK mediated desensitisation also commonly 
involves receptor interaction with arrestins. Phosphorylation of the receptor by a 
GRK increases the affinity of β-arrestin for the receptor by 10-30 fold (Pippig et al., 
1993). This results in the steric hinderance of GPCR/G-protein coupling and the 
subsequent uncoupling of the receptor from the G-protein (Benovic et al., 1987, 
Ferguson et al., 1996b).  
 
1.5.5.3  Arrestin mediated regulation 
 
The Arrestins comprise a family of four proteins, two of which are expressed 
exclusively in the retina (arrestin 1 and 4) and two that are ubiquitously expressed 
and are termed β-arrestin 1 and 2 (or arrestin 2 and 3) (Krupnick and Benovic, 
1998). ß-arrestins are thought to regulate most of the GPCRs (Attramadal et al., 
1992). Their localisation, established using green flourescent protein (GFP) tagged 
ß-arrestins, is cytosolic in the resting state with translocation to the cell membrane 
on agonist stimulation (Zhang et al., 1999). The binding of ß-arrestins to 
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phosphorylated receptors sterically hinders receptor, G-protein coupling and 
prevents further GTP/GDP exchange in the presence of continued agonist 
exposure. ß-arrestin further acts to modulate a cAMP response by recruiting 
phosphodieterases to the membrane which accelerate the degradation of cAMP 
(Perry et al., 2002).   
 
Although desensitisation by second-messenger protein kinases and GRKs were 
originally thought to be by distinct mechanisms, recent evidence has suggested 
some overlap between these two pathways. GPCRs have been shown to 
spontaneously move to an activated conformation in the absence of agonist 
suggesting that GRK can act in agonist unoccupied or constitutive states (Pei et al., 
1994, Rim and Oprian, 1995). In addition, inhibition of either PKA or GRK results 
in the complete abolition of olfactory receptor desensitisation suggesting interplay 
between these two kinases (Schleicher et al., 1993). This is supported by a report 
demonstrating that PKA and PKC can phosphorylate and activate GRK2 by 
promoting its βγ mediated membrane association (Winstel et al., 1996, Cong et al., 
2001).  
1.5.6 Internalisation of GPCRs 
 
Internalisation or endocytosis of GPCRs is a further mechanism of regulation of 
receptor signalling. The first evidence of this process was the observation that β-AR 
was lost from the surface of frog erythrocytes with a corresponding increase in 
cytosolic binding sites following continued agonist stimulation (Chuang and Costa, 
1979). This was supported by a study demonstrating β2-AR sites in different 
fractions of a sucrose gradient (Harden et al., 1980). Since then numerous studies 
have shown the internalisation of a variety of GPCRs visualized using green 
fluorescent  protein (GFP) tagged receptors transfected into cells (Barak et al., 
1997, Hudson et al., 2006).  
 
Several mechanisms of internalisation have been elucidated which include, 
internalisation by clathrin-coated pits (Trowbridge et al., 1993), caveolae  
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(Anderson, 1993), ubiquitin dependent processes (Katzmann et al., 2002) and non-
coated vesicles (Montesano et al., 1982). By far the most common and best 
characterised mechanism of internalisation is clathrin-mediated endocytosis. 
 
1.5.6.1  Clathrin mediated endocytosis 
 
Clathrin is a fibrous protein which forms triskelions that polymerize to form a 
polygonal lattice structure with an intrinsic curvature. These so-called clathrin 
coated pits are assembled by adapter proteins (AP) which have also been shown to 
bind to membrane proteins to determine which proteins are specifically included 
within the vesicle (Lodish, 1999). Continued polymerization causes an invagination 
within the membrane which is then pinched off by the GTPase dynamin thus 
forming a vesicle and internalising all the components within the region (Damke et 
al., 1994). This mechanism was first identified for the LDL Receptor (Anderson et 
al., 1977) however many other GPCRs have also been shown to internalise via 
clathrin-coated vesicles.  
 
GRKs and ß-arrestins, in addition to desensitising receptors, also regulate the 
endocytic process by allowing the recruitment of the GPCR to clathrin coated 
vesicles through direct binding to proteins involved in the process (Shiina et al., 
2001). GRK was also shown to bind phosphatidyl-inositol 3 kinase (PI3-K) and 
recruit it to the cell membrane in an agonist dependent manner where it contributed 
to receptor internalisation (Naga Prasad et al., 2001). A small GTP binding protein 
family, ADP ribosylation factor (ARF) is a well-known mediator of vesicular 
trafficking and receptor internalisation. This proteins GTPase activity is accelerated 
by the GTPase activating protein (GAP) activity of GRK interactor (GIT) protein 
which, as its name suggest has been demonstrated to interact with GRK (Premont 
et al., 2000, Premont et al., 1998). The link between receptor internalisation and 
ARF were demonstrated by the overexpression of GIT 1 and 2 which reduced 
receptor endocytosis (Claing et al., 2000). 
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β-arrestins also serve as adapters to link the receptor to the endocytic machinery 
(Goodman et al., 1996). Interaction with phosphorylated receptors causes a 
conformational change in ß-arrestin which exposes a clathrin binding region 
(Krupnick et al., 1997) and an AP2 binding region (Laporte et al., 2000) to facilitate 
targeting to the clathrin coated pit.  
 
1.5.6.2  Alternative mechanisms of internalisation 
 
Lipid raft mediated internalisation has attracted much interest in recent years. Lipid 
rafts are regions of the plasma membrane characterized by an abundance of 
cholesterol and sphingolipids (Lajoie and Nabi, 2007). These microdomains are 
more rigid and are detergent insoluble. It is thought that lipid rafts act to 
compartmentalise complexes of interacting molecules and thereby serve as 
signalling platforms. One specific type of lipid raft termed caveolae, are flask 
shaped invaginations characterized by the presence of caveolin-1, a cholesterol 
binding membrane protein (Rothberg et al., 1992). Dynamin has been shown to 
mediate the budding of caveolae vesicles in addition to clathrin coated vesicles (Oh 
et al., 1998). 
 
1.5.7 MC2R desensitisation and internalisation 
 
Desensitisation of the MC2R in the Y1 adrenocortical cell line has been previously 
investigated in our laboratory (Baig et al., 2001). Experiments suggested a 
heterologous mechanism of densensitisation whereby phosphorylation of the 
receptor by PKA uncoupled the receptor from its G-protein. The PKA antagonist 
H89 was shown to almost completely eradicate the early phase of densensitisation 
and in addition, when a ser-208 mutant was transfected into Y6 cells (a mutant 
variant of the Y1 cell line which does not express the MC2R), a similar effect on 
desensitisation was shown to that of H89 treated Y1 cells. However, treatment of 
Y1 cells with the β2 agonist isoproteronol, which caused an increase in cAMP 
similar to that of ACTH treatment, did not densensitise the ACTH response, 
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suggestive of a homologous mechanism with the possible involvement of a GRK. 
These observations are in support of overlapping mechanisms of heterologous and 
homologous desensitisation as previously discussed (section 1.5.5.3).      
 
Additional experiments in our lab also demonstrated the internalisation of the 
MC2R by a mechanism most likely to be dependent on clathrin-mediated 
endocytosis since internalisation could be significantly modulated after pre-
treatment with hypertonic sucrose, an inhibitor of internalisation (Baig et al., 2002). 
In contrast to many other GPCRs however, internalisation of the MC2R is thought 
to be limited to a small population of receptors since only around 20 % of cell 
surface receptors internalised following ACTH treatment. In addition, 
internalisation of the MC2R is slow with maximum internalisation after 1 hour. By 
contrast, the β-adrenergic receptor and AT1A receptor internalise completely 5 
mins after the addition of their respective agonists (Hunyady, 1999). 
 
1.5.8 Non-classical roles for GPCRs 
The activation of second messenger signalling cascades by agonist bound GPCRs 
through interactions with G-proteins, are generally very well characterised, in 
addition to the cellular effects of these pathways. However, in the last 20 years, 
alternative roles for GPCRs have emerged where in addition to classical second 
messenger signalling pathways, other signalling cascades are activated leading to 
effects such as proliferation, differentiation and apoptosis (Gu et al., 2000, 
Rozengurt, 1986, van Biesen et al., 1996). Gene knock-out studies have 
demonstrated that many GPCRs are necessary for cell growth under physiological 
conditions (Nagata et al., 1996).  Further support for the proliferative roles of 
GPCRs is the observation that activating mutations in GPCRs and G-proteins have 
been linked to several disease states including cancer. Constitutively activated Gαs 
leads to hyperplasia of endocrine cells found in pituitary and thyroid tumours 
(Dhanasekaran et al., 1995). Furthermore, a number of GPCRs have been shown to 
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transform contact inhibited cultures of rodent fibrobalsts when persistantly 
activated (Allen et al., 1991, Gutkind et al., 1991, Julius et al., 1989).  
A further non classical cellular effect of GPCR agonists has been demonstrated for 
β-adrenergic receptors in S49 cells and for the follicle-stimulating hormone (FSH) 
receptor, where binding of their respective ligands results in the induction of 
apoptosis (Gu et al., 2000, Amsterdam et al., 1998).  
It has long been debated that in addition to the major role of ACTH in 
steroidogenesis, ACTH may also be involved in the regulation of growth of the 
adrenal cortex. Although the mechanisms by which ACTH mediates these effects 
are not fully elucidated, there may be a direct effect of ACTH on the activation of 
mitogenic signalling pathways which lead to proliferation of adrenal cells as has 
been demonstrated for other GPCRs.    
 
1.6  ACTH IN THE REGULATION OF ADRENAL GROWTH 
 
There are a number of lines of evidence that support a growth promoting role of 
ACTH on the adrenal. These include clinical observations of syndromes of ACTH 
excess and ACTH deficiency, in vivo studies in rats looking at the effects of ACTH 
on adrenal weight and cell number, and the reversal of adrenal atrophy by ACTH 
administration to hypophysectomised rats (Farese and Reddy, 1963a, White et al., 
1987a, White et al., 1987b, Bransome and Reddy, 1964, Farese and Reddy, 1963b, 
Nussdorfer et al., 1973). Equally, in many studies ACTH has been demonstrated to 
have an anti-mitogenic effect on the adrenal cortex. The majority of this evidence 
arises from in vitro studies where ACTH inhibits the growth of primary cultures and 
cell lines (Gospodarowicz et al., 1977) however, there is also further in vivo evidence 
from a model of adrenal compensatory growth which suggests that a factor other 
than ACTH is responsible for the rapid growth of the remaining adrenal gland that 
arises in this model (Engeland et al., 1975).   
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1.6.1  Clinical observations 
 
Clinicians have long held the view that ACTH plays a role in the regulation of 
adrenal cortex growth, mainly due to the correlation between levels of circulating 
ACTH and adrenal cortex size.  This is clearly demonstrated in a well-characterised 
in-born error of steroidogenesis in humans, congenital adrenal hyperplasia, where 
there is a deficiency of cortisol production, leading to chronic elevations in 
circulating ACTH and resulting in hyperplasia of the adrenal cortex (New, 1998). 
Studies in our laboratory have shown constitutive activation of the MC2R in a point 
mutation present in a patient with ACTH-independent Cushings syndrome. The 
mutated receptor, when transfected into Y6 cells had impaired desensitisation and 
internalisation compared to wild type receptor leading to constitutive activation of 
the receptor, a possible mechanism for the adrenal hyperplasia seen in the patient 
(Swords et al., 2002).  In addition, inactivating mutations in the ACTH receptor are 
associated with adrenocortical hypoplasia (Clark and Weber, 1998). 
1.6.2  In vivo studies 
1.6.2.1  Intact animals 
 
Over the last 30 years, many studies have attempted to elucidate the growth or 
growth inhibitory effects of ACTH on the adrenal gland using several in vivo and in 
vitro models.  Early studies in the 1960’s supported the still widely held view that 
ACTH is involved in adrenal growth since administration of ACTH was found to 
increase adrenal weight, protein synthesis and nucleic acid content in rats 
(Bransome and Reddy, 1964, Farese and Reddy, 1963a).  However, an increase in 
adrenal weight does not necessarily indicate a true proliferative effect on the adrenal 
gland.  ACTH has been shown to cause a morphological change where cell size is 
greatly increased (Nussdorfer et al., 1978).  This effect is hypertrophic, possibly 
caused by a rapid vasodilatory effect of ACTH on the adrenal gland where there is 
increased blood flow to the gland and thus increased volume (Vinson et al., 1992). 
One study measured changes in RNA and DNA content in adrenals following 
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ACTH administration (Dallman et al., 1980).  An initial increase in RNA after 12 
hours was seen but an increase in DNA and therefore cell number was only seen 
after 72 hours of treatment implying that this proliferative effect only occurs as a 
result of ACTH induced cellular changes.  A review in 1984 by Dallman suggests 
that ACTH primarily causes adrenal hypertrophy followed by adrenal hyperplasia 
(Dallman, 1984).  
 
Other studies looked at changes in cell number as a direct measure of proliferation.  
A series of studies by Nussdorfer and co-workers in the 1970’s demonstrated that 
chronic treatment of rats with ACTH increased the number and volume of ZF cells 
where the effects on the other zones of the cortex were limited to increased cell 
volume (Belloni et al., 1978, Nussdorfer et al., 1977, Nussdorfer and Mazzocchi, 
1971, Mazzocchi et al., 1976).  Even after 36 days treatment, they found no 
proliferative effect on ZR cells (Mazzocchi et al., 1976).  In a study carried out in 
hamsters, ACTH treatment was shown to increase cell number from day 3 by 50% 
in the ZF and by 58% in the ZR following 9 days of treatment however there was 
no change in ZG cell number (Malendowicz and Dembinska, 1990).  This is 
supported by another in vivo study whereby the numbers of mitotic cells in the rat 
adrenal cortex in response to a synthetically made ACTH peptide (1-24) were 
measured (Payet and Lehoux, 1980).  ACTH treatment caused a dose-dependent 
increase in mitoses in the ZG but not in the ZF however the increase in the size of 
the gland was due to the ZF and not the ZG.  This suggests that newly proliferated 
cells in the ZG quickly differentiate into fasciculata cells.       
 
1.6.2.2  Hypophysectomy 
 
In the experimental hypophysectomy model, the pituitary gland is surgically 
removed. causing marked adrenal atrophy thus suggesting the requirement of one 
or more pituitary peptides in the maintenance of adrenal growth. In addition it was 
also demonstrated that administration of ACTH can reverse the adrenal atrophy 
caused by hypophysectomy (Nussdorfer et al., 1973).  It stimulated growth and 
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steroidogenic capacity of the ZG and this effect could be mimicked by cAMP.  
Another study showed that ACTH induced adrenal gland regeneration following 
hypophysectomy, involves cellular proliferation (Tchen et al., 1977). 
 
1.6.2.3  Adrenal compensatory model     
 
The experimental model of compensatory adrenal growth following unilateral 
adrenolectomy in rats, whereby the remaining adrenal undergoes hypertrophy and 
hyperplasia, has been extensively used as an experimental model for adrenal growth 
in the adult.  This model has provided most of the evidence against the role of 
ACTH as an adrenal mitogen.  One group measured plasma ACTH concentrations 
and found that levels did not increase following adrenalectomy and thus could not 
account for the rapid growth of the remaining adrenal (Engeland et al., 1975).  In 
the same study, it was demonstrated that compensatory adrenal hypertrophy 
occurred in adrenalectomised and hypophysectomised rats therefore suggesting that 
a pituitary peptide is not involved in this response. This was supported by two other 
reports, one which demonstrated that ACTH actually inhibited the growth response 
seen in adrenalectomised rats and the other which showed that administration of 
ACTH antiserum was able to reduce steroidogenesis but had no effect on adrenal 
weight (Dallman et al., 1980, Rao et al., 1978).  This was confirmed more recently 
(Nakayama et al., 1993). 
  
1.6.3  In vitro studies 
 
In vitro cell culture studies often represent a cleaner system in which to study cell 
signalling mechanisms.  However, earlier experiments that investigated the effects 
of ACTH in vitro were often on mixed populations of cells. One such study found 
that treatment of primary bovine adrenocortical cells with ACTH inhibited DNA 
synthesis and stimulated steroidogenesis and furthermore, that ACTH inhibited the 
growth stimulatory effect of FGF (Gospodarowicz et al., 1977). These findings 
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were confirmed in subsequent studies and a further study reported the same effect 
in adult and neonatal rat adrenal cells where ACTH inhibited thymidine 
incorporation (Hornsby and Gill, 1978, Ramachandran and Suyama, 1975, 
Simonian et al., 1982). In contrast to these findings one investigation found a 
significant increase in thymidine incorporation and in actual cell number in 
response to ACTH in adult rat inner zone cells (Armato and Nussdorfer, 1972).  
Arola et al however found a biphasic effect of ACTH on foetal rat adrenal cells 
where it was initially inhibitory of growth, a cAMP independent response, and then 
strongly stimulatory after 48 h, which was mimicked by cAMP analogues (Arola et 
al., 1993).  Since the early work in the 1970’s, groups have switched to using cell 
lines as supposedly more reproducible systems to try to determine the signalling 
mechanisms involved in the responses to ACTH.    
 
1.6.3.1  The Y1 adrenocortical cell line 
 
The Y1 cell line is an ACTH responsive, steroid secreting, clonal mouse cell line.  
First isolated in 1966 (Yasamura et al., 1966), it is a widely used cell line in studying 
the ACTH receptor and has been used extensively in recent years to look at 
mitogenic mechanisms in response to ACTH.   
 
ACTH has been shown to inhibit cell proliferation in the Y1 adrenocortical cell line 
by interfering with progression through the G1 phase of the cell cycle (Masui and 
Garren, 1971).  This growth inhibitory effect has been further demonstrated to be 
mediated through a cAMP-dependent mechansim, since cell lines expressing 
dominant inhibitory mutations in PKA, which disrupt cAMP-dependent signalling 
pathways, are resistant to the growth inhibitory actions of ACTH and cAMP 
analogues (Armelin et al., 1996, Schimmer and Schulz, 1985).  Contrastingly, in the 
same cell line, ACTH has been demonstrated to induce the expression of genes 
associated with cell cycle progression and proliferation.  For example, ACTH 
induced the expression of fos and jun protooncogenes (Kimura et al., 1993, Kimura 
and Armelin, 1990).  The fos and jun family of transcription factors are the 
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immediate early genes conventionally upregulated following the binding of growth 
factors to tryosine kinase receptors (Angel and Karin, 1991).  They form homo or 
heterodimers, widely termed AP1, which play a vital role in inducing genes involved 
in cell cycle progression.  This data suggests a growth-promoting action of ACTH.  
One study examined the regulation of the p42/p44 MAPK pathway otherwise 
called the extracellular signal related kinase (Erk1/2) pathway, one of the major 
pathways regulating mitogenesis, in response to ACTH, to reconcile this conflicting 
data (Lotfi et al., 1997).  They demonstrated that ACTH induced Erk1/2 
phosphorylation of serum-starved cells by 5 mins and over a range of 
concentrations.  Using the kin-8 (PKA defective) mutant they demonstrated that 
ACTH could still activate this pathway over the same concentration range, 
suggesting that this was a cAMP-independent mechanism.  They also showed that 
ACTH, given as a short pulse of up to 2 hours, stimulated an increase in BrdU 
labelling by 2 fold over unstimulated cells which approached the effects of serum 
and FGF.  ACTH was also found to stimulate cell cycle progression as 
demonstrated by an increase in thymidine incorporation compared to unstimulated 
cells.  To ascertain whether this signal could progress into an increase in mitosis, 
cells were stimulated for 5 mins and then left in SFM for 32 hours.  A 1.5 fold 
increase in cell number was found compared to unstimulated cells.  This study went 
on to look further at the signalling mechanism initiated by ACTH.  They found that 
the ACTH effect could be mimicked by the phorbol ester, phorbol 12-myristate 13-
acetate (PMA) but not by the inactive 4α-hydroxyl isomer of PMA suggesting a 
Protein kinase C (PKC) dependent mechanism.  
 
The above data do suggest a mitogenic component to ACTH signalling however 
studies comparing the strength of its mitogenic activity with that of FGF suggest 
that it is only a weak mitogen (Armelin et al., 1996).  A 2 h pulse of 1nM ACTH 
lead to a 2.6 fold increase in BrdU-labelling index whereas under the same 
conditions, 0.2nM FGF2 caused a 7-fold increase.  Furthermore, anti-sense 
oligonucleotides to either c-fos and c-jun were able to abolish DNA synthesis 
stimulated by ACTH, however to abolish the FGF2 mitogenic response, antisense 
to both c-fos and c-jun were required (Lotfi and Armelin, 2001).  In another study, 
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it was demonstrated that higher concentrations of the MEK 1 inhibitor PD98059 
(MEK being an upstream component in the Erk1/2 pathway) were required to 
inhibit an FGF induced Erk1/2 response than an ACTH Erk1/2 response (Le and 
Schimmer, 2001). 
Armelin and co-workers have focused on characterising the anti-mitogenic 
mechanisms of ACTH in the Y1 cell line by looking at the antagonising effects of 
ACTH on FGF stimulated mitogenesis.  They demonstrated that FGF2 elicits a 
strong mitogenic response in G0/G1 arrested Y1 cells that includes a rapid and 
transient activation of Erk1/2 (2 to 10 mins); transcriptional activation of c-fos, c-jun 
and c-myc (another protooncogene) genes (10 to 30 mins); induction of c-fos and 
c-myc proteins by 1 h and cyclin D1 protein by 5 h; and the stimulation of DNA 
synthesis within 8 h (Lotfi et al., 2000).  They found that a combination of FGF2 
and ACTH for a 30 min pulse, reduced the mitogenic activity of FGF2 by 50%, 
however, an initial 30 mins pulse of FGF2 followed by a 2 h pulse of ACTH 4-6 
hours later, completely abolished the mitogenic response (Lotfi et al., 1997).  They 
suggest that this inhibitory effect is due to ACTH being more effective in the 
middle of G1 phase (Armelin and Lotfi, 1999).  They have further dissected this 
mechanism by looking at another mitogenic pathway, the PI3-K/Akt pathway.  Akt 
is a mitogenic and anti-apoptotic serine/threonine protein kinase that is activated 
by phosphorylation of Thr308 and Ser473, through a process dependent on PI3-K 
and stimulated by growth factors (Chan et al., 1999).  They demonstrated that Y1 
cells have a constitutively high level of activated (phosphorylated) Akt, which may 
be significantly decreased with ACTH treatment within 2-5 min, and remaining up 
to 4 h (Forti and Armelin, 2000).  This response was abolished after pre-incubation 
with 7-38 ACTH, implying that the effect is specifically through the MC2R.  In 
PKA defective cells, ACTH did not dephosphorylate Akt suggesting a cAMP/PKA 
dependent mechanism.  In another study, this response was correlated with an 
induction of the cell cycle inhibitor p27kip1 after a 2 h treatment of ACTH (Forti et 
al., 2002).  Further, this group has demonstrated that ACTH post-transciptionally 
down-regulates c-myc and imply that this results in the growth inhibition seen in 
these cells (Lepique et al., 2000).  
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1.6.4  Conclusions  
 
With respect to in vivo ACTH effects, in the intact animal, it appears that ACTH is 
growth promoting, however the evidence for this is only suggestive.  The initial 
methods used such as adrenal wet weight may not be indicative of a proliferative 
effect, and the later studies showed conflicting evidence with regard to cell numbers 
in the different zones after ACTH treatment.  The hypophysectomy model is 
further supportive of an ACTH growth-promoting effect where a lack of ACTH 
coincides with adrenal atrophy, an effect that is reversed on administration of 
ACTH. The adrenal compensatory model is unsupportive of an ACTH mitogenic 
role, however results have also suggested that a pituitary peptide is not involved in 
this response, which does not concur with the hypophysectomy model of adrenal 
atrophy.  Furthermore, from POMC knockout studies, it is clear that a pituitary 
peptide is involved in adrenal growth since the knockout has demonstrated the 
presence of atrophy (Coll et al., 2004).  Thus, the adrenal compensatory model may 
be the result of an altogether different mechanism, which may not be 
physiologically relevant. 
 
Early cell studies into the growth effects of ACTH on adrenocortical cells have 
yielded mixed and confusing results.  ACTH was clearly inhibitory of growth in 
primary bovine adrenocortical cells whereas in rat inner zone cells, ACTH caused a 
significant proliferation (Gill, 1976, Nussdorfer et al., 1977).  These studies however 
have further been complicated because of the likelihood that these experiments 
were carried out on mixed populations of cells.  In addition there is some doubt 
over the purity of ACTH preparations used in these early experiments, which also 
applies to early in vivo experiments (Lotfi et al., 2000).  Some would argue that many 
of the proliferative effects seen were from a contaminant in these preparations.   
 
In recent years, synthetic ACTH has been commonly used but this still hasn’t 
solved the contradictory results.  Two groups have carried out the majority of more 
recent work on ACTH signalling mechanisms in Y1 cells.  It is clear that in these 
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cells ACTH does initiate a mitogenic pathway and in short pulses can bring about a 
proliferative response, an effect that is probably mediated by the PKC pathway.  
However, ACTH also initiates an anti-mitogenic mechanism with activation of the 
cAMP/PKA pathway leading to blockade of the PI3-K/Akt pathway (Lepique et 
al., 2000). Physiologically, ACTH plasma concentrations are variable throughout the 
day dependent on circadian rhythms (Vinson et al., 1992).  This may be important 
when assessing the effects of long periods of treatment of cells with ACTH.  It may 
be that the concentrations of ACTH required to initiate a response in the adrenal 
cortex (mitogenic or otherwise) may physiologically be experienced for shorter 
periods of time than those used in some cell studies.   
 
The local release of certain factors following treatment with ACTH has also been 
thought to play a role in the regulation of growth of the adrenal. One group 
demonstrated by slot blot and ribonuclease protection analysis that bFGF mRNA 
was present in very low amounts in total RNA from primary cultures of 
unstimulated human fetal adrenal cells but was increased 2-3 fold in cells exposed 
to 10nM ACTH 1-24 for 24 h (Mesiano et al., 1991). Another study has suggested 
that hyperplasia of adrenal cells may be the result of the effects of ACTH on the 
development of adrenal vasculature where ACTH stimulates Vascular endothelial 
growth factor (VEGF) production (Thomas et al., 2003).  
  
The most likely scenario is that mitogenic signalling through ACTH is a complex 
process involving the interplay between ACTH and many other factors including 
those produced locally. Further investigation into pathways initiated by ACTH is 
required to elucidate these mechanisms further. 
 
1.6.5  Other adrenal mitogens 
 
Whilst some investigators have concentrated on the role of ACTH in adrenal 
growth regulation, other groups have concentrated on alternative pituitary peptides 
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that may be involved. This is based on the premise that since hypophysectomy leads 
to adrenal atrophy, a pituitary derived peptide must be crucial for adrenal growth.  
In the 1980’s the group of Lowry and co-workers demonstrated adrenal mitogenic 
activity in hypophysectomised rats treated with peptides derived from the N-
terminus of the POMC peptide (Estivariz et al., 1982, Lowry et al., 1983, Lowry et 
al., 1984).  However, 1-76 POMC, which accounts for the pro-γ-MSH peptide 
secreted by the pituitary, had no mitogenic activity on the adrenals (Estivariz et al., 
1980).  Shorter fragments, that did not contain γ-MSH (1-28 POMC), did have a 
growth effect on hypophysectomised rats (Estivariz et al., 1988, Lowry et al., 1984).  
Furthermore, anti-sera to 1-48 POMC administered to rats after unilateral 
adrenalectomy, inhibited adrenal compensatory growth (Lowry et al., 1983).  Most 
of the evidence for an N-terminal POMC adrenal mitogen, was based on the use of 
pituitary extracts, which may have been contaminated with other pituitary peptides.  
More recently however, the case for an N-terminal POMC mitogen has been 
strengthened after the discovery of an adrenal serine protease that specifically 
cleaves rat POMC to derive a short fragment of N-terminal POMC that has already 
been shown to stimulate growth of the adrenal in vivo (Bicknell et al., 2001).  One 
study has looked at the effect of a sythetic 1-28 POMC on human H295R and Y1 
cells (Fassnacht et al., 2003).  They demonstrated that 1-28 POMC stimulated cell 
proliferation and rapidly activated Erk1/2 in both cell types and in primary bovine 
adrenal cells in a concentration dependent manner.  Although this data is 
convincing, there has as yet been no receptor found to 1-28 POMC. 
 
1.7  GROWTH PROMOTING SIGNALLING PATHWAYS 
 
There are a number of well-characterised signalling pathways that are thought to 
initiate the progression of the cell cycle and ultimately lead to proliferation of cells. 
The MAPK signalling pathway comprises a highly conserved cascade of at least 
three protein kinases, sequentially activated by phosphorylation, which culminates 
in the activation of a multi-functional MAPK. Fig. 1.8 shows the basic components 
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found in MAPK pathways and highlights some of the proteins involved in these 
pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.8 MAPK pathways. The MAPK pathways consist of MEKKs that respond to a variety of 
extracellular signals including growth factors and stress. The MEKKs can then activate one of several 
MEKs (or MKKs). MEKs are relatively specific for their target MAPKs. In turn MAPKs activate 
various targets including transcription factors which regulate their target gene expression bringing about 
effects such as growth, differentiation and apoptosis. 
 
MAPK pathways are activated by a diverse array of stimuli and act to transduce 
signals from the plasma membrane to exert a physiological effect. Transcription 
factors are the major targets of MAPKs. On phosphorylation, transcription factors 
are targeted to the nucleus whereon they regulate expression of their target genes. 
For example Erk1/2 activates AP1 (activating protein 1), an immediate early gene 
involved in cell cycle progression (Chen et al., 1993). A further target of MAPK is 
RSK2. Activated RSK2 can phosphorylate histone H3, an important protein in the 
restructuring of chromatin (Sassone-Corsi et al., 1999). 
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In addition to being involved in cell proliferation, MAPK pathways have also been 
implicated in differentiation, development, apoptosis and inflammatory responses 
(Raman et al., 2007). Although MAPK pathways are ubiquitous, specificity is 
conferred by the availability of cellular targets and by their association with 
scaffolding and anchoring proteins (Garrington and Johnson, 1999).  
 
Within the MAPK family several distinct pathways exist, the most widely studied of 
which is the Erk1/2 pathway. There are also MAPK pathways activated by cellular 
stress known as the stress-activated protein kinase (SAPK) pathway. This includes 
both the c-jun amino terminal kinases (JNKs) and p38 MAPK. In recent years the 
emerging role of Erk 5 has been investigated where is has been implicated in 
mediating the effects of numerous oncogenes (Wang and Tournier, 2006). 
 
The duration of MAPK signals is thought to be an important factor in determining 
the strength and type of a response. MAPK signalling is negatively regulated by 
MAPK phosphatases (MKPs) of which isoforms can be found in both the nucleus 
and the cytosol (Kondoh and Nishida, 2007) and it is these enzymes that are 
thought to determine the length of duration of the Erk1/2 signal.  It has been 
suggested that the immediate early gene product c-Fos, acts as a sensor for Erk1/2 
signal duration where prolonged Erk1/2 activation allows the stabilization of c-Fos 
and thus c-Fos signalling in contrast to shorter periods of Erk1/2 activation (Murphy 
et al., 2002). This may explain why shorter periods of Erk1/2 activation do not 
necessarily result in cell cycle progression.  
 
1.7.1  The Erk1/2 Pathway 
 
Erk 1 and 2 are proteins of 44 and 42kDa respectively. They share 85% sequence 
homology with a greater homology in the regions involved in substrate binding. 
Both contain a Threonine-glutamine-tyrosine (TEY) motif within an activation loop 
and it is here that their tyrosine and threonine residues are phosphorylated enabling 
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their activation (Payne et al., 1991). Both Erk 1 and 2 are ubiquitously expressed 
however their relative abundance is variable between cell types. Due to their 
homology and the fact that both are activated by a pair of closely related MEKs, 
MEK 1 and MEK 2, Erk 1 and 2 are most commonly treated as one entity. MEK1 
and 2 are activated by Raf isoforms. This family of kinases is made up of Raf-1, A-
Raf and B-Raf. Each Raf contains three conserved regions, two of which are found 
in the N-terminus and are thought to regulate their catalytic domain (Whitehurst et 
al., 1995). The third is contained in the kinase domain. Raf-1 is found ubiquitously 
whereas B-raf is most highly expressed in neuronal tissues and testes and A-ras 
mainly in urogenital tissue.  
1.7.2  Stress activated protein kinase pathways 
 
The JNKs were first isolated and characterized as stress activated kinases since they 
were activated in response to the inhibition of protein synthesis (Kyriakis et al., 
1994). The SAPK/JNK pathway is induced by cellular stress and extracellular 
signals including UV radiation, hyperosmolarity, toxins and inflammatory cytokines. 
Activation requires the sequential dual phosphorylation of tyrosine and throenine 
residues located in a TPY motif in its activation loop within its kinase domain. This 
pathway is extremely complex and may be phosphoylated by many MKKKs. SAPK 
has been reported to phosphorylate transcription factors such as c-Jun, ATF 2, Elk 
1 and c-Myc among others thus giving rise to its important roles in regulating cell 
proliferation, differentiation, transformation and apoptosis (Chang and Karin, 2001, 
Davis, 2000, Nishina et al., 2004).  
 
The p38 MAPK cascade is another stress activated MAPK pathway. The most well 
studied of these is the p38α pathway which is expressed in most cell types. These 
kinases were first discovered in a screen for drugs inhibiting TNFα induced 
inflammatory responses (Lee et al., 1994). P38 MAPK is activated by many stimuli 
including osmotic shock, heat shock, ligands for GPCRs and hormones, and its 
effects are most commonly in regulating cytokine production in the inflammatory 
response. 
 45 
1.7.3  Other MAPK pathways 
 
MEK 5 was identified by two groups using DNA cloning strategies (Zhou et al., 
1995, English et al., 1995). Following this its downstream substrate, Erk 5, was 
identified independently by two groups using a yeast two-hybrid approach and a 
degenerate PCR strategy (Zhou et al., 1995, Lee et al., 1995). The catalytic domain 
of Erk 5 appears most similar to Erk 2 however Erk 5 contains a stretch of 400 
amino acids, c-terminal to the kinase domain, that displays no similarity to any 
known proteins. Erk 5 contains 10 concensus sites for MAPK phosphorylation all 
of which may be autophosphorylated (English et al., 1998).  
 
1.7.4  Non MAPK growth promoting pathways 
 
The PI3-K/Akt pathway is a widely studied pathway that promotes cell survival and 
proliferation. The Akt protein consists of an amino terminal PH domain, a central 
kinase domain and a carboxy-terminal regulatory domain. The PH domain of Akt 
interacts with membrane lipid products such as phosphatidylinositol (3,4,5) 
triphosphate (PIP3) produced by PI3-K. Akt may also be activated independently of 
PI3-K. For example, it was shown that Akt could be activated by Ca2+/calmodulin 
dependent kinase (Perez-Garcia et al., 2004). Akt activation provides the cell with a 
survival signal allowing them to withstand apoptotic stimuli and is thus thought to 
be one of the most important pathways in regulating cell survival (Yao and Cooper, 
1995). Many of its targets are transcription factors involved in the regulation of 
apoptosis. These include the Forkhead family of transcription factors whose 
upregulation by Akt prevents the transcription of pro-apoptotic genes (Burgering 
and Medema, 2003). Akt is also involved in the regulation of CREB activity and as a 
consequence, the transcriptional regulation of CREB regulated survival genes.  
 
In addition to its role in cell survival, Akt has also been shown to have important 
roles in cross-talk with other signalling pathways. For example, Akt was 
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demonstrated to form complexes with Erk1/2, to regulate apoptosis in kidney 
proximal tubular cells (Sinha et al., 2004). 
 
1.8  ACTIVATION OF MAPK PATHWAYS BY GPCRS 
 
Since the discovery of the involvement of GPCRs in non-classical roles such as 
growth and apoptosis, an extensive amount of research into the steps that lead to 
these responses has been undertaken. Numerous GPCRs, including the MC2R, 
have been demonstrated to activate pathways such as the Erk1/2 signalling pathway 
however, of greater interest is the way in which such pathways are activated by 
GPCRs because this is important in determining the outcome of the response.  
 
1.8.1  G-protein involvement in the mediation of Erk1/2 signalling 
 
All three of the major G proteins (Gs, Gi/o and Gq/12) have been demonstrated to 
be involved in the transduction of Erk1/2 signals through agonist binding to GPCRs 
(Faure et al., 1994, Crespo et al., 1994). 
 
1.8.1.1 Gs coupled receptors 
 
In the case of Gs coupled receptors the effector molecule is most commonly the α 
subunit of the G-protein. Erk1/2 activation may be mediated by direct binding of 
the activated subunit to an effector molecule such as the tyrosine kinase src (Ma et 
al., 2000) or through mechanisms downstream of the activation of the cAMP/PKA 
pathway (Norum et al., 2003, Klinger et al., 2002) Since the MC2R is classically 
coupled to a Gs protein, this is a likely mechanism of activation of Erk1/2 by this 
receptor. This mechanism will be discussed in further detail later.  
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1.8.1.2  Gi/o coupled receptors 
 
Pertussis toxin (PTX) has been widely used to assess the involvement of Gi/o 
proteins in the transduction of the Erk1/2 cascade from Gi/o coupled GPCRs. PTX 
ribosylates G-protein α chains of Gi/o proteins in the αβγ state therefore 
preventing the dissociation of these subunits. Many groups have shown the 
activation of Erk1/2 to be PTX sensitive suggesting that the signal is dependent on 
coupling to either Gi or Go (Cook and McCormick, 1996). Further elucidation of 
these mechanisms has shown that the main effector molecules transducing signals 
to Erk1/2 from PTX sensitive GPCRs are the free βγ subunits. One study looked at 
Ras and Erk1/2 activation through endogenous Gi-coupled receptors, in response to 
lysophosphatidic acid (LPA), in a fibroblast cell line transfected with a polypeptide 
derived from the c-terminus of the GPCR kinase GRK2 (this acts as a Gβγ 
antagonist). They found that Erk1/2 activation was attenuated in transfected cells 
compared to wild-type cells, implying that Gβγ subunits dissociated from Gi 
mediate the Erk1/2 response (Koch et al., 1994).  This data was supported by similar 
studies where overexpression of Gβγ subunits activated the Erk1/2 cascade (Crespo 
et al., 1994, Faure et al., 1994).  
 
Gβγ proteins are thought to transduce signals through binding to proteins that 
contain a pleckstrin homology (PH) domain, a well-known lipid-binding domain 
(Lemmon et al., 1996). In addition a number of proteins that contain a PH domain 
have also been shown to regulate ras activity suggesting that Gβγ effects on ras 
regulatory proteins may mediate the activation of the Erk1/2 pathway (Langhans-
Rajasekaran et al., 1995). Fig. 1.9 depicts the activation of Erk1/2 through Gi 
coupled receptors through βγ subunits. 
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Fig. 1.9  ßγ activation of Erk1/2 pathway. On binding of an agonist to a Gi coupled GPCR, βγ 
subunits transduce the signal through binding to a ras regulatory protein (Ras RP) that contains a PH 
domain. The signal is then transduced through Ras to activate the Erk1/2 pathway. With the addition of 
agonist and pertussis toxin, Erk1/2 activation is prevented because pertussis toxin ribosylates (R) the Gi 
protein and prevents dissociation of the αβγ subunits.  
 
PI3-K has also been shown to be involved in Gβγ responses.  A PI3-K responsive 
to Gβγ proteins has been cloned (Stoyanov et al., 1995) which contains a potential 
PH domain near its amino terminus. In addition, inhibitors of the PI3-K/Akt 
pathway, wortmannin and LY294002 block the Erk1/2 activation induced by LPA, 
α2-adrenergic receptor or Gβγ proteins (Hawes et al., 1996). Events downstream of 
Gβγ binding to proteins containing PH regions tend to be the stimulation of Shc 
and further the activation of growth factor tyrosine kinase receptor pathways 
suggesting that Gβγ mediated activation of Erk1/2 converges with classical tyrosine 
kinase receptor pathways (Touhara et al., 1995, Hordijk et al., 1994). This process 
of activation will be discussed in more detail later. 
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1.8.1.3  Gq/11 coupled receptors 
 
Coupling of GPCRs to Gq proteins results in a stimulation of PKC activity through 
the production of diacylglycerol (DAG) and IP3. This process also involves Ca2+ 
influx through channels in the plasma membrane as well as intracellular Ca2+ release 
from the endoplasmic reticulum. Receptors coupled to Gq proteins often activate 
the Erk1/2 cascade through the activation of this classical second messenger 
pathway where Erk1/2 activation is down stream of Ca2+ mobilisation or PKC 
activation. PKCα was demonstrated to activate Raf-1 directly by phosphorylation 
(Kolch et al., 1993). In addition, activation of Erk1/2 following stimulation of the 
α1B adrenergic and M1 muscarinic receptors in fibroblasts occurs through a raf 
dependent but ras independent mechanism which can be blocked by PKC 
downregulation and mimicked by overexpression of PLC-β2 (Faure et al., 1994). 
The influx of Ca2+ ions can also cause the activation of Erk1/2 independently of 
PKC activation (Schliess et al., 1996). Fig 1.10 shows some of the mechanisms by 
which Gq coupled receptors are able to initiate Erk1/2 activation. Although the 
MC2R is not thought to couple to Gq directly, Ca2+ has long been thought to play a 
role in the binding of ACTH to its receptor (Cheitlin et al., 1985). Furthermore, 
intracellular Ca2+ has also been demonstrated to enter adrenal cells after stimulation 
with ACTH through a PKA mediated depolarisation of cells (Enyeart and Enyeart, 
1998, Catalano et al., 1986). This may suggest a mechanism through which ACTH 
mediates Erk1/2 activation and indeed previous experiments in Y1 cells 
demonstrated that PMA, an activator of PKC, could mimic ACTH induced Erk1/2 
activation (Lotfi et al., 1997). 
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Fig. 1.10 Gq coupled receptor mediation of Erk1/2 activation. Following agonist binding, 
PKC is activated in the usual manner along with an increase in Ca2+ concentration following release from 
the ER and influx through calcium channels. Active PKC may then bind and activate Raf and initiate the 
Erk1/2 pathway. In addition Ca
2+ ions may activate the Erk1/2 pathway via Raf or Ras. 
 
1.8.1.4  Switching of coupling of GPCRs 
 
An interesting additional mechanism of Erk1/2 activation by GPCRs has been 
described in which PKA phosphorylation of the β2 adrenergic receptor (Daaka et 
al., 1997) and the murine prostacyclin receptor (Lawler et al., 2001) leads to a switch 
in coupling from Gαs to Gαi with subsequent Erk1/2 activation through βγ subunits 
(Lefkowitz et al., 2002). Numerous other receptors have also been shown to couple 
to a variety of G proteins in heterologous cells (reviewed in (Rashid et al., 2004). 
However, highlighted in this review is the fact that many of these studies involved 
the expression of recombinant receptors in heterologous cell types making the 
observations slightly artificial. For ACTH responses, a switching of coupling of its 
receptor from a Gs to a Gi protein is unlikely since our laboratory has previously 
shown that PKA phopshorylation of the MC2R does not lead to a switch of G 
protein coupling in Y1 cells (Baig et al., 2001). 
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1.8.2  cAMP/PKA mediated activation of Erk1/2 
 
Many Gs coupled GPCRs have been previously shown to activate the Erk1/2 
cascade, many of which by mechanisms at least partially dependent on the 
activation of the cAMP/PKA pathway. Earlier studies indicated that a constitutively 
active Gαs mutant, forskolin and a cAMP analogue could activate the Erk1/2 
pathway in COS-7 cells (Faure et al., 1994). This effect in some cases was 
dependent on PKA and Ras activation (Norum et al., 2003, Klinger et al., 2002). 
However, in many cases the mechanism of Erk1/2 phosphorylation was found to be 
dependent on the activation of a small Ras superfamily guanine nucleotide binding 
protein Rap1A, independently of PKA activation (Kawasaki et al., 1998). In 1998, a 
guanine nucleotide exchange factor (GEF) that is activated by binding to cAMP 
was cloned (de Rooij et al., 1998). It was found that once activated this factor is able 
to activate Rap1 by promoting its release of the guanine nucleotide GDP and its 
binding to GTP. This factor was named ‘exchange protein directly activated by 
cAMP or EPAC. Following Rap1 activation, B-Raf is preferentially activated giving 
rise to Erk1/2 activation (Ohtsuka et al., 1996, Vossler et al., 1997). This mechanism 
has since been shown to be a common way in which Gs coupled receptors mediate 
Erk1/2 signals (Schinelli et al., 2001, Fujita et al., 2002). It is also worth noting that in 
some cell types, Rap 1 may negatively interfere in Ras signalling to Erk1/2 (Carey et 
al., 2000, Cook et al., 1993, Kitayama et al., 1989). Figure 1.11 depicts the pathway 
by which Erk1/2 may be activated by Gs coupled GPCRs. 
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Fig. 1.11  Activation of Erk1/2 by Gs coupled GPCRs dependent on the cAMP/PKA 
pathway. Agonist binding to the GPCR promotes an increase in intracellular cAMP and the 
subsequent activation of PKA. PKA may act to enhance Rap 1 activity. In addition cAMP may directly 
activate Epac which in turn enables activation of Rap 1 by promoting GDP/GTP exchange. Rap 1 may 
then promote the Erk1/2 pathway through Raf activation.  
 
1.8.3 .   Transactivation of tyrosine kinases in GPCR mediated activation  
of Erk1/2 
 
Research into the mechanisms that activate MAPK cascades over the past decade 
has identified converging pathways linking GPCR stimulation and classical growth 
factor receptor stimulation in the activation of these cascades. The first evidence 
linking a GPCR to tyrosine kinase activation was the use of genistein, a non-specific 
tyrosine kinase inhibitor that prevented LPA induced p21ras activation in Rat-1 
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fibroblasts (van Corven et al., 1993). This group also demonstrated that protein 
tyrosine kinase phosphorylation could be induced by LPA (Hordijk et al., 1994). 
Since then numerous groups have identified GPCRs that transduce signals to the 
Erk1/2 cascade through tyrosine kinase dependent processes. 
 
1.8.3.1  Transactivation of receptor tyrosine kinases 
 
The most notable mechanism involving tyrosine kinases is through the 
transactivation of the epidermal growth factor (EGF) receptor following 
stimulation with GPCR agonists  (Daub et al., 1996, Mifune et al., 2005, van Biesen 
et al., 1995). In addition, the PDGF receptor has been implicated in the 
transduction of an Erk1/2 signal through the dopamine D2 receptor and the P2Y 
receptor (Wang et al., 2005, Milenkovic et al., 2003); and the IGF-1 receptor is 
transactivated in response to angiotensin II in smooth muscle cells (Zahradka et al., 
2004).  
 
The mechanisms that result in the transactivation of tyrosine kinase receptors are 
not fully understood however they may involve the direct interaction of a GPCR 
with the receptor as in the case of the angiotensin II receptor type I which interacts 
with the EGF receptor in rat hepatic C9 cells (Olivares-Reyes et al., 2005). A 
perhaps more common mechanism however is the cleaving of membrane anchored 
isoforms of EGF receptor ligands by the activation of matrix metalloproteases 
(MMPs) (reviewed in Higashiyama and Nanba, 2005). These enzymes constitute a 
large family of endopeptidases that have important roles in development, wound 
healing and a variety of pathological processes. An initial study demonstrated the 
activation of a MMP by Gβγ subunits that released the growth factor heparin-
binding (HP) EGF, which subsequently activated the Erk1/2 cascade (Prenzel et al., 
1999). Since then numerous MMPs have been shown to be involved in GPCR 
mediated growth factor receptor transactivation (Thomas et al., 2005, Yano et al., 
2004). Fig. 1.12 shows the steps involved in the transactivation of growth factor 
receptors by GPCRs leading to Erk1/2 activation. 
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Fig. 1.12  Binding of an agonist to a GPCR causes the activation of a MMP possibly 
via βγ subunits. This causes the cleavage of a membrane bound heparin-binding growth factor enabling 
binding and activation of a growth factor receptor with the subsequent activation of the Erk1/2 cascade. 
 
1.8.3.2  Src tyrosine kinase involvement in GPCR mediated Erk1/2 activation 
 
An additional family of non-receptor tyrosine kinases shown to be involved in 
GPCR mediated signalling to the Erk1/2 cascade are the src family tyrosine kinases 
(Dikic et al., 1996, Ptasznik et al., 1995). The viral-src (v-src) oncogene was found to 
be a transmissible agent responsible for tumorigenesis in chickens and since then 
the cellular homologue c-src has been found to be over expressed in a number of 
human cancers (Irby and Yeatman, 2000). Src recruitment and activation is a pre-
requisite of Erk1/2 activation by several GPCRs. Overexpression of c-src kinase, 
(CSK) an inhibitor of src activity, impairs Gβγ mediated LPA and α2 adrenergic 
receptor stimulation of EGF receptor phosphorylation (Luttrell et al., 1997). In 
addition, activation of c-src was evident following stimulation of angiotensin II type 
1 receptors via a Gq and Ca2+ dependent process in vascular smooth muscle cells 
(Eguchi et al., 1998). In the case of Gs coupled receptors it has been shown that the 
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activated α subunit can interact directly with src leading to its activation (Ma et al., 
2000, Ma and Huang, 2002). Src has also been shown to bind directly to agonist 
occupied GPCRs as in the case of the β2 and β3 adrenergic receptors (Fan et al., 
2001, Cao et al., 2000). Src phosphorylates a number of cytoskeletal-associated 
proteins and probably contributes to the activation of raf-1 and PI3-K (Erpel and 
Courtneidge, 1995). Conversely to its role in activating the Erk1/2 pathway, src has 
also been demonstrated to be involved in mediating the inhibition of cell growth via 
cAMP and Rap1 (Schmitt and Stork, 2002). 
 
1.8.4  Internalisation and scaffolding of signalling complexes 
 
In addition to regulating cell surface receptor number as previously discussed, 
internalisation of a number of GPCRs has been demonstrated to be a pre-requisite 
for other signalling pathways including Erk1/2 signalling. For example, LPA, 
thrombin and bombesin activation of Erk1/2 was sensitive to 4 different chemical 
inhibitors of internalisation (Luttrell et al., 1997); β2AR mediated Erk1/2 signalling 
through Gi coupled receptors is sensitive to dominant negative dynamin 
transfection (Daaka et al., 1998); and Erk1/2 activation by the serotonin 5HT1A 
receptor requires Ca2+/calmodulin dependent internalisation of the receptor (Della 
Rocca et al., 1999). 
 
In recent years, much research has been conducted into the role of β-arrestins in 
transducing signalling pathways. For example it was shown in HEK 293 cells that 
stimulation of the β2 adrenergic receptor triggers colocalisation of the receptor with 
β-arrestins and src kinases in clathrin coated pits (Luttrell et al., 1999). This has lead 
to the speculation that it is β-arrestin that acts as a scaffold for recruitment of 
components of signalling pathways since it was found that src can directly bind to β-
arrestin 1 (Miller et al., 2000). This interaction has also been linked to activation of 
the Erk1/2 pathway (Luttrell et al., 1999, DeFea et al., 2000b). Assembly of a β-
arrestin-Erk1/2 complex was shown to be required for the activation of Erk1/2 by 
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the PAR2 receptor since expression of a truncated form of β-arrestin that inhibits 
endocytosis, prevented Erk1/2 activation (DeFea et al., 2000b). A further example is 
the NK1 receptors where activation of these receptors by substance P causes 
formation of complexes containing src, β-arrestin and Erk1/2 (DeFea et al., 2000a). 
β-arrestin has additionally been found to form complexes with components of 
other MAPK pathways for example β-arrestin 2 was shown to interact with JNK 3 
in a yeast two-hybrid system (McDonald et al., 2000). 
 
The functional role of β-arrestin-Erk1/2 complexes is not entirely understood 
however it has been shown that such complexes may be retained within the 
cytoplasm of the cell thus preventing nuclear translocation and subsequent 
transcription factor activation. For example, a mutant PAR2 receptor that is unable 
to bind to β-arrestin, induces nuclear translocation of Erk1/2 and cell proliferation 
whereas the wild type receptor does not (DeFea et al., 2000b). A further example is 
in a paper that utilised chimeric V2 vassopressin (V2R) and β2 adrenergic receptors 
(β2R) (Tohgo et al., 2003). The wild-type V2R formed a stable complex with β-
arrestin whereas the wild-type β2R formed a transient complex. However, when the 
c-terminal tails were exchanged, the complexes formed corresponded to the level of 
β-arrestin binding. It was shown that the wild-type V2R generated a larger cytosolic 
pool of phospho-Erk1/2 and a smaller amount of nuclear Erk1/2 than that of the 
chimeric receptor. In addition, the chimeric V2R was able to elicit a mitogenic 
response unlike the wild-type receptor.  
 
It may be therefore that a cytosolic pool of Erk1/2 has non-nuclear substrates and 
thus differing roles to that of an Erk1/2 pathway generated where β-arrestin is not 
involved. Fig. 1.13 shows the possible mechanisms involved in the activation of 
Erk1/2 via a mechanism involving β-arrestin. 
 
These mechanisms of Erk1/2 activation are of relevance to the MC2R since our lab 
has previously demonstrated that the MC2R is internalised via a clathrin coated pit 
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mechanism in Y1 cells (Baig et al., 2001). This raises the possibility that 
internalisation may be a pre-requisite for Erk1/2 signalling by ACTH.  
 
 
 
 
Fig. 1.13  Binding of an agonist to its receptor leads to activation of its classical 
second messenger pathway. GRK phosphorylates agonist occupied receptors on their third 
intracellular loop and c-terminal domains and this increases receptor affinity to β-arrestins. Following this 
β-arrestin recruits components of the clathrin-dependent endocytic machinery and allow internalisation to 
occur. β-arrestins also recruit components of the Erk1/2 pathway resulting in its activation. 
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1.9  THESIS AIMS 
 
Although much work has been undertaken in the past to establish the proliferative 
and non-proliferative roles of ACTH on the adrenal gland, there is only limited data 
available on the mechanisms behind these responses. Studies in the Y1 
adrenocortical cell line have established that the Erk1/2 pathway is activated in 
response to ACTH and that this response may lead to a proliferative effect over 
short exposure times (Lotfi et al., 1997) however the mechanisms that lead to 
initiation of this pathway are as yet uncharaterised. Studies with other GPCRs have 
revealed interesting and complex mechanisms of activation of MAPK pathways 
including transactivation of growth factor receptors, cross-talk with other signalling 
pathways and the requirement of β-arrestin for Erk1/2 signalling. It is the aim of this 
thesis therefore to investigate the mitogenic signalling mechanisms initiated in 
adrenal cells in response to ACTH in order to give a clearer understanding of the 
regulation of adrenal growth, and to contribute to the expanding field of GPCR 
induced mitogenic signalling. 
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2  MATERIALS AND METHODS 
 
Laboratory reagents were supplied by Sigma-Aldrich (Poole, UK) unless otherwise 
stated. Chemicals were all certified as analytical grade. Plasticware was purchased 
from Greiner Bio-one Ltd (Gloucestershire, UK) unless otherwise stated. Ultra 
pure water (dH2O) was obtained using the Purite Select Analyst HP water purifier, 
and used when making all solutions. Where sterility was required, solutions were 
autoclaved using (Priorclave tactrol 2) or filtered through a 0.2 µm membrane 
(Nalgene).  
2.1 GENERAL BUFFERS AND SOLUTIONS 
 
PBS - 0.2g/L KCl, 0.2g/L KH2PO4 (anhydrous), 8.0g/L NaCl, 1.15g/L Na2HPO4 
(anhydrous), pH 7.4 (Sigma) 
 
Phenol - Add 10ml of equilibration buffer (10mM Tris pH 10 - Sigma) to 100ml of 
equilibrated phenol (pH6.7) (Sigma) to adjust to pH 7.9. Add 8-Hydroxyquinoline 
to final concentration of 0.1%. Store in the dark at 4ºC. 
 
3M Sodium Acetate - Dissolve 40.8g of sodium acetate.3H2O in 80ml of H2O. 
Adjust to pH5.2 with glacial acetic acid, make up to a final volume of 100 ml and 
autoclave. 
 
TE - 10mM Tris pH 8.0, 1mM EDTA 
 
TAE (50x) - 2M Tris-acetate and 100mM Na2EDTA (pH 8.3 at 1x conc.) 
(National Diagnostics, UK) 
 
6X loading dye - 0.5mM EDTA, 40% sucrose, 0.25% Orange G. 
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RNAase free dH2O - Diethyl pyrocarbonate (DEPC) was added to dH2O to a 
final concentration of 0.1 % and incubated overnight in a fume cupboard prior to 
autoclaving. 
 
Ethidium bromide - Dissolve 0.5g ethidium bromide in 50ml of 0.1M EDTA 
solution and store at RT in a light sealed container. 
 
dNTPs - 100 mM dNTPs (New England Biolabs, MA, US) were combined in a 
1:1:1:1 ratio of dATP:dCTP:dGTP:dTTP and diluted in dH2O to make a 10 mM 
stock solution which was stored at –20 °C. 
 
Tris buffers – Solutions of 1 M Tris-OH and 1 M Tris-HCl were prepared. To 
prepare a solution of Tris buffer at a particular pH, the two solutions were mixed at 
the appropriate ratio according to the table 2.1 and pH confirmed using a calibrated 
pH meter. 
 
 
Table 2. 1  Ratios Tris-HCl to Tris-OH for required pH.
pH 1 M Tris-HCl 1 M Tris-OH
6.8 969 31
7.2 889 111
7.3 867 133
7.4 837 163
7.5 804 196
7.6 767 233
7.7 724 276
7.8 673 327
7.9 618 382
8.0 562 438
8.1 509 491
8.2 448 552
8.3 389 611
8.4 334 666
8.5 208 792
8.6 232 768
8.7 190 810
8.8 156 844
8.9 122 878
9.0 96 904
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2.2  CELL CULTURE 
 
All work involving the culture of cells was carried out in a class II sterile cell culture 
hood. Hoods were regularly cleaned with virkon (Antec International, Sudbury, 
UK) and sprayed down with 70 % ethanol before and after use. All sterile culture-
ware was purchased from Greiner unless otherwise stated. Other laboratory plastic-
ware and media was autoclaved prior to use and opened only in the cell culture 
hood. Gloves were worn at all times during cell culture procedures. All cells were 
incubated in a humidified Sanyo MCO-17A/C incubator (Jencons-PLS, East 
Grinstead, UK) at 37 °C and 5 % CO2.  
2.2.1 Maintenance and sub-culture of H295R cells 
 
Solutions: 
 
• Dulbecco’s Modified Eagle’s Medium (DMEM) – 4500 mg/L glucose, 
0.584 g/L L-Glutamine, 3.7 g/L NaHCO3  (Sigma #D5796) 
• F12 nutrient media (Ham) – 1802 mg/L glucose, 0.146 g/L l-glutamine, 
1.18 g/L NaHCO3 (Gibco, Paisley, UK) 
• Penicillin/Streptomycin – formulated to contain 10,000 units/ml 
penicillin and 10 mg/ml streptomycin in 0.9% sodium chloride (Sigma) 
• ITS (100 x) – 1 mg/ml insulin, 0.55 mg/ml human transferrin, 0.5 µg/ml 
sodium selenite, 50 mg/ml bovine serum albumin and 0.47 mg/ml linoleic 
acid (Sigma #I3146) 
• Trypsin-EDTA 1x Solution (T/E) – 0.5 g/L of trypsin and 0.2 g/L 
EDTA.4Na in Hanks’ balanced salt solution (Gibco). 
 
Where serum free medium was required, a 1:1 mix of DMEM and F12 was made 
with the addition of 10 ml/L of penicillin/streptomycin solution. Fully 
supplemented media contained a 1:1 mix of DMEM:F12, 10 ml/L 
penicillin/streptomycin, 10 % foetal bovine serum (FBS – Gibco) and 1 X ITS 
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solution. H295R cells were grown in fully supplemented media, which was replaced 
every three days. Cells were not allowed to reach confluence but were passaged 
when around 80 % confluent. Passaging of cells involved aspirating the media and 
then washing the cells in pre-warmed PBS. Cells were then incubated in 3 ml 
trypsin solution for 3 min at 37 °C. The flask was then gently tapped to release the 
cells from the plastic surface and allow them into solution. An equal volume of fully 
supplemented medium was added to inactivate the trypsin and the solution pipetted 
up and down in order to fully disperse the cells.  This solution was then diluted 1 in 
5 into new cell culture flasks. 
2.2.2 Maintenance and sub-culture of Y1 adrenocortical cells 
 
Y1 cells (ATCC, US) were maintained in a 1:1 mix of Ham’s F10 (Gibco) and 
DMEM (Sigma) with the addition of 2 mM Glutamine, 10 ml/L 
penicillin/streptomycin solution and 15 % heat-inactivated horse serum and 2.5 % 
heat inactivated FBS (Gibco). Media was changed every 3 days and cells were 
passaged 1 in 10 when 80 % confluent. 
 
2.2.3 Maintenance and sub-culture of primary bovine adrenal cells  
(SBACs) 
 
SBACs (ECACC) were maintained in Ham’s F12 media containing 500 pg/ml 
recombinant FGF (Sigma), 2 mM Glutamine, 10 ml/L penicillin/streptomycin 
solution and 10 % heat inactivated FBS (Gibco). Media was changed every 3 days 
and sub-confluent cells were passaged 1:3 to 1:6. 
 
2.2.4  Maintenance and sub-culture of immortilised bovine adrenal cells 
 
Immotalised bovine adrenal cells (a kind gift from P. J. Hornsby) were maintained 
in a 1:1 mix of Ham’s F12 and DMEM media containing 100 pg/ml recombinant 
FGF, 2 mM Glutamine, 10 ml/L penicillin/streptomycin solution, 10 % heat-
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inactivated horse serum and 10 % heat inactivated FBS. Cells were seeded onto 
collagen coated plates (see section 2.2.7) and sub-confluent cultures were passaged 
1:3 to 1:6. 
2.2.5  Storage of cells 
 
Solutions: 
 
• Freezing medium - 90 % FBS and 10 % DMSO  
 
In order to keep stocks of cells for long-term storage, cells were frozen in liquid 
nitrogen. Cells were trypsinised as previously described and pelleted in 15 ml 
polypropylene tubes by centrifugation at 100 g for 5 min. The supernatant was 
aspirated and the pellet resuspended in the required volume of freezing medium. 
Cells were pipetted into 2 ml cryogenic vials (Nalgene), wrapped in bubble wrap (to 
ensure a slow freezing process) and transferred to the –80 °C freezer overnight. 
The next day tubes were transferred to liquid nitrogen for long-term storage.  
  
2.2.6  Thawing cells 
 
Vials were removed from liquid nitrogen storage and quickly thawed in a 37 °C 
waterbath.  Cells were plated in warm, fully supplemented medium. The next day, 
after the cells had adhered, the medium was changed for fresh fully supplemented 
medium in order to remove DMSO. 
 
2.2.7  Collagen coating of plates 
 
Solutions: 
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• Collagen solution – 1 mg/ml collagen in 0.1 N acetic acid (Sigma 
#C8919) 
 
In some circumstances it was necessary to facilitate attachment of H295R cells to 
plasticware by coating plates with collagen. Collagen solution was diluted 1:100 in 
sterile dH2O and pipetted onto cell culture plates so that the entire area was just 
covered. The solution was left on overnight at room temperature. The next day, the 
solution was aspirated and the plates dried at 37 °C for 2 hours or overnight at 
room temperature. Plates were washed twice with PBS prior to use. 
 
2.3  TRANSFECTION OF CELLS 
2.3.1  Transient transfection of H295R cells 
 
H295R cells were transiently transfected using the FuGENE 6 Transfection 
Reagent (Roche, UK). This lipid based reagent forms complexes with DNA and 
then transports it into cells. To ensure the highest possible protein expression, the 
optimal ratio of FuGENE 6 reagent to DNA was determined, utilising the renilla-
luciferase assay system (Promega, UK). In this system, a Renilla expression plasmid 
is transfected into cells and transfection efficiency is quantified in an assay where 
the substrate coelenterazine is converted to coelenteramide + light catalysed by 
renilla luciferase.  
 
H295R cells were transfected in 6 well plates when they were 50-70 % confluent. 
Various ratios of FuGENE to Renilla DNA were tested according to the 
manufacturers guidelines. Complexes were pre-formed in a tube by adding serum 
free medium (SFM) followed by FuGENE followed by DNA, where the final 
volume was 100 µl. The cells were washed twice in SFM and the pre-formed 
complexes added. After 4 h, FBS was added to the wells to give a final 
concentration of 10 %. The transfection reagent remained in the culture dish until 
the cells were harvested 48 h later. 
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Cells were harvested and assayed according to the instructions given by Promega. A 
BioOrbit 1253 luminometer was used to measure luciferase activity. The optimal 
ratio of FuGENE to DNA was found to be 6 µl FuGENE to 1 µg DNA when 
transfecting a well of a 6 well plate. These amounts were scaled up or down 
depending on the surface area of the culture dish. Where more than one expression 
plasmid was transfected, the total amount of DNA remained the same. Generally, 
where Renilla luciferase was used to control for transfection efficiency, only one 
tenth of this plasmid was transfected compared to co-transfected plasmids to 
ensure that all cells expressing Renilla would also be likely to be expressing the co-
transfected plasmid(s). 
 
2.3.2  Stable transfection 
 
Solutions: 
 
• G418 (100 mg/ml) – 1 g of geneticin (Sigma #A1720) was dissolved in 10 
ml dH2O and sterile filtered through a 2 µm filter. 
 
Stable H295R cell lines were produced by transfecting constructs containing a 
neomycin resistance gene, and cells expressing the construct were preferentially 
selected based on their ability to grow in media containing G418. Colonies of cells 
expressing the constructs were isolated individually and expanded. To determine 
the concentration of G418 in which to select, a kill curve was performed in which 
untransfected cells were grown in media containing a range of concentrations of 
G418 from 0.1-1 mg/ml. The minimum concentration that caused complete cell 
death in 7 days was selected and for H295R cells this was found to be 500 µg/ml. 
 
H295R cells that were 50 % confluent were transfected in 9 cm dishes, overnight, 
using FuGENE as previously described. For each stable transfection, a mock 
transfection (one which contained no DNA) was carried out. The next day, the 
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media was aspirated and replaced with G418 containing media. This was changed 
every three days resulting in the eventual death, over 7 days, of most of the cells. 
Cells that were expressing the construct were resistant to G418 and started to form 
in isolated colonies by around two weeks. These colonies were likely to be specific 
if the mock-transfected plate of cells were completely dead.  
 
2.3.2.1  Monoclonal cell lines 
 
When the colonies were approximately 2 mm in diameter, 3 ml of trypsin was 
added to the dish and incubated for 3 min at 37 °C. The trypsin was then aspirated 
without disturbing the cells and colonies harvested by pipetting around 10 µl of 
medium onto the colony and then aspirating the colony. For each construct 10-20 
colonies were isolated and plated into individual wells of a 96 well plate. Cells were 
pipetted up and down in order to disperse them. Cells were progressively moved 
into larger culture dishes by trypsinisation when they had reached near confluence. 
To confirm that the cells were expressing the desired construct, RNA was extracted 
from the cells and an RT-PCR carried out with a forward primer designed to the 
plasmid polylinker and the reverse primer to the gene encoded within the plasmid.   
 
2.3.2.2  Polyclonal cells 
 
Once the mock transfected cell had died, a polyclonal stable cell line could be 
obtained by passaging the plasmid transfected cells. Cells were maintained as usual 
in G418 containing medium. 
 
2.4  TREATMENT OF CELLS WITH INHIBITORS 
 
H295R cells were plated into 6 well plates and when around 70 % confluent were 
washed once in SFM and left subsequently in SFM overnight. The next day, 
inhibitors were added in SFM to the indicated concentrations, one hour (unless 
otherwise stated) prior to adding a 10x stock of the appropriate stimulant for the 
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times indicated. Cells were harvested as described for Western blotting or cAMP 
assays. 
 
2.5  MANIPULATION OF DNA AND RNA 
2.5.1  Agarose gel electrophoresis 
 
Nucleic acids were separated according to their size using the Sub-Cell GT® 
Agarose Gel Electrophoresis System (BioRad). An appropriate amount of agarose 
(Sigma #A9539) was dissolved in 1 X TAE to make a final concentration of 1% - 
2% (w/v) depending on the size of the fragment to be visualised. Agarose solution 
was heated until it had completely dissolved before adding ethidium bromide 
solution to a final concentration of 0.1 µg/ml. The agarose was poured into the 
moulding apparatus and left to set. Samples were loaded with Orange G loading dye 
(6x) and electrophoresed in 1 x TAE buffer at 120 V for around 30 min alongside 
0.5 µg GeneRulerTM 1kb DNA ladder (MBI Fermentas). The gel was visualised on a 
UV light box and the Kodak EDAS 120 digital camera system (Gibco). For agarose 
separation of RNA see section 2.4.8. 
 
2.5.2  Nucleic acid quanitification 
 
The concentration and purity of a nucleic acid preparation was determined using 
the GeneQuant RNA/DNA calculator (Pharmacia Biotech). A sample was 
appropriately diluted and its OD260 measured in a glass cuvette. An OD260 of 1 
corresponds to approximately 50 µg/ml for double stranded DNA and 40 µg/ml 
for single stranded DNA and RNA. Thus the following formula was used: 
 
OD260 x f x d = concentration of nucleic acid (µg/ml) 
 
Where:            OD260 = optical density of the sample at 1 cm path length 
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f = 40 for RNA or 50 for DNA  
d = dilution factor of sample   
 
The purity of a nucleic acid sample could be ascertained by determining the ratio of 
OD260/OD280. Pure preparations of DNA and RNA have a ratio of 1.8 and 2.0 
respectively. These values were much reduced when there was contamination with 
either phenol or protein. 
 
2.5.3  Phenol Extraction and Precipitation 
 
In order to purify a DNA or RNA sample from contaminating proteins, for 
example from an enzymatic reaction, samples were first phenol extracted followed 
by ethanol precipitaion. An equal volume of phenol to sample was added and 
vortexed vigorously for 2 min. The tube was centrifuged at 12,000 g for 2 min to 
separate the aqueous from the organic phase. RNA was partitioned in the aqueous 
phase whereas contaminating proteins associate with the organic phase. The 
aqueous phase was carefully transferred to a fresh microcentrifuge tube for ethanol 
precipitation.  
 
1/10 of the volume of 3 M sodium acetate, pH 5.2, 2.5 times the volume of 
absolute ethanol and approx. 20 µg glycogen (Ambion, UK) was added to the 
nucleic acid sample. This solution was vortexed briefly and left on dry-ice for 15 
min. The solution was centrifuged at 12,000 g for 10 min to pellet the precipitated 
nucleic acid. The supernatant was removed and discarded and the pellet washed 
with 1 x volume of 70 % ethanol. The sample was centrifuged again for 2 min, the 
ethanol aspirated and the pellet allowed to air dry for 10 min. The pellet was then 
resuspended in an appropriate volume of dH2O. 
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2.5.4  Amplification of plasmid DNA 
 
To amplify plasmid DNA, bacterial cells were made to take up plasmid DNA and 
those that contained the plasmid were selected based on their ability to grow on 
agar plates containing antibiotics. These bacteria could then be expanded in culture, 
and plasmid DNA extracted from these bacterial cells. 
 
Solutions: 
 
• LB - 10 g of LB (Sigma #L-3022) was dissolved in 500 ml dH2O and 
autoclaved 
• LB Agar - 10g of LB and 7.5 g of Agar (Sigma #A-5054) was made up to 
500 ml in dH2O and autoclaved. This could be allowed to cool to 50°C and 
then used to pour plates or could be allowed to cool completely and melted 
in the microwave when required 
• Ampicillin stock solution (Sigma #A-9518) - 1 g of ampicillin was 
dissolved in 10 ml of dH2O to give a 100 mg/ml stock solution and stored 
at 4 °C until required 
 
2.5.4.1  Pouring Agar plates 
 
Ampicillin stock solution (or another appropriate antibiotic) was added to melted 
LB agar (at no higher than 50 °C) to a final concentration of 100 µg/ml. Around 20 
ml of this solution was poured into each 90 mm sterile petri dish in a sterile 
environment, and the agar left to solidify. Dishes could be wrapped in parafilm and 
stored at 4 °C for up to one month.  
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2.5.4.2  Plasmid transformation 
 
JM109 Competent Cells (>108cfu/µg, Promega #L2001) were thawed on ice for 5 
min and then 50 µl of cells were aliquoted into sterile microcentrifuge tubes (one 
per transformation reaction). 1-50 ng of plasmid DNA was added, mixed and 
incubated on ice for 10 min. Cells were then heat-shocked at 42 °C for 50 s and 
returned immediately to ice for a further 2 min. 950 µl of SOC medium (Invitrogen 
#15544-034) was added and the cells incubated for 1 h at 37 °C with constant 
shaking. Cells were then pelleted by centrifugation at 6000 g and resuspended in 
100 µl of SOC medium. This was spread onto an agar/ampicillin plate using a 
sterile glass spreader and incubated overnight at 37 °C. 
 
2.5.4.3  Amplification and preparation of plasmid DNA 
 
A sterile wire loop was used to pick an individual colony from the agar plate and 
innoculate a solution of LB containing 100 µg/ml ampicillin. This was grown 
overnight at 37 °C in a shaking incubator. Depending on the volume of culture, 
plasmid DNA was extracted using a Qiagen mini or midi kit according to the 
manufacturers instructions. Briefly, cells were pelleted by centrifugation at 3000 g 
for 10 min. Supernatant was removed and the pellet resuspended in the supplied 
resuspension solution. Lysis buffer was added and the cells were left on ice for 5 
min prior to the addition of neutralisation buffer. Lysates were passed through spin 
columns containing Qiagen Anion-Exchange Resin in a low salt buffer. A series of 
wash buffers were passed through the column before eluting the plasmid DNA. 
2.5.5  Extraction of RNA from cultured cells 
 
Solutions: 
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• RLN buffer: 5mM Tris-HCL, pH8, 140mM NaCl, 1.5mM MgCl2, 0.5% 
(v/v) Nonidet P-40, 1000 U/ml RNase inhibitor, 1mM DTT (added fresh). 
This was made with RNAse free dH2O. 
• RLT buffer: As supplied but with the addition of 10µl/ml of β-
mercaptoethanol prior to use. 
For the isolation of RNA from cultured cells, RNAase free tips were used with all 
reagents. To avoid contamination of RNA with genomic DNA, the method of 
cytoplasmic RNA extraction was used thus yielding a sample that contained only 
mRNA that had been exported from the nucleus. The Qiagen RNeasy Mini kit 
was used for this procedure according to the manufacturers protocol. To extract 
RNA from approximately 1 x 107 cells, the cells were first scraped in 1 ml of ice-
cold PBS, transferred to a microfuge tube and pelleted at 13,000 g for 15 s in a 
microcentrifuge. The PBS was aspirated and the pellet resuspended in 175 µl of 
cold RLN buffer and incubated on ice for 5 min to lyse the cells. The lysate was 
centrifuged at 300 g at 4 °C for 2 min to pellet the nuclei. The supernatant was 
transferred to a new tube and 600 µl of RLT buffer added. Since RNA is rapidly 
degraded by RNAases that are present within the cell, a combination of both β-
mercaptoethanol, a reducing agent, and guanidine salt, a potent denaturing agent are 
essential to allow isolation of intact RNA. These agents are both present in RLT 
buffer.  430 µl of absolute ethanol were added and the lysate applied to an RNeasy 
column where RNA selectively binds to the silica-gel membrane. A series of wash 
steps using the supplied buffers removed any contaminants prior to eluting with 50 
µl dH2O. 
 
2.5.6  DNase I digestion 
 
Although isolation of cytoplasmic RNA should reduce genomic DNA 
contamination, DNase digestion was also carried out as an extra measure. A 
reaction containing 2 µg RNA, 1 x transcription optimised buffer (Promega), 30 
Units RNasin (Promega #N211A) and 208 U DNase I (0.75 µl)(Sigma #D-7291) 
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made up to a final volume of 15 µl, was incubated at 37 °C for 15 min. The 
reaction was terminated by the addition of 100 µl of TES (10 mM Tris-HCl, pH 8, 
1 mM EDTA and 0.1 % w/v SDS). RNA was then phenol extracted and 
precipitated as described previously.  
 
2.5.7  Agarose gel electrophoresis of RNA 
 
Since RNA degrades very rapidly, the gel tank, combs and moulding apparatus were 
soaked for 1 h in a solution of 0.1M NaOH and 1mM EDTA and rinsed in 
RNAase free dH2O prior to running the gel. 
 
To assess the quality of an RNA preparation, a small amount of sample was 
separated on a 1 % non-denaturing agarose gel and visualised. Ribosomal RNA 
(rRNA), the most abundant type of RNA in the cell, could be seen to run as two 
sharp bands of 28S and 18S rRNA. The 28S rRNA was approximately twice as 
bright as the 18S rRNA for good quality RNA. 
2.5.8  Reverse Transcription 
 
First strand synthesis of cDNA from mRNA is catalysed by the enzyme RNA-
dependent DNA polymerase or reverse transcriptase (RT). In order to initiate DNA 
synthesis, this enzyme requires an RNA or DNA primer.  
 
First, a reaction containing 2 µg of RNA, 0.5 µg/µl of random primers (Promega 
#C118A) and RNAase free dH2O up to a final volume of 12 µl was incubated at 70 
°C for 4 min to allow binding of the random hexamers throughout the mRNA. The 
tubes were immediately returned to ice for 3 min before adding 8 µl of the RT 
reagents as follows: 
 
• 1 µl of 10 mM dNTP mix (final concentration of 0.5 mM) 
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• 1 µl M-MLV (Moloney murine leukaemia virus RT, Promega) (200 U) 
• 1 µl RNasin ribonuclease inhibitor (20 U) 
• µl 5 X M-MLV RT buffer (Promega) 
• 1 µl dH2O (RNase free) 
 
This was added to the RNA/random primer mix and incubated at 37 °C for 1 h 
and the resulting cDNA stored at –20 °C until required. RT enzyme was omitted 
from one reaction to serve as a negative control for genomic DNA contamination 
in the subsequent PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as a general house-keeping gene to compare the amount of cDNA in each 
sample by PCR (see list of primers, table 2.2) 
 
2.5.9  Polymerase chain reaction (PCR) 
 
The PCR reaction is used to amplify a segment of DNA that lies between two areas 
of known sequence catalysed by the enzyme DNA polymerase. Two 
oligonucleotides that flank the region of interest and that are complimentary to 
sequences that lie on opposite strands of the DNA are synthesized. The template is 
first denatured by heating to 95 °C and then cooled to a temperature that is optimal 
for the annealing of the oligonucleotide primers (which are in excess). After this, 
DNA polymerase extends the annealed primers in the presence of excess of the 
four dNTPs. This cycle is repeated and, since each new product can serve as a 
template for the next cycle, there is a doubling in quantity of the desired DNA 
fragment with each cycle. The DNA polymerase used in the reaction is derived 
from the thermophilic bacterium, Thermus Aquaticus and this is used because it is not 
denatured at high temperatures. 
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Target Forward (5’ to 3’) 
 
Reverse (5’ to 3’) Ta 
(°C) 
Amplicon 
size 
GAPDH  TGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTC 55 198 
hGRK2 GTGATCAGGAGCTCTACCGC GCTATCGCACTGCAAAATGA 55 407 
hGRK3 CTTCTGAGAGGTCACAGCCC CAGCGTTCAGAGATGACCAA 55 401 
hGRK4 GAAAGGCAACCCGTAACAAA TGCCCAGGTTGTAAATGTGA 55 310 
hGRK5 CCTGGGCTGGAGTGTTACAT AGAGGATCTCTGCCGCATAA 55 667 
hGRK6 CGAGAACATCGTAGCGAACA GGTGTTTTTGGTCACTGGCT 55 547 
hDyn 1 CGAGCTGGCTTACATGAACA CACGGTCTTGTTGACAATGG 55 589 
hDyn2 GGACTTACGACGGGAGATCA TCTGCTCCGTGTTGAAGATG 55 635 
hßarr1 GCCTCTAGCACCCTGTTGAG CCTTGTCATCCTTCATGCCT 55 286 
hßarr2 TGGAGCTGCCTTTTGTTCTT TCATCCTTCATCCCCTTCAG 55 193 
GRK 
stable 
TAATACGACTCACTATAGGG CCTCTGTCTCCAGCTTCTCG 55 343 
Dyn 
stable 
TAATACGACTCACTATAGGG AGTGACTCGGTCGGTCTCAG 55 400 
ßarr 
stable 
CCTCATGTCGGACAAGCC TCCACAGCCACGTCACCG 60-50 
TD 
482 
 
Table 2.2 Primers. Primer sequences, annealing temperatures used and size of 
resulting amplicon. TD (touch down). 
 
2.5.9.1 Designing primers 
 
Where possible primers were designed as intron spanning. The full intron/exon 
sequence of the gene of interest was obtained from www.ensembl.org, and forward 
and reverse primers designed so that the product would span at least two exons. 
Generally, a product size of between 200 and 400 base pairs (bp) was favoured to 
increase the chances of the PCR working on the first occasion. To design the 
primers, a few guidelines were followed: 
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• One or more G or C residues were included at the 3’ end of the primer to 
increase binding efficiency 
• The primers were made at least 18 bp long to minimize secondary 
hybridisation 
• Long stretches of single bases were avoided, especially G or C 
• Primers with secondary structure were avoided 
• Primers that could hybridize to form dimers were avoided 
• Ideally, primers with melting temperatures (Tm) of between 55 °C - 65 °C 
were designed 
 
Alternatively, PCR primer pairs were designed using Biology Workbench software. 
Primers were synthesized by Sigma-Genosys. 
 
2.5.9.2 PCR Reaction 
 
• PCR buffer (10x) (Sigma #D6677): 100mM Tris-HCl pH 8.3, 500mM 
KCl, 15mM MgCl2 
 
The following reagents were combined in PCR tubes (Abgene): 
 
µl                 Reagent                                                             Final concentration 
2.5               10x PCR buffer                                                   1x 
0.5               dNTPs (10 mM)                                                  0.2 mM 
0.25             Taq DNA polymerase (5u/µl, Sigma #D56677)  1.25 U 
0.5               forward primer (10 mM)                                      0.2 mM 
0.5               reverse primer (10 mM)                                       0.2 mM 
X                 Template cDNA                                                  50-200 ng 
dH2O made up to a final volume of 25 µl 
 
Thermal cycling was performed in a GeneAmp® PCR System 9700 (Applied 
Biosystems). Cycle number and annealing temperature (Ta) were optimised for each 
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primer pair. However, the Ta could be estimated by multiplying the number of G 
/C residues by 4 and the number of A/T residues by 2 and adding the two 
numbers together. Extension times were 1 min/kb of product. 
 
2.6  HARVESTING CELLS FRACTIONS 
2.6.1  Harvesting cell lysates 
 
Solutions: 
 
• 10x Cell lysis buffer - 200 mM Tris pH 7.5, 1.5 M NaCl, 10mM EDTA, 10 
% Triton X-100 
• Protease inhibitor cocktail (Sigma #P-8340) - 104 mM AEBSF, 0.08 mM 
Aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, 1.4 mM E-
64 in DMSO. Added to lysis buffer at a dilution of 1:1000.   
• Phosphatase inhibtor cocktail I (Sigma, #P-2850) - phosphatase 
inhibitors in DMSO. Added to lysis buffer at 1:100. 
• Phosphatase inhibtor cocktail II (Sigma, #P-5726) - phosphatase 
inhibitors in DMSO. Added to lysis buffer at 1:100. 
• 1x Cell lysis buffer - 1 x cell lysis buffer with protease and phosphatase 
inhibitor cocktails added just prior to use. 
 
Cell plates were placed on ice and the culture medium aspirated. Cells were washed 
once in ice-cold PBS before adding an appropriate volume (100 µl for a well of a 6 
well plate) of 1 x cell lysis buffer with additives, and incubated on ice for 5 min. 
Lysates were transferred to microcentrifuge tubes and left on ice for a further 15 
min with intermittent vortexing. Cell debris was removed by centrifugation at 
13,000 g for 3 min at 4 °C, and the supernatant frozen at –80 °C until required. 
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2.6.2  Preparation of nuclear extracts 
 
Nuclear proteins were extracted using Nonidet P-40 mediated cytoplasmic lysis 
(Whiteside et al., 1992) adapted from original protocol (Dignam et al., 1983). 
 
Solutions: 
 
• Buffer A - 10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT, protease inhibitor cocktail (DTT and protease inhibitors were added 
just prior to use). 
• Buffer C - 20 mM Hepes pH 7.9, 25 % (v/v) glycerol, 0.42 M NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, protease inhibitor cocktail (DTT 
and protease inhibitors were added just prior to use). 
 
The following volumes were suitable for cells in a well of a 6 well plate. Cells were 
washed in ice-cold PBS and then scraped in 1 ml of PBS and transferred to a 
microcentrifuge tube. Cells were pelleted by centrifugation for 15 s at 13,000 g. All 
remaining PBS was aspirated and the cell pellet resuspended in 400 µl buffer A. 
This solution was incubated on ice for 5 min to allow the cells to swell. 5 µl of 10 
% Nonidet P-40 was added to lyse the plasma membrane, and the tube immediately 
mixed. The solution was centrifuged for 30 s at 13,000 g to pellet the nuclei. The 
supernatant (cytoplasmic fraction) was stored at –70 °C if required. The nuclear 
pellet was resuspended in 25 - 50 µl of buffer C and nuclear proteins extracted by 
vigorous shaking at 4 °C for 1 h. The solution was centrifuged for 10 min at 13,000 
g and at 4 °C and the supernatant retained as pure nuclear protein. 
 
2.7  IMMUNOPRECIPITATION 
 
Lysates were precleared using around 0.5µg of a nonspecific antibody and 25µl (bed 
volume) protein A/G agarose beads (Roche) for 30 mins at 4°C on a rotating 
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wheel. The mixture was then centrifuged for a few seconds at 10,000 g and the 
beads discarded. 0.5µg of the primary antibody of interest was then added to the 
solution and incubated again at 4°C on a rotating wheel over night. Protein A/G 
beads (50µl bed volume) were then added for a further 1 hour incubation under the 
same conditions. The sample was centrifuged and the beads retained and washed in 
ice cold lysate buffer a further 3 times (with centrifugation and retaining of the 
beads on each occasion). Finally, bound proteins were dissociated from the beads 
by the addition of SDS sample buffer (see below for recipe) and heating of the 
sample for 5 mins at 95°C. Samples were subsequently anaylsed by SDS-
polyacrylamide gel electrophoresis (see 2.6). 
 
2.8  SDS - POLYACRYLAMIDE GEL ELECTROPHORESIS  
 
Solutions: 
 
• 10 x Tris-glycine - 0.25 M Tris base, 2 M glycine  
• 3X SDS Sample Buffer - 187.5mM Tris-HCl pH6.8 at 25°C, 6% SDS 
(w/v), 30% glycerol (v/v), 150mM dithiothreitol (DTT), 0.03% 
bromophenol blue (w/v).  
 
Denaturing polyacrylamide gel electrophoresis was carried out using the mini-
protean II system (Biorad) and Tris-HCl ready gels (Bio-rad). Samples were 
prepared by adding an appropriate volume of 3 x SDS sample buffer to make a 1 x 
solution and subsequently denaturing the proteins by heating at 95 °C for 5 min. 
Samples were then loaded on to the gel and run alongside 10µl of 10-250 kDa Full 
Rainbow Molecular Weight Markers (Amersham). Gels were electrophoresed in 1 x 
Tris-glycine buffer with 0.1 % SDS for 1 h at 120 V. Gels were then subjected to 
Western Blotting. 
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2.9  WESTERN BLOTTING 
 
Solutions: 
 
• Blotting buffer - 1 x Tris-glycine (pre-chilled) 
• 10 x Tris-buffered saline (TBS) - 0.2 M Tris pH 7.6, 1.46 M NaCl 
• Wash buffer - 1 x TBS, 0.1 % (v/v) tween 20 
• Blocking buffer - 5 % Marvel in wash buffer 
 
The mini-protean II system was used for the transfer of fractionated proteins in the 
gel to a PVDF membrane to allow for probing with antibodies. Gels were removed 
from the apparatus and soaked in blotting buffer. Sponge pads, provided with the 
system were also pre-soaked in blotting buffer along with 2 pieces per gel of 3mm 
Whatman filter paper (pre-cut to the same size as blotting pads). Hybond PVDF 
membrane (Amersham) was soaked for 1 min in methanol prior to soaking in 
blotting buffer. A sandwich containing all these components was created as in Fig. 
2.1. 
 
 
 
 
 
 
 
Fig. 2.1  Assembly of Western blotting components 
 
With each added layer, blotting buffer was poured on to ensure proper transfer. 
Electrophoresis was carried out at 80 V for 1 h in blotting buffer. Following this, 
the PVDF membrane was removed, inserted into a 50 ml tube and incubated in 5 
ml blocking buffer, either overnight at 4 °C or for 1 h at room temperature, on a 
 
-
gel
PVDF
3 mm
Blotting pad
3 mm
Blotting pad
+
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rolling platform. Primary antibody was diluted in blocking buffer (the dilution was 
either recommended by the antibody manufacturer or determined by a dose 
titration) and 5 ml incubated with the membrane, again either over night at 4 °C or 
for 1 – 2 h at room temperature on a rolling platform. Following this, the blot was 
washed for 3 x 10 min in washing buffer, prior to incubation with 5 ml of 
horseradish peroxidase (HRP) labelled secondary antibody for 1 h at room 
temperature. The secondary antibody recognised the species in which the primary 
antibody was raised. Peroxidase labelled rabbit anti-mouse antibodies were from 
Cell Signalling Technology and peroxidase labelled donkey anti-rabbit from 
Amersham. The membrane was washed with 3 x 10 min of washing buffer and 
incubated for 5 min with the ECL Plus Western Blotting Detection Reagent 
(Amersham). This was then drained from the membrane, the membrane wrapped in 
Saran wrap (VWR, UK) and exposed to film (Hyperfilm ECL, Amersham, UK). 
 
2.9.1  Stripping of membranes 
 
Solutions: 
• Stripping buffer - 62.5 mM Tris pH 6.8, 100 mM β-mercaptoethanol, 2 % 
SDS 
 
Membranes were regularly stripped so that they could be reprobed with a different 
antibody. For this, membranes were incubated at 50 °C in stripping buffer for 30 
min with occasional agitation. Membranes were then washed for 3 x 20 min with 30 
ml wash buffer. Membranes could then be blocked and reprobed as described 
previously.  
 
2.9.2  Densitometry 
 
Bands on x-ray film were scanned on an HP ScanJet 6300C scanner. Densitometry 
was then performed using Image J Software with adjacent background sections of 
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the same area subtracted from each band. Each experiment was repeated at least 3 
times. 
 
2.10  ERK1/2 IN VITRO KINASE ASSAY 
 
The Erk1/2 in vitro kinase assay (Cell Signaling Technology) was used to give a 
measure of the activity of phosphorylated Erk1/2 in the sample. The assay was 
carried out according to the manufacturer’s instructions. The following solutions 
were supplied by the manufacturer. 
 
Solutions: 
 
• 10X Kinase Buffer - 1X concentration: 25mM Tris (pH 7.5), 5mM b-
Glycerolphosphate, 2mM DTT, 0.1mM Na3VO4, 10mM MgCl2 
• 10X Cell Lysis Buffer - 1X concentration: 20mM Tris (pH 7.5), 150mM 
NaCl, 1mM EDTA, 1mM EGTA, 1% Triton, 2.5mM sodium 
pyrophosphate, 1mM b Glycerolphosphate, 1mM Na3VO4, 1µg/ml 
Leupeptin 
• ATP - 10mM (50 µl) 
• Immunoprecipitation antibody - Immobilized Phospho- p44/42 MAP 
Kinase (Thr202/Tyr204) Monoclonal Antibody: 
• Primary antibody - phospho-Elk-1 (Ser383) antibody (rabbit polyclonal 
IgG, affinity purified) 
• Substrate - Elk-1 Fusion Protein: GST fused to Elk-1 codons 307–428.  
 
Briefly, Cells were appropriately treated and then to harvest, the media was 
aspirated and washed once with ice-cold PBS. 200 µl of ice-cold 1X cell lysis buffer 
containing 1 mM phenylmethylsulfonyl fluoride (PMSF) and plates incubated on ice 
for 5 minutes. Cells were transferred to cold microcentrifuge tubes and sonicated 
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on ice. Lysates were subsequently centrifuged at 10,000 g for 5 minutes at 4°C and 
the supernatant transferred 
to a new tube. Lysates were stored at –80°C until required. 
 
15 µl of immobilized antibody bead slurry were added to 200 µL of cell lysate and  
incubated with gentle rocking overnight at 4°C. Samples were centrifuged at 10,000 
g for 30 seconds at 4°C. Pellets were washed twice 500 µL of 1X cell lysis buffer 
(samples were kept on ice during washes). 
 
Pellets were then washed twice with 500 µL of 1X Kinase Buffer. Pellets were then 
suspended in 50 µl of 1X Kinase Buffer supplemented with 200µM ATP and an 
appropriate quantity of Elk-1 fusion protein. Reactions were incubated for 30 
minutes at 30°C. The reaction was subsequently terminated with 25 µL 3X SDS 
sample Buffer (see 2.8). Samples were vortexed then centrifuged at 10,000g for 30 
seconds. 
 
Samples were analysed according to the western blotting protocol (2.6). Blots were 
probed with the phospho-Elk-1 (Ser383) antibody (rabbit polyclonal) and secondary 
antibody was that described in section 2.6. 
 
2.11  GAL 4-ELK LUCIFERASE ASSAY 
 
In order to quantify the transcriptional activity of MAPK activated in response to 
ACTH, a Gal4-Elk-1 luciferase reporter assay system was used (Roberson et al., 
1995). This system consisted of a Gal4 Elk-1 expression vector encoding the DNA 
binding domain of Gal4 (amino acid residues 1-147) linked to the carboxy-terminal 
transcription activation domain of Elk-1 (residues 307-428) and a 5 x Gal4-E1b-
luciferase (referred to as Gal4-luc) expression vector containing Gal4 binding sites 
upstream of the luciferase gene. On MAPK activation, Gal4-Elk-1 is 
phosphorylated leading to transcription of the luciferase reporter. 
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H295R cells were plated into 6 well plates and transfected as previously described 
(2.3.1) with 0.45 µg Gal4 Elk-1, 0.45 µg Gal4-luc and 0.1 µg Renilla per well. After 
24 hours cells were transferred to SFM and incubated over night. The next day cells 
were treated with 10-7 M ACTH in SFM, SFM alone or medium containing 10 % 
serum for the indicated times. After stimulations cells were transferred back to SFM 
and were left for a total of 6 hours from the beginning of treatment. Cells were 
harvested and luciferase activity assayed using the Dual Luciferase reporter assay 
system (Promega) according to the manufacturer’s instructions. 
 
2.12  PROLIFERATION ASSAY 
 
Solutions: 
 
• MTS/PMS solution - Just prior to use 50 µl of PMS solution (0.92 mg/ml 
in PBS) was added to every 1 ml of MTS solution (0.5 mg/ml in PBS)  
 
Proliferation assays were carried out on H295R cells using the CellTiter 96 
AQueous proliferation assay (Promega). This assay relies on a novel tetrazolium 
compound, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulphophenyl)-2H-tetrazolium, salt) and an electron-coupling reagent, PMS 
(phanazine methosulphate). MTS is reduced by dehydrogenase enzymes in 
metabolically active cells, into a soluble formazan product (Fig. 2). The quantity of 
formazan produced is measured by reading the absorbance at 490 nm, and this 
measurement is proportional to the viable cell number. 
 
In order to increase the sensitivity of the assay, the assay was performed in 12 well 
plates in preference to 96 well plates. Plates were also coated with collagen to 
facilitate adherence of the cells as described previously. Briefly, H295R cells were 
plated so that the next day they were around 30 % confluent. Cells were washed 
twice in SFM and left for 48 h in the incubator to induce growth arrest. Following 
this, cells were treated with appropriate reagents for 72 h. Medium was aspirated 
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and 500 µl of SFM added to each well. 100 µl of MTS/PMS solution was added 
directly to each well and incubated for 1 h at 37 °C and 5 % CO2. 100 µl of each 
well was pipetted into a 96 well plate and the absorbance read at 490 nm on a 
Molecular Devices Kinetic Microplate Reader. There were 6 replicates for each 
treatment and experiments were performed at least three times.       
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2  Structures of MTS tetrazolium salt and its soluble formazan product 
 
2.13  MEASUREMENT OF CELLULAR CAMP  
 
This assay is based on a saturation assay method designed by Brown et al (Brown et 
al., 1971). It is a competitive binding assay that allows the measurement of cAMP 
accumulation in response to ACTH or other stimulators of the cAMP pathway. The 
assay is based on the ability of binding protein, prepared from bovine adrenals, to 
bind cAMP in the sample in competition with a fixed amount of 3H-cAMP. 
Activated charcoal is added to bind to and remove (by centrifugation) unbound 
cAMP, and a proportion of the 3H-cAMP in the remaining sample is counted in a 
scintillation counter. The resultant count is thus inversely proportional to the 
amount of cAMP in the original sample. The principle of the assay is summarised in 
Fig. 2.3. 
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Fig. 2.3 Summary of competitive cAMP assay. A fixed amount of 3H-cAMP is added to a 
sample containing an unknown amount of cAMP. Binding protein competitively binds cAMP and 
sequesters it in solution. Activated charcoal binds to unbound cAMP and is pelleted leaving bound cAMP 
in solution, a proportion of which is counted in a scintillation counter. 
 
2.13.1  Preparation of binding protein 
 
Solutions: 
 
• Buffer – Tris- HCl pH 7.4, 250 mM sucrose, 25 mM KCl, 5 mM MgCl2, 50 
mM 
• 10 bovine adrenal glands 
 
10 bovine adrenal glands were collected as soon as possible after slaughter and 
transported on ice. The fat and connective tissue were removed and the cortices 
separated from the medulla and weighed. This was subsequently finely chopped and 
homogenised in 1.5 volumes (based on the weight of the tissue) of ice-cold buffer. 
The resultant homogenate was filtered through nylon mesh and then centrifuged at 
Sample/standard Add 3H-cAMP Add binding 
protein
Add charcoal 
and centrifuge
Cold cAMP
3H-cAMP
Binding protein
Add to scintillant 
and count
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2000 g at 4 °C for 5 min. The supernatant was centrifuged at 5000 g at 4 °C for 15 
min and the supernatant aliquoted into 1 ml aliquots and stored at –70 °C until 
required. A working solution of binding protein was prepared by diluting 1/10 to 
1/20 in Tris buffer. This dilution was determined for each batch of binding protein 
prepared so that Bo/Total count ratio was 30-50 % (the B0 control is explained 
later). 
 
2.13.2  Stimulating and harvesting of samples 
 
Cells were plated into 6 well plates and grown to around 90 % confluence. Prior to 
stimulation, cells were washed and left in SFM for 1 h. Treatments were carried out 
in 1 ml of SFM in the presence of 1 mM IBMX (Sigma #I5879). To harvest, plates 
were transferred to ice and cells were scraped into their stimulation medium. Cells 
and media were transferred to 1.5 ml microcentrifuge tubes, boiled for 5 min and 
centrifuged at 10,000 g for 5 min. The supernatant was transferred to fresh tubes 
and stored at –20 °C until the cAMP assay was performed. 
 
2.13.3  cAMP assay 
 
Solutions: 
 
• Tris buffer - 50 mM Tris-HCl pH 7.4, 1 mM IBMX, 6 mM β-
Mercaptoethanol. 
• Charcoal solution - Tris buffer containing 5 % (w/v) activated charcoal 
(BDH#332034F), 0.15 % (w/v) bovine serum albumin. This was prepared a 
day before the assay and kept at 4 °C with constant mixing until required.  
• [2,8-3H] cAMP - 1 µCi [2,8-3H] adenosine 3’5’cyclic phosphate NH4 salt 
(35 Ci/mmol, Amersham) was diluted 1:6000 in dH2O and stored at 4 °C 
until required. 
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• Binding protein - prepared as described above and diluted to the working 
concentration 
• cAMP - (Sigma A-4137) reconstituted in dH2O to give a stock solution of 
100 pmol/µl and aliquoted. Stock was diluted to 1 pmol/µl in Tris buffer 
prior to use. 
 
Binding reactions were prepared as follows in 0.5 ml microcentrifuge tubes: 
 
Vol                  Reagent 
100 µl            sample/standard/tris buffer 
50 µl             [2,8-3H] cAMP 
100 µl            Binding protein 
 
Standards were prepared by making serial dilutions of cAMP standard in tris buffer 
between 0.5 and 32 pmol. Samples with unknown amounts of cAMP were 
quantified by assaying alongside these standards. Binding reactions were mixed by 
vortexing and incubated at 4 °C for 1.5 – 2 h. After this time, 200 µl of charcoal 
solution was added to each sample in batches of 16 tubes, vortexed and centrifuged 
at 10,000 g for 7 min. 200 µl of supernatant was added to 4 ml of scintillation fluid 
(Ecoscint A, National Diagnostics) vortexed and counted for 2 min using a Wallac 
D1409 DSA Liquid Scintillation Counter (Perkin Elmer Lifesciences). A number of 
controls were included for each assay: 
 
Non-specific binding: A reaction containing no cAMP and no binding protein 
controlled for the ability of charcoal to remove all of the unbound cAMP in the 
sample. The resultant count was subsequently subtracted from each count.  
 
Total count: Binding protein and cold cAMP were substituted for tris buffer and 
charcoal was not added. This gave a measure of the total 3H-cAMP added to the 
sample. 
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Bo: Sample/standard was substituted with tris buffer to control for the ability of 
binding protein to sequester cAMP in the solution. This was affected by the 
concentration of binding protein, which as mentioned previously, was determined 
for each batch of binding protein so that Bo/Total count ratio was 30-50%. To 
control for each centrifugation step and a possible change in Bo with time, a Bo 
was also included for every 16 tubes. 
 
Samples, standards and controls were assayed in duplicate. After subtraction of 
non-specific binding, each reaction was averaged and expressed as a percentage of 
the Bo. The standard curve was a plot of % Bo for each standard against log10 of 
the cold cAMP concentration. An equation of the line was obtained (via Excel) and 
the amount of cAMP in a sample could be calculated using this equation. 
 
2.14  125I-ACTH BINDING ASSAY 
 
Solutions: 
• 125I-ACTH - 10 µCi [125I] (iodotyrosyl23) ACTH (2000 Ci/mmol 
Phoenix Pharmaceuticals) was reconstituted in 100 µl of dH2O, 
aliquoted and frozen at -20°C until required. 
• Acid glycine - 50mM glycine, 100 mM NaCl, pH 3  
• Wash solution - 0.9 % (w/v) NaCl 
• Lysis buffer - 0.5 M NaOH, 0.4 % (w/v) sodium deoxycholate 
 
A competitive binding assay was performed to determine specific binding of ACTH 
to the surface of H295R cells (Penhoat et al., 1993). Cells were seeded onto 12 well 
plates and when confluent left in SFM for 1 hour. Cells were then washed twice in 
wash solution and then incubated for 10 mins in 500 µl of acid glycine solution to 
remove surface bound ligands. Cells were subsequently washed a further two times 
in wash solution and then incubated with 0.025 pmol of 125I-ACTH with increasing 
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concentrations of “cold” ACTH (10-5-10-12 M) in SFM containing 0.5 % BSA for 60 
mins at 20 °C. After this time, solutions were removed and the cells washed three 
times in ice-cold wash solution. Cells were then lysed in 500 µl of lysis buffer for 10 
mins, and radioactivity assessed by γ counting. A displacement curve was obtained 
where specific binding, expressed as the percentage of total binding where no 
“cold” ACTH was present, was plotted against the concentration of “cold” ACTH. 
 
2.15 125I-ACTH INTERNALISATION ASSAY 
 
Solutions used are the same as those used in the ACTH binding assay (2.14). 
H295R cells were seeded into 12 well plates and when confluent were transferred to 
SFM for 1 hour. Cells were then washed twice in wash solution and then incubated 
in acid glycine for 10 mins. Cells were washed a further two times in wash solution 
before incubation for the indicated times with 0.025 pmol 125I-ACTH in SFM with 
0.5 % BSA (Incubations were started at different times so that all the harvesting 
could be done at the same time). Cells were then placed on ice and washed three 
times in ice-cold wash buffer and incubated in 500 µl of acid glycine on ice for 10 
mins. This fraction was harvested and its radioactivity assessed as the extracellular 
bound ACTH. Cells were washed once more in wash solution and then lysed in 500 
µl of lysis buffer and the radioactivity assessed as the internalised ACTH fraction. 
Results were expressed as the proportion of internalised ACTH (i.e. intracellular / 
(extracellular + intracellular) against time. For the zero time-point, cells were 
incubated on ice for 5 mins (to eliminate internalisation) before the addition of 125I-
ACTH for around 30 seconds. This reading was deducted from all subsequent 
readings to correct for background. Where inhibitors were used, cells were pre-
treated for 1 h in SFM containing 0.5 % BSA, prior to the addition of 125I-ACTH 
for the appropriate times. 
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2.16  BIOTIN METHOD OF INTERNALISATION 
 
This method is based on that described in Roberts et al (Roberts et al., 2001). Cells 
were serum starved over night prior to pretreatment with 0.3mM Monodansyl 
cadaverine (MDC) in PBS or PBS alone for one hour.  Surface labelling was 
performed at 37°C with 0.2 mg/ml NHS-SS-biotin (Pierce) in PBS for 30 min. 
Labelled cells were washed in 50mM Tris pH 8 and transferred to SFM with or 
without 10-7M ACTH with or without MDC, at 37°C.  
 
At the indicated times, the medium was aspirated, and the dishes were rapidly 
transferred to ice and washed twice with ice-cold PBS. Biotin was removed from 
proteins remaining at the cell surface by incubation with a non cell permeable 
reducing agent containing 20 mM 2-Mercaptoethanesulphonic acid sodium salt 
(MesNa) in 50 mM Tris (pH 8.6) and 100 mM NaCl for 15 min at 4°C. MesNa was 
quenched by the addition of 20 mM iodoacetamide (IAA) for 10 min, and the cells 
were lysed in PBS with protease inhibitor cocktail (Sigma #P-8240 at 1:1000).  
 
Samples were subsequently immunoprecipitated (see 2.7) using 0.5µg of an antibody 
(goat) that recognises the C-terminal portion of the MC2R (Santa Cruz, CA). 
Samples were run on an SDS-PAGE gel and immunoblotted with 1:100 dilution of 
anti-biotin antibody (Cell Signaling Technology, MA). 
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3 CHARACTERISATION OF ADRENAL CELL LINES 
AS MODELS OF ACTH INDUCED ERK1/2 SIGNALLING  
 
3.1  INTRODUCTION 
 
Previous in vitro studies concerning the mitogenic role of ACTH, have used a variety 
of primary adrenal cells from diverse species, in addition to transformed cell lines. 
As it has already been discussed, these investigations have yielded mixed results and 
as yet no clear mechanisms have been established at a molecular level to describe 
the effects on adrenal growth seen in vivo. Finding a suitable cell system in order to 
continue these studies is complicated by several factors. Firstly, the reproducibility 
of experiments using primary cells is inherently difficult because of differences 
between animals, in addition to the variation involved in making cell preparations. 
Furthermore, obtaining sufficient numbers of cells for experiments limits the size 
of animal that can be used. A further complication though, is the fact that studying 
mitogenic pathways is intrinsically difficult in transformed cell lines because these 
cells usually display abnormal growth regulation. An additional consideration when 
looking at ACTH signalling in adrenal cells is that the majority of primary adrenal 
cells and adrenal cell lines have lost ACTH responsiveness and are incapable of 
producing a steroid output, therefore looking at growth mechanisms in response to 
ACTH may be futile. This introduction aims to give a brief overview of some of the 
cell systems available for the study of the proliferative mechanisms initiated by 
ACTH. 
 
3.1.1  The murine Y1 adrenocortical tumour cell line 
 
The Y1 cell line was derived from an adrenal tumour that arose in an adult LAF1 
male mouse following exposure of the mouse to radiation from an atomic blast 
(Cohen et al., 1957). The tumour was propagated by intramuscular transplantation 
and was initially found to be highly metastatic. The tumour was able to produce 
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corticosterone and responded to ACTH by increasing steroid output and was thus 
thought to be ZF in origin. In subsequent passages, the tumour lost its metastatic 
properties and the ability to produce corticosterone however it maintained its 
ACTH responsiveness and steroidogenic capacity (Bloch and Cohen, 1960). The 
tumour was adapted to grow in vitro by alternately dispersing cells and growing the 
cells as a monolayer, followed by propagating the tumour in the mouse (Buonassisi 
et al., 1962). The Y1 cell was subsequently cloned from this adapted tumour 
(Yasamura et al., 1966). The American Type Culture Collection (ATCC) and the 
European Collection of Cell Cultures (ECACC) currently hold the Y1 cell line. 
However, the current passage of cells held by ATCC, although able to produce 
steroids has lost its ACTH responsiveness. When originally isolated, the Y1 cell line 
produced steroids at a rate of 3.7 µg/mg protein per hour at maximal stimulation 
(Yasamura et al., 1966) however this output has been shown to decline with 
continual culturing (Schimmer, 1979) and consequently many strains of Y1 cells 
exist with varying phenotypes.  
 
The use of the Y1 cell line in characterising the MC2R has already been discussed in 
section 1.4 however this cell line has also proven to be an invaluable tool in 
elucidating some of the key steps in steroidogenesis. In contrast to the normal 
mouse adrenal gland whose major steroid output is corticosterone, Y1 cells produce 
20α-dihydroxyprogesterone and 11β-20α-dihydroxyprogesterone (Pierson, 1967). 
This abnormal profile is due to the lack of the 21-hydroxylase enzyme (CYP 21) 
and an increase in 20-keto-reductase activity (Parker et al., 1985). Despite this slight 
abnormality, the regulation of steroid synthesis is similar to that seen in cells 
cultured from normal adrenal glands with regard to ACTH responses. Thus 
important discoveries such as the role of Steroid acute regulatory protein (StAR) 
have utilised the Y1 cell line (Lin et al., 2001, Lin et al., 1995). 
 
The Y1 cell line has also been of major importance in characterising some of the 
mitogenic and anti-mitogenic properties of ACTH as discussed in section 1.6.3.1 
(Lotfi et al., 1997). However, these cells are not ideal in studying growth 
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mechanisms for a number of reasons. Firstly, Y1 cells have a very fast doubling 
time of 30-40 h and therefore have markedly different growth rates to that of in vivo 
adrenal growth. Secondly, Y1 cells have been shown to over express c-Ki-ras due to 
an amplification of the protooncogene, leading to over activation of the Erk1/2 
pathway (Schwab et al., 1983). Constitutive over activation of this pathway and 
potentially other growth promoting pathways in this cell line would make the study 
of the effects of ACTH on these pathways difficult.  
 
3.1.2  NCI-H295 and H295R cell lines 
 
The NCI-H295 cell line is a human adrenocortical carcinoma cell line initially 
established from an invasive primary adrenocortical carcinoma present in a 48 year 
old female (Gazdar et al., 1990). The tumour was finely minced and the resulting 
suspension cultured for a year in a variety of SFM and serum containing media. 
Many of the steroids secreted by these cells were identified and it was found that 
the cells seemed to contain all of the major adrenocortical enzyme systems 
spanning all three zones of the adrenal cortex. From this suspension cell line, sub-
strains have been derived using alternative growth conditions and by encouraging 
growth of clones that attached to a cell culture flask. These cells have been 
designated H295R cells. In order to maintain steroidogenic capacity and to increase 
cell growth rate, a number of supplements were added to the cell culture media 
such as Ultroser and Nu-serum, both low protein serum substitutes which replace 
the need  for BSA (Hornsby and McAllister, 1991).  
 
It has been established through binding studies using 125I Angiotensin II (Ang II) 
that H295R cells express AT1 receptors (Bird et al., 1994, Bird et al., 1993). 
Consequently the cell line has been used to look at intracellular signalling pathways 
in response to Ang II in addition to looking at the regulation of Ang II mediated 
aldosterone production (Bird et al., 1993, Wu et al., 2001). By contrast, the H295R 
cell line is thought to be only mildly responsive to ACTH in some strains and 
completely resistant to ACTH in others. The lack of response to ACTH may reflect 
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the low level expression of MC2R in this cell line (Mountjoy et al., 1994). Some 
experiments aimed towards looking at the cAMP pathway, have used forskolin to 
directly activate adenylate cyclase or cAMP analogues, to mimick the effect of 
ACTH (Bird, 1993).  
 
3.1.3  Bovine adrenocortical cells 
 
Primary cultures of bovine adrenal cells have been widely used to study adrenal cell 
function. These are attractive because of the large size of the organ and therefore 
the relative abundance of primary cells that can be isolated from them. They are 
also readily available from abattoirs. Previous studies have investigated an ACTH 
growth promoting effect and found ACTH to be inhibitory to DNA synthesis and 
to reverse the growth promoting effect of FGF (Gospodarowicz et al., 1977).  
 
Bovine adrenocortical cells also require very specific growth conditions to maintain 
expression of 11ß hydroxylase and 21-hydroxylase including the addition of IGF-1 
and cAMP (Cheng and Hornsby, 1992). 
 
An alternative may be the use of an immortalized bovine cell line derived from the 
forced expression of telomerase ribonucleoprotein complex (TERT) (Thomas and 
Hornsby, 1999). In this study it was found that transplantation of immortalized cell 
clones into SCID mice, formed functional tissue with a similar rate of cell division 
to transplanted bovine cells with a finite lifespan. This would suggest that these cells 
behave as functioning adrenal cells and do not have the cell cycle abnormalities 
associated with other cancer derived cell lines. These cells may therefore be of use 
in our studies as they are likely to behave consistently with each passage. 
Furthermore, they have not previously been used in studies of mitogenic pathways 
and may prove a useful tool. 
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3.1.4  Other cell lines 
 
Several attempts have been made to establish cell lines from adrenal tumours in 
mice carrying Simian Virus 40 T-antigen as a transgene (Mellon et al., 1994, 
Kananen et al., 1996). These cells however were not responsive to ACTH but 
required the use of 8-bromo-cAMP for progesterone synthesis. In addition a 
number of attempts have been made to produce ras transformed rat adrenal cells 
however these cells do not maintain their steroidogenic capacity (Auersperg et al., 
1977, Auersperg et al., 1981). Furthermore since they have a ras transformation, 
they would not be ideal for investigating ras signalling pathways. 
 
3.1.5  Strategies 
 
For these studies, it was decided to attempt to use the Y1 adrenocortical cell line in 
order to reproduce previous work by Armelin and co-workers on the activation of 
the Erk1/2 signalling pathway in response to ACTH and its downstream 
proliferative effects, and to further characterise the signalling molecules and protein 
complexes that transduce a signal from binding of ACTH, through to the activation 
of the Erk1/2 pathway. Should this cell line prove unresponsive to ACTH, 
alternative cell systems would be sought to investigate the mitogenic effects of 
ACTH. 
 
The primary method of investigation will be to use immunoblotting to detect levels 
of phospho Erk1/2 vs total Erk1/2 in cell lysates derived from ACTH treated and 
untreated cells. If necessary, to ensure that phospho Erk1/2 detected is actually 
capable of activating a downstream kinase, an Erk1/2 activity assay will be 
performed whereby its ability to phosphorylate Elk-1 in an in vitro kinase reaction 
will be determined (Marshall, 1995).  
 
The ability of ACTH to induce a proliferative effect will be measured using the 
colorimetric MTS assay (see 2.8). According to the manufacturers, this assay is 
equally as sensitive as a [3H] thymidine incorporation assay and gives a measure 
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proportional to viable cell number. It is important that it is a sensitive measure as 
the effects of ACTH would be expected to be minimal as has been previously 
shown in Y1 cells (Lotfi et al., 1997). Furthermore, it is also an extremely simple 
method requiring the addition of the solution to the culture dish and measurement 
1-4 hours later and thus should reduce experimental error in comparison to other 
methods such as cell counting. 
 
3.2     METHODS 
3.2.1 Reagents 
 
ACTH (1-39) was obtained from Bachem as a lyophilized solid. It was reconstituted 
in dH2O to give a stock solution of 10-4 M and aliquoted and stored at –20 °C. 
Basic fibroblast growth factor (bFGF) was obtained from BD Biosciences 
(Bedford, UK), reconstituted in dH2O to 10 µg/ml, aliquoted and stored at –20 °C. 
Epidermal growth factor was obtained from Sigma and reconstituted in SFM 
containing 0.1 % BSA to give a stock solution of 10 µg/ml. This was aliquoted and 
stored at –20 °C. 
 
3.3 RESULTS  
3.3.1 Activation of Erk1/2 in Y1 adrenocortical cells 
 
Previous studies in Y1 cells that looked at the activation of the Erk1/2 pathway, used 
long periods of serum starvation in order to growth arrest cells so that differences 
in phosphorylated Erk1/2 could be seen.  Armelin and co-workers used a 72 h 
period of serum starvation in order to achieve growth arrest at the G0/G1 phase of 
the cell cycle prior to looking at the effects of ACTH (Lotfi et al., 1997). To visually 
assess the viability of cells after long periods of serum starvation of Y1 cells, cells 
were grown to around 60% confluence and then maintained in SFM for up to 72 h. 
After a period of 24 h of serum starvation, cells were generally unchanged in 
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appearance and had continued to grow. After 48 h, cells had become more 
confluent and by 72 hours there was no obvious increase in growth. By this time 
however, cells have become very clustered and were only loosely attached to the cell 
culture flask. Cells were not suitable for use at this stage because they became 
detached with a change of medium. Since cells were unusable at 72 h of serum 
starvation and were still proliferating at 24 h, it was decided to use 48 h of serum 
starvation in order to growth arrest cells, prior to stimulations.  
 
In an initial experiment, intended to confirm the findings of Armelin and co-
workers, Y1 cells were grown in 6 well dishes and serum starved for 48 hours at 
60% confluence. The medium was then replaced with SFM containing a range of 
ACTH concentrations from 10-12 M to 10-6 M, along with positive and negative 
controls of SFM supplemented with FBS and SFM alone, respectively. Cells were 
placed on ice after 5mins and protein extracts made. These were then 
electrophoresed and western blotted with antibodies against phospho Erk1/2 and 
total Erk1/2, which served as a loading control. Fig. 3.1A shows the results of these 
experiments where densitometry of the resulting films was performed, normalised 
to total Erk1/2 in each case.  The positive control (serum) produced an 
approximately three-fold increase in Erk1/2 phosphorylation and there is a clear 
dose response to ACTH which at 10-7 M gives an equivalent increase to that of 
serum.  
 
However, these findings proved not to be very reproducible due to an often very 
high basal activation of Erk1/2, even after 48 h of serum starvation. A time-course 
of Erk1/2 activation was also very inconsistent with peak phosphorylation ranging 
between 5 mins and 2h (data not shown). There was a possibility that this was a 
consequence of the methodology employed to assess Erk1/2 activation and so an 
Erk1/2 in vitro kinase assay was carried out in order to confirm these findings. This 
was to give a measure of the activated Erk1/2 that was capable of phosphorylating a 
down-stream transcription factor, Elk-1. Fig 3.1B is a representative blot 
demonstrating high basal activation of Erk1/2 leading to phosphorylation of Elk-1. 
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There was no significant increase in Elk-1 phosphorylation across the ACTH time 
course compared to a large increase in the serum control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 1. ACTH induced Erk1/2 responses in Y1 cells. A, 48 h serum starved cells were 
stimulated for 5 min with increasing concentrations of ACTH or serum supplemented media. Cell lysates 
Western blotted and probed using phospho-erk1/2 antibody. X-ray films were scanned and the densitometry 
of bands determined as a percentage of the serum response. N=3. Error bars represent SEM. B, Y1 cells 
were serum-starved and stimulated with 10-7 M ACTH or serum supplemented media for the times shown. 
Lysates were used in an Erk1/2 in vitro kinase assay and resultant reactions Western blotted and probed 
for phospho Elk-1. 
 
 
After initial success with this cell line, the high constitutive levels of activated Erk1/2 
already present in the serum starved cells made any subtle differences between 
treatments very difficult to visualise. In order to try to reduce constitutive activation 
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of Erk1/2, cells were pre-treated for 24 h with 1 µM dexamethasone after an initial 
24 h serum starvation, prior to stimulation with ACTH. Dexamethasone is known 
to increase MAPK phosphatase (MKP-1) expression, which acts to 
dephosphorylate Erk1/2 (Lasa et al., 2002). Cells were also pre-treated for 1 h with a 
MEK1 inhibitor U0126 in order to try to reduce constitutive activation of this 
pathway.  Pre-treatment of Y1 cells with dexamethasone did not reduce basal Erk1/2 
activation (Fig. 3.2A) and thus treatment with FGF, a known activator of this 
pathway, did not induce Erk1/2 activation above basal levels. Pre-treatment of cells 
with U0126 abolished constitutive levels of Erk1/2 activation (Fig.3.2B lane 1) 
however this effect was removed with the addition of SFM or PBS for 5 min, with 
phosphorylated Erk1/2 levels increasing back to those of untreated cells maintained 
in serum (lanes 2 and 3 compared to lane 4). 
 
Although other groups have shown a positive effect of ACTH on Erk1/2 activation, our 
data, using our sub-line of Y1 cells, has demonstrated a constitutive activation of this 
pathway. It was felt that the Y1 cell line would not be a useful system in which to study the 
potentially weak mitogenic activity of ACTH and it was decided to investigate other 
adrenal cells to find an appropriate model for the study of ACTH-MC2R mitogenic 
signalling mechanisms.  
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Fig. 3.2 Treatment of Y1 cells with dexamethasone and U0126 to reduce basal 
Erk1/2 stimulation. A, Y1 cells were left in SFM for 24 h before addition of dexamethasone (1µM) 
or SFM for a further 24 h.  Cells were either untreated (in SFM) or treated with 100 ng/ml FGF or 10-
7 M ACTH for 5 mins.  Cell lysates were immunoblotted for phosho-erk1/2. B, Y1 cells were treated with 
U0126 (1µM) in SFM overnight or left in serum supplemented medium (untreated). Cells were then 
washed twice in SFM and harvested immediately or washed twice before the addition of fresh medium or 
PBS for 5 mins.  Immunoblotting for phospho Erk1/2 was carried out on cell lysates. 
 
3.3.2  Bovine adrenal cells 
 
Primary bovine adrenal cells (SBAC) obtained from ECACC and a telomerase 
ribonucleoprotein complex (TERT) immortalized bovine adrenal cell line, a kind 
gift from P.J. Hornsby (Thomas et al., 2000, Thomas and Hornsby, 1999), were 
assessed for their suitability for studying ACTH and MC2R interactions. Responses 
to ACTH were assessed by cAMP assay in comparison to Y1 cells (Fig. 3.3).  
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Fig. 3.3 Comparison of adrenal cell responses. Y1, SBAC and TERT cells were treated for 
45 min with increasing concentrations of ACTH and analysed for cAMP accumulation. Results are 
expressed as a percentage of unstimulated for each cell line and are results from one experiment with three 
replicates. Error bars represent SEM. 
 
Y1 cells produced a typical dose response to ACTH with an EC50 of 5nM. SBAC 
and TERT immortalized adrenal cells however did not respond to ACTH. In 
addition to cAMP assays, cells were also assessed for the activation of Erk1/2 
following ACTH treatment over a time-course of 1 hour. Neither cell type activated 
the Erk1/2 pathway compared to untreated cells (data not shown). These cells were 
clearly not useful for these studies. 
 
3.3.3  The H295R cell line as a model for ACTH induced mitogenic 
signalling pathways 
 
To test the viability of the H295R cell line for our studies we first sought to check 
the expression of the MC2R and the response of the cells in terms of cAMP 
production after ACTH stimulation (Fig 3.4). 
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Fig. 3.4A demonstrates the presence of the MC2R in H295R cDNA, comparable to 
that of the positive control human adrenal cDNA. MC2R expression was not 
present in a negative control, HeLa cDNA. To ascertain whether this MC2R was 
functionally expressed, cells were treated with varying concentrations of ACTH, 
and assessed for cAMP accumulation in the presence of the phosphodiesterase 
inhibitor IBMX. Forskolin was used as a positive control. Although the results were 
not initially significant, the trend suggested that the cells were responding in a dose 
dependent manner (Fig 3.4B). In order to establish significance, three of the points 
(unstimulated, 10-7 M Forskolin and 10-7 M ACTH) were repeated and after 
performing this experiment seven times indicated a significant increase in cAMP 
accumulation (p<0.001) (Fig 3.4B) although this was only a 0.8-fold increase 
compared to a 6-fold increase with forskolin treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.4 Characterisation of a functional MC2R. A, PCRs using MC2R primers on human 
adrenal, H295R and HeLa cDNA (35 cycles). B, H295R cells were treated with various concentrations 
of ACTH or 10 -5 M forskolin for 45 min. Cells were subsequently harvested and analysed for cAMP 
content (n=3 for 10-10, 10-8 and 10-6M, for other conditions n=7). Error bars represent SEM  
 
 
To further assess whether the MC2R was functionally expressed at the cell surface, 
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curve was performed where 0.025 pmol of 125I-ACTH was incubated with 
increasing concentrations of “cold” ACTH (Fig. 3.5). These results showed specific 
binding with an IC50 of 4.68 x 10-7 M. Taken together, these results demonstrate 
that ACTH induces a significant, albeit it weak, cAMP response in H295R cells and 
furthermore that ACTH is able to specifically bind to the surface of these cells. This 
suggests that the H295R cell line may be a useful model for the study of the effects 
of ACTH on mitogenic pathways since they express a functional MC2R. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5 Binding of I125 ACTH in H295R cells. A, a fixed quantity of I125 ACTH (0.025 
pmol) was added to cells in the presence or absence of various concentrations of “cold” ACTH (1-39) for 1 
h. Specific binding was expressed as a percentage of total binding i.e. in the presence of no cold ACTH. 
The experiment was performed 4 times in triplicate. Error bars represent SEM.  
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3.3.4 Characterisation of activated pathways in H295R cells 
 
Having established that H295R cells express functional MC2R, it was possible to 
determine whether ACTH initiates any mitogenic signalling pathways in this adrenal 
cell line. It was decided first to look at the activation of the Erk1/2 pathway in 
response to ACTH. An initial study determined that an overnight incubation in 
SFM was sufficient to give very low basal activation of Erk1/2 (Fig 3.6A, lane 1). 
H295R cells were grown in 6 well dishes, serum starved overnight and then treated 
with 10-7 M ACTH over a time course. This concentration of ACTH was chosen 
because it appeared to give the maximal response in the cAMP assay (Fig 3.5B). 
Cells were harvested over a 1h time course and Erk1/2 phosphorylation was 
visualised by western blotting. Fig 3.6A shows that Erk1/2 phophorylation was 
transiently induced by treatment with 10-7 M ACTH maximally at 5 min and this 
activation was maintained to a lesser extent up to 30 min (Fig. 3.6A and B). The 
extent of activation was comparable to that of a 15 min treatment with medium 
containing 10 % serum. Furthermore, Erk1/2 was activated in a dose dependent 
manner at 5 mins (Fig. 3.7). Densitometry of this dose response gave an EC50 for 
Erk1/2 phosphorylation of 3 nM. 
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Fig. 3.6 ACTH stimulation of Erk in H295R cells. H295R cells were serum starved 
overnight.  The next day media was changed to leave 1 ml SFM and 30 mins later were stimulated by 
adding 10x stock solutions of ACTH directly to the well or the same volume of SFM or 10 % serum (15 
min) for the times indicated.  Cell lysates were analysed for phopsho erk1/2.  Blots were stripped and 
reprobed for total erk1/2. A, time-course of ACTH stimulation. B, densitometry where net intensity of 
phospho erk1/2 /total erk1/2 was determined and expressed as a percentage of unstimulated (n=3). Error 
bars represent SEM. 
  1        2       3        4       5      6        7        8       9       10      11     
12 
- - + - + - + - + - + -
5 10 15 30 600
ACTH (10-7M)
Time (mins)
Phospho erk1/2
Total erk1/2
Serum
A 
0
100
200
300
400
500
600
700
0 10 20 30 40 50 60
Time ACTH stimulation (mins)
Ph
o
sp
ho
/to
ta
l E
rk
1/
2
B 
 106 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7 Erk1/2 dose response to ACTH. H295R cells were serum starved overnight.  The next day media 
was changed to leave 1 ml SFM and 30 mins later cells were stimulated by adding 10x stock solutions of ACTH, 
serum or the same volume of SFM, directly to the well for 5 mins Cell lysates were analysed for phospho-erk1/2 
(upper panel).  Blots were stripped and re-probed for total erk1/2 (lower panel).This is representative of three 
independent experiments. 
  
 
These findings suggest that, as has been found previously in Y1 cells, ACTH is able 
to activate the Erk1/2 signalling pathway in H295R cells (Lotfi et al., 1997). 
However, we wanted to investigate the activation of other classical mitogenic 
pathways to characterise the mitogenic potential of ACTH in H295R cells. The 
stress activated MAPK pathways, JNK and p38 MAPK were investigated for this 
reason in addition to PI3-K/Akt pathway.  
 
H295R cells were stimulated with ACTH over a time course and cell lysates 
analysed by western blotting for phospho JNK (Fig. 3.8A). As a positive control, 
cells were treated for 5 and 30 minutes with hypertonic sucrose (0.4 M) in order to 
induce osmotic shock and thus JNK activation. Treatment for 30 minutes with 
sucrose caused an increase in levels of phospho p46 and p54 JNK however 
treatment with ACTH caused no increase above that of untreated. The effect of 
ACTH on p38 MAPK activity was also analysed in the same way however no 
induction was seen (data not shown). 
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Levels of activated Akt were determined following ACTH treatment for a time-
course (Fig. 3.8B). Interestingly, there was a very slight increase in phosphorylation 
of Akt over a relatively high basal level by 5 min, however this was not significant 
with repeated experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.8 JNK and Akt activation by ACTH. H295R cells were left in SFM overnight prior to 
stimulation with 10-7 M ACTH, 0.4 M sucrose or an equivalent volume of SFM for the indicated times. 
A, lysates were analysed for phospho JNK levels by Western blotting (upper panel). Blots were stripped 
and re-probed for total JNK (lower panel). B, lysates were analysed for phospho Akt levels (upper panel). 
Blots were then stripped and re-probed for total Erk1/2 (lower panel). 
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3.3.5  ACTH effect on nuclear translocation of Erk1/2 
 
An important question to answer was whether the activation of the Erk1/2 pathway 
by ACTH in H295R cells would actually allow translocation of Erk1/2 to the 
nucleus where it could upregulate target genes, or whether Erk1/2 was retained in 
the cytoplasm following phosphorylation. If Erk1/2 was retained in the cytoplasm, 
this would indicate that a proliferative response would not follow (Smith et al., 
2004). In Y1 cells, ACTH was previously shown to induce upregulation of the 
immediate early genes, c-fos and c-jun (Kimura et al., 1993) thus indicating that 
Erk1/2 was translocated to the nucleus to bring about this effect. In order to 
investigate this, a luciferase assay system was utilised whereby co-transfection of a 
Gal4-Elk, Gal4-luc and Renilla constructs allowed the measurement of MAPK 
ability to induce target gene expression following treatments with ACTH. This 
assay was used to assess both the effect of long-term treatment (6 h) as well as 
short-term treatment (30 min) of ACTH compared to 10 % serum (Fig. 3.9A).  
 
Fig. 3.9A demonstrates around a 3-fold activation of transcription following 
treatment with ACTH for 30 mins compared with that of serum which caused a 6-
fold increase in luciferase activity. Interestingly though, a more prolonged treatment 
with serum caused a cumulative increase in luciferase activity with time, however 
ACTH induced luciferase activity did not increase above that of the 30 min time-
point. This suggests that although ACTH does induce the translocation of phospho 
Erk1/2 to the nucleus and the subsequent transcription of MAPK target genes, it is a 
relatively short-lived effect that may be regulated by feedback mechanisms. The 
upregulation of Elk-1 was shown to be a MEK dependent process since the effect 
could be inhibited by pre-treatment with the inhibitor U0126 (Fig. 3.9B). 
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Fig. 3.9 Transcriptional activation of Elk-1. H295R cells were plated into 6 well plates and 
when at around 50 % confluence were transfected with Gal4-Elk, Gal4-Luc and Renilla plasmids using 
a 6:1 ratio of fugene:DNA. The next day cells were washed once in SFM and left in SFM overnight. A, 
the following day, cells were stimulated for the indicated times with 10-7 M ACTH, 10 % serum or SFM 
alone and then transferred back to SFM for the remaining time. Cells were harvested after 6 hours of total 
treatment time and luciferase and renilla activity measured using the dual luciferase assay kit (Promega) 
and results expressed as a percentage of unstimulated. The experiment was performed on three separate 
occasions in duplicate.  B, cells were pre-treated with 1 µM U0126 for 1 h or SFM followed by 
stimulation with 10-7 M ACTH or SFM for 30 min. Cells were transferred back to SFM for the 
remaining time (6 h in total) and then analysed for luciferase and renilla activity. The experiment was 
performed three times in duplicate. 
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3.3.6  ACTH effect on Proliferation 
 
Having demonstrated that ACTH induces the activation of Erk1/2, a classically 
proliferation inducing pathway, and that short treatments with ACTH induce the 
upregulation of Erk1/2 target genes, it was necessary to investigate whether ACTH 
would lead to proliferation of H295R cells. 
  
The MTS proliferation assay (Promega) was used to quantify proliferation. Initial 
experiments suggested that an overnight period of serum starvation was not 
sufficient to enable the measurement of an effect of a 24h 10% serum treatment 
compared to SFM in H295R cells (data not shown). Consequently, a period of 48h 
of serum starvation was preferred to ensure that cells had stopped dividing prior to 
treatment. To investigate the effect of short-term treatment with ACTH on 
proliferation of H295R cells, cells were first serum-starved for 48 hours prior to 
treating with 10-7 M ACTH or 10 % serum for 5 min to 1 h. Cells were then 
transferred to SFM and left for a further 24, 48 and 72 h and the MTS proliferation 
assay subsequently performed. Results demonstrated no difference between 
untreated cells and those treated with either ACTH or 10 % serum for all of the 
time-points studied suggesting that the MTS assay was not sensitive enough to look 
at these short stimulations or that these particular cells do not respond to such 
short treatments in terms of proliferation. However, it was decided to use this 
method to look at the effect of long-term treatments with ACTH compared to 
serum alone and also the effect of ACTH treatment in the presence of serum. Fig. 
3.10 shows a 3-fold increase in cell number after treatment for 72 h with 10 % 
serum compared to untreated (unstim). On the other hand, treatment with various 
concentrations of ACTH in SFM consistently had no effect on proliferation of 
cells.  
 
ACTH at various concentrations in the presence of serum appeared to show a trend 
towards a dose-dependent effect, but this was not significantly different from that 
obtained with serum alone.  
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Fig. 3.10 Proliferative response to ACTH. H295R cells were plated into 12 well plates and the 
next day left in SFM for 48 hours. Medium was replaced with SFM containing the indicated 
concentrations of ACTH or medium containing 10 % serum with various concentrations of ACTH for a 
further 72 h. The MTS assay was then performed. N=3 with 6 replicates per treatment. Error bars 
represent SEM. 
 
3.4 DISCUSSION 
 
3.4.1 The Y1 adrenocortical tumour cell line 
 
The use of the mouse Y1 adrenocortical cell line to look into the mitogenic 
signalling responses to ACTH was initially sought for a number of reasons. This 
was primarily because Y1 cells express the MC2R and respond to ACTH in terms 
of a potent increase in levels of cAMP and in terms of synthesizing and secreting 
steroids (Yasamura et al., 1966, Schimmer, 1979), Y1 cells resemble the human 
adrenal cortex in that the major melanocortin receptor expressed is the MC2R thus 
allowing the study of the effects of ACTH MC2R interactions, and ruling out the 
complications of lower affinity ACTH binding to alternative receptors. Secondly, 
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this model has been used extensively by a number of groups to investigate signalling 
mechanisms other than the cAMP/PKA pathway, initiated by ACTH, and its effect 
on mitogenesis (Masui and Garren, 1971, Lotfi et al., 1997, Forti et al., 2002, 
Watanabe et al., 1997).  
 
The aim of this thesis was to characterise the mitogenic mechanisms initiated by 
ACTH in the adrenal using this mouse adrenal cell line, Y1. Previously published 
data described an increase in Erk1/2 phosphorylation in response to ACTH 
following a 72 h period of serum starvation in order to growth arrest cells in G1 
phase of the cell cycle (Lotfi et al., 1997). Initial experiments to gauge the viability 
of cells following increasing times in SFM, indicated that at 72 h cells were no 
longer in a healthy state and could not be used. However, at 48 h in SFM there was 
no reproducible and significant effect of ACTH on Erk1/2 phosphorylation over 
that of untreated cells (Fig.3.2B). Attempts to try to reduce the constitutive 
activation of this pathway were unsuccessful; long-term treatment with 
dexamethasone, which is known to upregulate MAPK phosphatase expression 
(Lasa et al., 2002), did not reduce basal activation of Erk1/2 and, pre-treatment with 
U0126 only temporarily abolished constitutive Erk1/2 phosphorylation, an effect 
that was reversed immediately by removal of the inhibitor.  
 
Explanations for the lack of responsiveness to ACTH in terms of Erk1/2 
phosphorylation could be explained by a change in phenotype of the cells over 
time. Y1 cells have been previously shown to change with passage number, for 
example, they lost their capacity to produce corticosterone over time, probably due 
a deficiency of the 21-hydroxylase enzyme (CYP 21) (Parker et al., 1985). The 
current passage of the Y1 clone present at the ATCC has lost responsiveness to 
ACTH although are still able to produce steroids. Aside from a lack of Erk1/2 
activation in response to ACTH, cells also did not respond to FGF (Fig. 3.3A), a 
known adrenal mitogen and activator of this pathway (Viard et al., 1993, Hornsby et 
al., 1983, Lotfi et al., 1997) thus to look at the effect of ACTH, a so-called weak 
mitogen, was not possible using this model.  
 
 113 
The explanation for the varied findings in ACTH responses in Y1 cells are probably 
the result of different groups investigating alternative strains of cells. Many strains 
of Y1 cells have been previously described as expressing a large amplification of c-
Ki-ras protooncogene thus leading to over activation of the Erk1/2 pathway 
(Schwab et al., 1983). One report has summarized previously published data on the 
amplification, chromosomal location, expression, and activity of c-Ki-ras proto-
oncogene in Y1 cells (Rocha et al., 2003).  In their particular Y1 cells they found a 
10 to 20-fold increase in both mRNA expression and protein levels of Ki-ras 
compared to mouse 3T3 fibroblasts in addition to higher constitutive levels of c-Ki-
ras in its active, GTP bound form. It may be that in our strain of Y1 cells, this 
enhanced c-Ki-ras proto-oncogene expression and activity is even more 
pronounced leading to loss of responsiveness even to FGF. 
 
3.4.2  Bovine adrenocortical cells 
 
Alternative adrenal derived cells were investigated to find an appropriate model for 
the study of ACTH induced mitogenesis. Bovine adrenocortical cells (SBAC) were 
purchased from ECACC and cultured according to the instructions given by the 
supplier. SBACs are primary cells that have been previously published to require the 
addition of IGF-1 and cAMP as well as extracellular matrix components, to 
maintain the expression of 11β hydroxylase and 21-hydroxylase (Cheng and 
Hornsby, 1992).  
 
Experiments were performed to ascertain the signalling characteristics of this cell 
line in response to ACTH. Treating cells with increasing doses of ACTH caused no 
increase in cAMP production or Erk1/2 phosphorylation compared to untreated 
cells, when stimulations were for 45 mins and 5 mins respectively (Fig. 3.4 and data 
not shown). This is in contrast to previous findings by a group who demonstrated 
potent stimulation of steroid production following treatment of ACTH derived 
from pituitary extracts (Shah and Murray, 2001). The lack of a functional MC2R 
therefore rules out these cells for further study. 
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We also investigated an immortalized bovine adrenocortical cell line derived from 
the forced expression of telomerase ribonucleoprotein complex (TERT) (Thomas 
et al., 2000, Thomas and Hornsby, 1999). When transplanted into SCID mice, these 
cells form fully functional tissues However, we found that when grown in vitro these 
cells do not respond to ACTH to produce cAMP and further do not increase Erk1/2 
phosphorylation in response to ACTH. This suggests either that cell culture 
conditions were not optimised to allow the cells to be fully functional or that these 
adrenal cells require other factors that are present in vivo to enable them to function 
normally.  
 
3.4.3  NCI-H295R cells  
  
Although H295R cells express all of the major adrenocortical enzyme systems, they 
have been primarily and most successfully used in the study of ZG responses. 
Investigations into the mechanisms regulating adrenal cell responses to angiotensin 
II have been carried out where the activation of PKC has been shown to be 
mediated through the AT1 receptor (Bird et al., 1993, Bird et al., 1994). However, 
the investigation into ZF responses i.e that of ACTH effects, have not been 
investigated fully since these cells have a low level of MC2R expression and 
therefore ACTH responsiveness  (Mountjoy et al., 1994). Thus most experiments 
used to investigate cAMP dependent pathways have used the direct stimulation of 
adenylate cyclase with forskolin or cAMP analogues to allow a potent stimulation of 
cAMP production, PKA activation and cortisol synthesis and release (Rainey et al., 
1993).  
 
We however have characterised this cell line further in terms of it responses to 
ACTH to ascertain whether it could be used to study mitogenic signalling. Results 
from this chapter confirmed the expression of the MC2R in H295R cells that could 
be visualised at 30 cycles and furthermore, a small but significant response to 
ACTH in terms of cAMP production. This was in contrast to stimulation with 
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forskolin, which gave a 5-fold increase in cAMP production (at 10-5 M) compared 
to a maximum of a 1.5-fold increase with 10-7 M ACTH (Fig. 3.4). The lack of a 
potent response to ACTH may simply reflect the relatively low level expression of 
the MC2R, however it is possible that it may reflect a problem of coupling of the 
receptor to Gs proteins, which may not be limited to only this receptor. For 
example, H295R cells express the β2 Adrenergic receptor (Kosti et al., 2002), 
however they do not respond to isoproterenol by accumulating cAMP (data not 
shown).  
 
Aside from the cAMP response, homologous displacement binding experiments 
demonstrated specific binding of 125I-ACTH to H295R cells with an IC50 of 4.68 x 
10-7 M (Fig. 3.5). Furthermore, this curve spreads over only two log units suggesting 
binding to only one receptor sub-type. This affinity is not in accordance with that 
found previously in Y1 cells where the IC50 was 0.13 nM (Schioth et al., 1996). 
Although the 125I-ACTH peptide is very difficult to use due to its “sticky” nature, 
the results were very reproducible and thus a difference in affinity probably reflects 
a difference in behaviour of the MC2R in this cell line. The possibility of cofactors 
present in either of the two cell lines that alter the affinity of the MC2R for ACTH 
cannot be ruled out however there is currently no evidence for this in the literature. 
Table 3.1 shows the affinities of ACTH (1-39) and α-MSH for the different 
melanocortin receptors, determined by transient transfection in COS-1 cells, or Y1 
cells in the case of the MC2R (Schioth et al., 1996, Schioth et al., 1997). ACTH 
binds with various affinities to all of the melanocortin receptors however the closest 
affinity to that found in our experiments is that of the MC3R, however there is still 
a 3-fold discrepancy.  
 
The possible binding of ACTH to alternative melanocortin receptors in order to 
mediate an Erk1/2 response will be further investigated in Chapter 4. 
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Ligand Receptor 
 MC1R MC2R MC3R MC4R MC5R 
ACTH (1-39) 3.95 0.13 135 2170 4920 
α-MSH 0.113 - 44.7 357 2440 
 
Table 3.1 IC50 of POMC peptides for melanocortin receptors (nM) adapted from (Schioth 
et al., 1997, Schioth et al., 1996). 
 
3.4.4 Signalling pathways activated by ACTH 
 
With limited availability of adrenal cell lines for the study of ACTH effects on 
mitogenesis, we thought it a reasonable and novel course of action to study these 
effects in H295R cells, a cell line that expresses the MC2R and responds 
functionally to its stimulation with ACTH. Furthermore, growth characteristics of 
these cells have not been studied extensively.  
 
There are many strains of H295R cells available that have been selected to grow in 
different media based on their ability to maintain their steroidogenic capacity. For 
example, the growth supplement Ultroser G (Biosepr SA, France) was found to 
allow cells to retain their steroidogenic capacity (Hornsby and McAllister, 1991). 
However, due to the problems with importation of Ultroser to North America, 
other growth media such as Nu-Serum (Collaborative Biomedical products) and 
Cosmic calf serum (Hyclone) have also been tested. Nu-Serum and Ultroser were 
required in order to maintain responses to Angiotensin II and K+ however many 
groups have grown H295R cells in media supplemented with 10 % FBS 
(Montanaro et al., 2005, Li and Wang, 2005). Since the responses to Angiotensin II 
were not our primary focus, we initially grew cells in 10 % FBS. When investigating 
the Erk1/2 response following ACTH treatment we found a potent increase in 
Erk1/2 phosphorylation after 5 mins stimulation which decreased over 1 h back to 
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basal levels (Fig. 3.6). This was also a dose dependent effect with an EC50 of around 
3 nM (Fig. 3.7). Responses in cells grown in Ultroser containing media were also 
investigated and shown not to be as potent (data not shown). The reason for this 
may be that of a differentiation of cells where they lose glomerulosa phenotype and 
gain a more fasciculata phenotype which may account for why these responses have 
not been previously investigated in this cell line. This is supported by previous 
observations where changes in phenotype of H295R cells occurred dependent on 
whether treated with angiotensin II or forskolin. Angiotensin treatment promoted 
glomerulosa phenotype and the associated expression of CYP11B2 and production 
of sterone and forskolin treatment promoted CYP11B1 expression and the 
production of cortisol (Cobb et al., 1996).  
 
The effect of ACTH on other mitogenic and anti-apoptotic pathways was also 
investigated. The JNK (SAPK) and p38 MAPK pathways are generally activated by 
stress stimuli (Kyriakis et al., 1994). The JNK pathway has previously been 
demonstrated to be activated by ACTH in vivo in rat adrenals and in Y1 cells 
(Watanabe et al., 1997) whereas activation of the p38 MAPK pathways has not been 
reported. This paper however also showed a decrease in Erk1/2 activity following 
ACTH treatment for 15 mins in contrast to that found by other groups (Lotfi et al., 
1997). We found no activation of either of these stress-activated pathways pathways 
in H295R cells in response to ACTH. 
 
In investigating the activity of the PI3K/Akt pathway, results showed a high 
constitutive activation of Akt however no significant change following ACTH 
stimulation (Fig. 3.8 B). This observation was in contrast to that seen in Y1 cells 
where a high constitutive activation of Akt was dephosphorylated by 5 mins of 
ACTH treatment, an effect that was maintained for at least 4 hours (Forti et al., 
2002). Furthermore, that study demonstrated that inactivation of Akt by ACTH or 
wortmannin was responsible for increased levels of p27Kip1 protein. These effects 
were shown to be mediated by a mechanism dependent on cAMP/PKA activation, 
and thus may account for the difference seen in the H295R cell line where there is 
no potent cAMP response.  
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In view of the data summarised above it was decided to investigate whether ACTH 
could stimulate the transcription of Erk½ target genes and cause proliferation of 
H295R cells. 
 
3.4.5  Proliferative effect of ACTH on H295R cells 
 
The increase in luciferase activity induced by ACTH in the MAPK luciferase 
reporter assay suggested that as well as inducing the phosphorylation of Erk1/2, 
ACTH also allows the translocation of active Erk1/2 to the nucleus to affect 
transcription of the target gene Elk-1 (Fig. 3.9A). This was a specific effect of 
Erk1/2 activation because it was inhibited by the MEK1 inhibitor U0126 (Fig. 3.9B). 
Luciferase activity was increased 3-fold over untreated cells in contrast to a 6-fold 
activation of cells treated with 10 % serum (at the 30 min time-point). This is 
perhaps not surprising as serum is a potent mitogen that is likely to enhance other 
pathways driving Elk-1 transcription.  
 
Although luciferase activity was induced with ACTH stimulation this effect was 
only seen up to 30 mins, at which point there was no further induction. This is in 
contrast to serum treatment which caused an increase in luciferase activity with 
time. This suggests that short periods of ACTH treatment have a positive effect on 
Erk1/2 target genes, and further, that there is likely to be a regulatory feedback 
mechanism whereby uncontrolled transcription is prevented. This feedback 
mechanism may be the ACTH induced upregulation of MAPK phophatase 1 
(MKP-1). This has been previously described in Y1 cells in response to ACTH 
where its protein levels are increased by 30 mins and act to depshophorylate Erk1/2 
(Bey et al., 2003). These observations are supportive of the literature describing the 
differential effects of short-term versus long-term treatment of ACTH on the 
proliferation of Y1 cells (Lotfi et al., 1997).   
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Erk1/2 signals can lead to various outcomes such as proliferation, cell cycle arrest or 
differentiation and it is thought that signal duration is a crucial determinant of the 
signal potential (Assoian, 2002). Recent insights into the effect of Erk1/2 signal 
duration on the stabilisation of c-fos have been investigated where it was 
demonstrated that although both transient and sustained Erk1/2 activation lead to c-
fos gene transcription, the c-fos protein is relatively unstable unless Erk1/2 activity 
remains (Murphy et al., 2002). Sustained Erk1/2 activation has been associated with 
a progression through the G1 phase of the cell cycle in a number of systems 
(Meloche et al., 1992, Cook and McCormick, 1996, Weber et al., 1997, Vouret-
Craviari et al., 1993). The activation of Erk1/2 in response to ACTH in H295R cells 
however is very much a transient response (Fig. 3.7B). Transient Erk1/2 activation is 
often not associated with proliferation (Murphy et al., 2002, Cook and McCormick, 
1996) however this is not always the case. For example it was demonstrated in 
mouse embryonic fibroblasts (MEFs) obtained from an A-raf, Raf-1 double knock-
out mouse had delayed ability to enter the S-phase of the cell cycle which was 
associated with a reduction in levels of transiently induced MEK and Erk1/2 
activation with no alteration in sustained Erk1/2 activation (Mercer et al., 2005).  
 
Due to the probable dual effects of ACTH on adrenal cells i.e. that of growth 
promoting and growth inhibitory, the approach to investigating this was to look at 
both short-term treatments (5 min to 2 hours) and long-term treatments (72 h) on 
the proliferation of H295R cells. The MTS assay was used as a measure of cell 
number and thus was a late marker of proliferation. There was no effect of 
treatments from 5 mins to 2 h on proliferation of H295R cells for both ACTH and 
serum (data not shown). This probably reflects a lack of sensitivity of the MTS 
assay and does not necessarily suggest a pro or anti-proliferative effect of ACTH.  
 
Pro-longed treatment of H295R cells with various concentrations of ACTH in SFM 
also showed no increase or decrease in proliferation compared with SFM alone (Fig. 
3.10). However, during these experiments it was decided not to change the media to 
prevent following 72 hours in SFM, cells from detaching from the plate. This may 
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however have decreased any effects that may have been seen if the media was 
changed daily. 
 
ACTH was also incubated at various concentrations in the presence of 10 % serum 
however there was no significant difference in these treatments compared with 
serum alone. Cells treated with serum showed only a 3-fold increase in proliferation 
compared to those in SFM, therefore, if ACTH was behaving as a weak mitogen or 
indeed an anti-proliferative agent, its effects may not necessarily be evident using 
this assay.  
 
The proliferation experiments on H295R cells were therefore inconclusive. 
Although there was no significant increase or decrease in proliferation of cells 
treated with ACTH in the presence of serum, any small change may have been 
masked by the presence of serum. However without serum, effects may have been 
masked by loss of cells through peeling off. In order to gain more useful results, the 
study may be improved in the future by incubating cells in a lower concentration of 
serum in order to allow the cells to remain healthy at the same time as reducing any 
masking effects of the serum. Also, ideally, a more sensitive marker of proliferation 
could be used to determine any small changes which would allow the quantification 
of any short-term effects of ACTH. 
 
3.4.6 Conclusions 
 
One of the aims of this chapter was to find a suitable in vitro model for the analysis 
of classical mitogenic pathways in the adrenal gland. Initial studies in Y1 cells lead 
to results contradicting those which I was trying to repeat i.e. a complete lack of 
effect of ACTH on Erk1/2 signalling. An alternative strategy using primary bovine 
adrenal cells (SBAC) was thought to be a good alternative mainly because the cells, 
if used at early passages, would not display cell cycle irregularities and would thus be 
a truer reflection of the normal adrenal cell. However, much has been published in 
the literature that primary bovine adrenal cells require a cocktail of growth factors 
to maintain their steroidogenic capacity in vitro and furthermore do not accumulate 
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cAMP following ACTH stimulation (Cheng and Hornsby, 1992). The bovine 
adrenal cells immortalised by TERT have yet to be studied extensively in vitro and 
may require optimisation of growth conditions in order for cells to respond to 
ACTH. In the H295R model, we found a cell line that although studied extensively 
for its glomerlosa like functions and angiotensin II responses, also displays a 
number of characteristics of performing fasciculata functions. Its weak cAMP and 
cortisol response to ACTH was already known however this is the first time this 
cell line has been shown to potently stimulate Erk1/2 activity similar to that seen by 
other GPCRs. The fact that no effect of ACTH on the PI3 kinase/Akt pathway 
was seen is a very important observation because it was the dephosphorylation of 
Akt that was thought to be responsible for mediating the anti-proliferative effect of 
ACTH in Y1 cells (Forti et al., 2002). Although proliferation experiments were 
inconclusive, I would hypothesize that although the Erk1/2 response to ACTH 
seems to be regulated to prevent over activation of the pathway, there would be no 
anti-proliferative effect of ACTH on this cell line due to the lack of a potent cAMP 
response. This characteristic also enables the closer study of the steps involved 
following the binding of ACTH to an adrenocortical cell through to the nuclear 
targeting of Erk1/2, seemingly without the complication of cAMP mediated effects. 
It may be that the lack of regulation of the cell cycle by a cAMP/PKA dependent 
mechanism may have contributed to the malignancy of the original adrenal tumour 
in which H295R cells were derived. 
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4  MECHANISMS OF ERK1/2 ACTIVATION 
4.1  INTRODUCTION 
 
The activation of the Erk1/2 signalling cascade is a common feature of a range of 
cellular responses to a vast array of stimuli and is present in virtually all cell types. 
Since this is such a common feature, the specificity of each signal is thought to be 
dependent on the mechanisms by which this pathway is activated. For example, the 
final outcome and intracellular targets of the signal may be affected by the cellular 
location of activated Erk1/2 and the components recruited into signalling complexes 
(Tohgo et al., 2003). There are numerous steps involved in the transduction of an 
Erk1/2 signal from a GPCR agonist, many of which have been elucidated for other 
GPCRs. These pathways may be specific to certain cell types, certain receptors, or 
depend on the G-protein to which they are coupled. Some of these steps include 
PKA or cAMP dependent pathways; pathways dependent on the transactivation of 
a growth factor receptor; those dependent on an increase in PKC activity, 
sometimes by the switching of G protein coupling; and pathways dependent on the 
internalisation of a GPCR and/or the binding of β-arrestins which act as scaffolds 
for Erk1/2 signalling (Ohtsuka et al., 1996, van Corven et al., 1993, Daaka et al., 
1997, Luttrell et al., 1997). Such mechanisms have been discussed in detail in 
section 1.8. 
 
We established in the previous chapter that the H295R cell line is a good alternative 
model to Y1 cells for studying the effects of ACTH on Erk1/2 signalling. These cells 
express the MC2R, show specific binding to I125-ACTH and furthermore, respond 
to ACTH to produce cAMP. H295R cells also have a potent response in terms of 
activation of the Erk1/2 cascade following ACTH treatment. The aim of this chapter 
is to look in greater detail at the processes involved in ACTH signalling to Erk1/2, 
from the binding of ACTH to a receptor, coupling of the receptor to a G protein 
and the subsequent pathways which lead to an increase in the phosphorylation of 
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Erk1/2. The aim is to gain a greater understanding of the factors involved in these 
signalling mechanisms both for the MC2R and GPCRs in general. 
 
In order to look more closely at the intermediate steps involved, it was decided to 
use a strategy that would utilise many of the very specific inhibitors that are now 
available, to try to modulate the activities of important components in such 
signalling pathways and to look at the effect of these on Erk1/2 phosphorylation 
using western blotting. These inhibitors and their mechanisms of action are 
discussed below as follows: 
 
4.1.1  Inhibitors of PKA pathway 
 
H89 is a widely used cell-permeable inhibitor of PKA activity and although it is 
thought to be very selective at a concentration of 10-7 M, at higher concentrations it 
is thought to inhibit other protein kinases such as PKC (Cohen, 2002). Use of this 
inhibitor will allow us to investigate the role of PKA in ACTH induced Erk1/2 
activation. Another inhibitor, SQ22536 (9-(tetrahydro-2-furyl)-adenine), is a cell 
permeable inhibitor of adenylate cyclase activity. This inhibitor, an analogue of 
adenosine, was originally found to inhibit adenylate cyclase activity in human blood 
platelets and has been used previously in investigating the role of cAMP in Erk1/2 
signalling (Harris et al., 1979, Li et al., 2004). SQ22536 will allow us to investigate 
Erk1/2 activation independently of PKA. 
 
4.1.2  Pertussis toxin 
 
Pertussis toxin is secreted by the bacterium causing whooping cough, Bordetella 
pertussis. The S1 subunit of the toxin catalyzes the addition of ADP-ribose to the α 
subunit of Gi proteins irreversibly. This prevents the release of GDP thus locking it 
in the GDP bound state and abrogating its inhibitory effect on adenylate cyclase 
(Hsia et al., 1984). Experimental conditions for the use of this inhibitor vary from a 
few hours pre-treatment to 2 days. In order to be consistent with previous 
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conditions an overnight pre-treatment in SFM is deemed sufficient to investigate 
the role of Gi proteins in the transduction of the Erk1/2 signal by ACTH. 
 
4.1.3  Tyrosine kinase inhibitors 
 
To investigate the role of transactivation of tyrosine kinases, a number of general 
and specific chemical inhibitors are available. Genistein is a soy isoflavone with a 
structure similar to that of estradiol (Borras et al., 2006). It has been used widely as 
a potent inhibitor tyrosine kinase activity affecting the activity of all growth factor 
receptors and non-receptor tyrosine kinases such as c-src and may therefore be used 
to assess the general involvement of tyrosine kinases in the Erk1/2 pathway 
(Akiyama et al., 1987). AG1478 on the other hand is one of a range of AG 
compounds available that specifically and potently inhibits EGF receptor activity, a 
receptor commonly involved in the transduction of Erk1/2 signals by GPCRs. It has 
been used in a variety of studies including for example determining the role of EGF 
receptor transactivation following stimulation of endothelin-1, LPA and thrombin 
receptors in rat-1 fibroblasts (Kranenburg and Moolenaar, 2001, Xu et al., 2007). 
 
In investigating specifically the role of src family kinases various chemical inhibitors 
are available. PP1 and PP2 are related compounds, both found to be potent, 
selective inhibitors of src family kinases at nanomolar ranges (Hanke et al., 1996, 
Karni et al., 2003). However one study reported the inhibition of the PDGF 
receptor by both chemicals therefore use of another inhibitor, SU6656, which is 
also a cell permeable, potent src inhibitor that does not inhibit PDGF receptor 
activity is a further alternative in investigating the role of src family kinases in Erk1/2 
acitivation (Blake et al., 2000).  
 
4.1.4  PKC and Ca2+ pathway inhibitors 
 
Several inhibitors of the PKC pathway are available for investigation of these 
components in ACTH induced Erk1/2 activation. GF109203X is a highly selective, 
cell permeable PKC inhibitor that competitively binds to the ATP-binding site of 
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many of the PKC isoforms (Toullec et al., 1991). Calphostin C is also a highly 
specific inhibitor of PKC however it binds to its regulatory domain and therefore 
competes for the binding of DAG and phorbol esters (Kobayashi et al., 1989).  
 
To investigate whether an influx of Ca2+ following ACTH binding to the MC2R is 
involved in mediating an Erk1/2 response, the L-type Ca2+ channel blocker, 
nifedipine, may be used as one of the most extensively studied inhibitors of this 
process. Nifedipine is also used clinically as a vasodilator. In addition however, 
BAPTA-AM is a cell permeable form of BAPTA, a Ca2+ chelator, which will allow 
an investigation into the involvement of intracellular Ca2+ release in mediating the 
Erk1/2 response (Tsien, 1980).  
 
4.1.5  Inhibitors of Akt pathway 
 
The cell permeable fungal metabolite, wortmannin, is a potent, selective and 
irreversible inhibitor of PI3-K catalytic activity that has been widely used in 
investigating the role of this component in various signalling mechanisms (Yano et 
al., 1993). Although other inhibitors such as LY294002 have been developed, 
wortmannin is still the inhibitor of choice for most researchers. 
 
4.1.6  Inhibitors of internalisation 
 
Two widely used inhibitors of receptor internalisation are sucrose and mono 
dansylcadaverine (MDC). Sucrose has been shown previously in our laboratory to 
inhibit internalisation of ACTH, possibly by causing abnormal polymerization of 
clathrin into empty microcages thus rendering clathrin unavailable to form coated 
pits (Heuser and Anderson, 1989, Baig et al., 2002). MDC is also a widely used 
inhibitor of receptor endocytosis, which functions by preventing clathrin coated pit 
formation through covalent coupling to the membrane (Davies et al., 1984). 
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4.2 METHODS 
4.2.1  Pre-treatment of H295R cells with inhibitors and stimulators 
 
Pertussis toxin, SQ22536, genistein, MDC, AG1478, PP2, SU6656, GM6001, 
Calphostin C and GF109203X were obtained from Calbiochem (Nottingham, UK), 
and used at the concentrations indicated. H89, nifedipine, Phorbol 12-myristate 13-
acetate
 
(PMA)
 and human recombinant epidermal growth factor (EGF) were 
obtained from Sigma-Aldrich (Poole, UK). BAPTA-AM was obtained from AG 
Scientific (San Diego, CA). NDP-αMSH and 11-24 ACTH was obtained from 
Bachem (Merseyside, UK). The anti phospho tyr-417 src antibody was purchased 
from Cell Signaling Technology (Danvers, MA, US) and the monoclonal anti-src 
clone GD11 antibody was from Upstate Cell Signaling Solutions (Lake Placid, NY).  
 
Table 4.1 demonstrates the vehicle in which chemicals were dissolved and 
concentrations at which inhibitors were reconstituted, stored and used. 
 
Inhibitor Form Final 
concentration 
(M) 
Details 
H89 10-2 M in 
DMSO 
10-5 Aliquot and store at -20°C. Dilute in 
SFM. 
SQ22536 Lyophilised  10-4 and 10-5 Reconstitute in H2O to 0.1 M, aliquot 
and store at -20°C. Dilute in SFM. 
PTX Lyophilised 100 ng/ml Reconstitute in sterile dH2O to 50µg/ml, 
aliquot and freeze. Dilute in SFM. 
Genistein Lyophilised 5 x 10-6 Reconstitute in DMSO to 0.01 M, aliquot 
and store at -20°C. Dilute in SFM. 
AG1478 Lyophilised 10-6 Reconstitute in DMSO to 0.01M, aliquot 
and store at -20°C. Dilute in SFM. 
PP2 10-2 M in 
DMSO 
10-6 Aliquot and store at -20°C. Dilute in 
SFM 
SU6656 10-2 M in 
DMSO 
10-6 Aliquot and store at -20°C. Dilute in 
SFM 
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GF109203X Lyophilised 5 x 10-6 Reconstitute in DMSO to 0.01 M, aliquot 
and store at -20°C. Dilute in SFM. 
Calphostin C Lyophilised 10-6 Reconstitute in DMSO to 10-3 M, aliquot 
and store at -20°C. Dilute in SFM. 
Nifedipine Lyophilised 10-6 Prepare a stock solution of 10-3 M in 
DMSO. Aliquot and store at -20°C. 
Dilute in SFM. 
BAPTA-AM Lyophilised 5 x 10-5 Reconstitute in DMSO to 0.01 M, aliquot 
and store at -20°C. Dilute in SFM. 
Wortmannin Lyophilised 10-7 Reconstitute in DMSO to 10-2 M, aliquot 
and store at -20°C. Dilute in SFM. 
Sucrose Solid 0.45 Prepare fresh in SFM 
MDC Lyophilised 3 x 10-4 Reconstitute in DMSO to 10 mg/ml, 
aliquot and store at –20°C. Dilute in 
SFM. 
 
Table 4.1 Summary of inhibitors and their preparation. 
 
4.3 RESULTS 
4.3.1  Investigating the role of the MC2R in Erk1/2 activation 
 
Previous reports demonstrate that ACTH binds with by far the highest affinity to 
the MC2R (see table 1.1), and is therefore the most likely receptor to mediate the 
action of ACTH in terms of the Erk1/2 response. However, ACTH also binds with a 
lower affinity to other melanocortin receptors raising the possibility of ACTH 
acting through a different receptor to produce this response. In addition, data from 
binding studies in the previous chapter imply that binding of 125I ACTH to H295R 
cells is a very low affinity interaction with an IC50 of 1.11 x 10-6 M in contrast to a 
previously described IC50 for ACTH binding in Y1 cells of 0.3 nM (Schioth et al., 
1996). This suggests that ACTH may bind to an alternative melanocortin receptor 
in the H295R cell line, which could in turn mediate activation of the Erk1/2 
pathway. To test this hypothesis we used an analogue of α-MSH. α-MSH and γ-
MSH are natural endogenous hormones for the human melanocortin-1, 3, 4 and 5 
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receptors. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone 
(NDP-MSH) is a synthetic analogue of α-MSH and was initially found to act as a 
highly potent melanotropin with long bioactivity, and also acts as a potent agonist at 
these four receptors but has no affinity for the MC2R (Sawyer et al., 1980, Joseph et 
al., 2003). This peptide was used in a time-course of activation of H295R cells to 
investigate whether NDP-MSH could mimic the Erk1/2 response given by that of 
ACTH (Fig. 4.1).  
 
Fig. 4.1 demonstrates that there is no significant activation of Erk1/2 along a time-
course of 30 mins after treatment with 10-7 M NDP-MSH compared with 
unstimulated cells and with 10-7 M ACTH stimulated cells at 5 min.  
 
 
 
 
 
 
 
 
 
 
 
Fig 4.1 H295R cells were plated into 6 well plates and when 70-90 % confluent left in SFM overnight. 
The next day cells were treated with either 10-7 M NDP-MSH or 10-7 M ACTH for the indicated 
times. Lysates were harvested and analysed for phospho Erk1/2 (upper panel). Blots were stripped and re-
probed for total Erk1/2. This is representative of two independent experiments. 
 
4.3.2  Involvement of cAMP and PKA in Erk1/2 activation by ACTH  
 
The most common mechanism by which Gs coupled GPCRs mediate Erk1/2 
responses is through cAMP and PKA dependent processes. Although the cAMP 
response to ACTH was modest, we attempted to mimic this elevation of cAMP 
NDP-MSH (10-7 M)
5 10 15 30
unstim
5
ACTH
Phospho Erk1/2
Total Erk1/2
Time (mins)
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using a submaximal dose of forskolin. At 10-6 M forskolin a comparatively similar 
cAMP stimulation to that obtained with 10-7 M ACTH was seen (Fig. 4.2A). This 
induced Erk1/2 phosphorylation almost as effectively as ACTH implying that 
forskolin and ACTH are acting through the same pathway (Fig. 4.2B).  
 
 
 
Fig. 4.2 Forskolin activation of cAMP production and Erk1/2. H295R cells were left in SFM for either 
1 h (A) or overnight (B). Cells were then treated for 30 min (A) or 5 min (B) with SFM, 10-7 M 
ACTH or 10-6 M forskolin. Measurement of cAMP production (A) and Erk activation (B) were then 
analysed. For A, n=3 and error bars represent the SEM. For B, n=2. 
 
However, when a combination of ACTH and forskolin was investigated, it was 
apparent that ACTH was additive to a maximal dose of forskolin implying the 
presence of an alternative ACTH dependent pathway (Fig. 4.3A). The PKA 
inhibitor, H89 (10-5 M) was only partially effective at reducing the forskolin 
response however it was ineffective at reducing the ACTH induced Erk1/2 
activation (Fig. 4.3B). An inhibitor of adenylate cyclase activity, SQ22536, was used 
to investigate the involvement of cAMP in the ACTH induced Erk1/2 response. At 
the two concentrations used no significant effect on Erk1/2 activation was seen (Fig. 
4.3C). 
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Fig 4.3 The role of the cAMP pathway in transducing the ACTH induced Erk1/2 
signal. A, H295R cells were pre-treated with forskolin for 1 hour followed by the addition for 5 minutes 
of the indicated reagents and analysed for phospho Erk1/2 levels. B, Cells were pre-treated for 1 hour with 
SFM or 10-5 M H89 prior to the addition of either SFM, forskolin (10-6 M) or ACTH (10-7 M). The 
graph shows densitometry on the results of 3 independent experiments with error bars representing SEM. 
C, Cells were pretreated for 1 hour with vehicle or SQ22536 (at the indicated concentrations) prior to the 
addition of SFM or ACTH at 10-7 M. The above results are representative of three experiments in each 
case. 
 
4.3.3 Involvement of alternative Gi protein subunits 
 
We investigated the possibility that the Erk1/2 signal is mediated by the switching of 
coupling of the MC2R from Gs to Gi by use of pertussis toxin (PTX). Fig. 4.4 
shows the result of a 24 hour pre-treatment with pertussis toxin followed by a 5 
minute treatment with either SFM or 10-7 M ACTH. No effect on Erk1/2 activation 
is seen suggesting that ACTH induced Erk1/2 activation is not dependent on Gi 
proteins.  
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Fig. 4.4  Effect of PTX on Erk1/2 activation. H295R cells were plated into 6 well plates and when 
around 70 % confluent were serum-starved over-night in the presence or absence of 100 ng/ml PTX. Cells 
were treated for 5 min with ACTH or SFM and harvested for analysis of Erk1/2 phosphorylation. This 
is representative of three independent experiments. 
 
4.3.4 Transactivation of a receptor or non-receptor tyrosine kinase 
 
Common intermediary components involved in the transduction of Erk1/2 signals, 
from agonist binding at GPCRs, are growth factor tyrosine kinases. Genistein, a 
general inhibitor of tyrosine kinases, was used initially to assess their involvement 
(Fig. 4.5).  
 
Fig. 4.5A demonstrates partial inhibition of EGF induced Erk1/2 activation by 50 
µM genistein however it was unable to modulate ACTH induced Erk1/2 
phosphorylation. This suggests that tyrosine kinase activity is not involved in the 
ACTH induced Erk1/2 response. To further confirm this a number of other, more 
specific, inhibitors of tyrosine kinase activity were also tested. AG1478, a potent 
and specific inhibitor of EGF receptor activity was used to confirm that Erk1/2 
phosphorylation was not mediated through transactivation of the EGF receptor, as 
the most commonly activated receptor in the mediation of the Erk1/2 cascade from 
GPCRs. Fig 4.5B shows the potent inhibition of EGF induced Erk1/2 by this 
compound but the lack of effect on Erk1/2 activation by ACTH, further suggesting 
that the EGF receptor has no role in this particular response. 
 
 
- + - + 
PTX SFM 
Phospho Erk1/2 
Total Erk1/2 
ACTH (10-7 M) 
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Fig. 4.5 Transactivation of a tyrosine kinase receptor does not mediate Erk activation. H295R cells were 
plated into 6 well plates and when around 70 % confluent were left in SFM overnight. The next day cells 
were pre-treated for 1 h with either vehicle alone, 50 µM Genistein (A) or 1 µM AG1478 (B) prior to 
the addition of ACTH (to a final concentration of 10-7 M), EGF (to a final concentration of 100 ng/ml) 
or SFM (-) for 5 mins. Cells were harvested and analysed for phospho and total Erk1/2 levels. 
Densitometry of results from 3 independent experiments are shown with error bars representing SEM. 
0
200
400
600
800
1000
1200
1400
Un ACTH EGF Un + AG ACTH +
AG
EGF + AG
- + - + - + - +EGF ACTH
Vehicle Genistein Vehicle Genistein
Phospho Erk1/2
Total Erk1/2
- ACTH EGF ACTH-
AG1478
EGF
Phospho erk1/2
Total erk1/2
A
B
0
100
200
300
400
500
600
700
800
Un ACTH EGF Un + gen ACTH +
gen
EGF + gen
Ph
o
sp
ho
/T
o
ta
l E
rk
1/
2
(%
 
u
n
st
im
u
la
te
d)
Ph
o
sp
ho
/T
ot
al
 
Er
k 1
/2
(%
 
u
n
st
im
u
la
te
d)
Ph
o
sp
ho
/T
o
ta
l E
rk
1/
2
(%
 
u
n
st
im
u
la
te
d)
Ph
o
sp
ho
/T
ot
al
 
Er
k 1
/2
(%
 
u
n
st
im
u
la
te
d)
Ph
o
sp
ho
/T
o
ta
l E
rk
1/
2
(%
 
u
n
st
im
u
la
te
d)
Ph
o
sp
ho
/T
ot
al
 
Er
k 1
/2
(%
 
u
n
st
im
u
la
te
d)
 133 
 
 
Src family members are often involved in transducing an Erk1/2 signal from a GPCR 
agonist therefore it was decided to look at the role of these tyrosine kinases in the 
ACTH response. Firstly, specific inhibitors of Src family kinases, PP2 and SU6656, 
were investigated (Fig. 4.6A).   
 
 
 
 
 
 
 
 
 
 
Fig. 4.6 A, H295R cells were pre-treated for 1 h with either, vehicle alone, PP2 (10-6 M) or SU6656 
(10-6 M) prior to addition of ACTH to the medium (final concentration of 10-7 M) and lysates were 
analysed for phosphorylation of Erk1/2. Densitometry on 3 independent experiments was performed with 
error bars representing SEM. B, H295R cells were treated for 5 mins with SFM, ACTH or 10 % 
serum and lysates were analysed for phospho src. The blot was stripped and re-probed with anti-Src (Clone 
GD11). 
 
No difference was seen between ACTH stimulation alone versus pre-treatment 
with either PP2 or SU6656 suggesting that, as implied previously with genistein pre-
treatment, the Src family tyrosine kinases are not involved in this response. 
However, to confirm this, it was decided to look at whether members of this family 
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were phosphorylated following ACTH stimulation. Using a phospho Tyr-417 
specific Src family kinase antibody, H295R cells treated with SFM, ACTH (10-7 M) 
or 10 % serum for 5 mins were analysed by Western blotting for Src 
phosphorylation and for total Src protein (Fig. 4.6B). No phosphorylation of Src 
was seen with ACTH treatment and furthermore, treatment with serum produced 
only a faint band that could only be seen after a long exposure. This may be 
explained by low expression of Src in this cell line as evidenced by the total Src 
antibody. 
 
4.3.5 Investigation into the role of the PKC pathway 
 
As previously mentioned, a possible role for Ca2+ in the binding of ACTH to its 
receptor and the influx of Ca2+ after ACTH stimulation has been demonstrated 
(Cheitlin et al., 1985, Enyeart and Enyeart, 1998), thus the involvement of Ca2+ and 
the possible activation of the PKC pathway in the Erk1/2 cascade were investigated. 
PKC inhibitory compounds were tested for their ability to inhibit PKC activation 
using the phorbol ester PMA, a potent activator of this pathway, as a positive 
control (Fig. 4.7B). PMA activated Erk1/2 at 10-7 M and this was inhibited using 5 x 
10-6 M GF109203X. Calphostin C, used at 10-6 M did not inhibit this activation 
(data not shown), however this is not surprising since this inhibitor competes for 
binding of DAG but has no effect on Ca2+ induced stimulation of PKC activity. 
These inhibitors were then used at the same concentrations to look at the effect on 
Erk1/2 activation after ACTH treatment of H295R cells for 5 mins (Fig. 4.7B). No 
inhibition of Erk1/2 was evident (calphostin C – data not shown) and since these 
inhibitors cover a broad spectrum of PKC isoforms, this suggests that the 
activation of PKC is not required for Erk1/2 activity.  
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Fig. 4.7 A, H295R cells were pre-treated with 5 x 10-5 M BAPTA-AM or 10-6 M nifedipine prior to 
stimulation with ACTH (10-7 M) and analysed for phospho and total Erk1/2. Densitometry was 
performed on results of 3 independent experiments with error bars representing SEM. B, cells were treated 
with 10-6 M  calphostin C or 5 x 10-6 M GF109203X prior to the addition of PMA (10-7 M) or 
ACTH (10-7 M) for 5 mins and analysed for phospho Erk1/2. Densitometry was performed on results of 
3 independent experiments with error bars representing SEM. 
 
A
B
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To investigate whether the influx of Ca2+ following ACTH binding to the MC2R 
was mediating an Erk1/2 response, the L-type Ca2+ channel blocker, nifedipine was 
used at 10-6 M. In addition, to look at the involvement of intracellular Ca2+ release 
in mediating the response, BAPTA-AM, a Ca2+ chelator, was used at 5 x 10-5 M. 
Fig. 4.7A shows that pre-treatment with these inhibitors also had no effect on the 
activation of Erk1/2 by ACTH suggesting that the activation of this pathway is not 
mediated by a mechanism involving Ca2+. 
 
4.3.6 Interaction with the PI3-Kinase/Akt pathway 
 
As discussed previously, many studies of GPCRs have demonstrated the upstream 
activation of the PI3-K/Akt pathway prior to Erk1/2 activation. Furthermore the 
activity of this pathway has been previously shown in Y1 cells to be altered 
following ACTH exposure although its levels are not significantly altered in H295R 
cells (see Chapter 3). It was therefore decided to look at the effect of inhibition of 
this pathway on ACTH induced Erk1/2 activation. Fig. 4.8A demonstrates the 
potent inhibition of constitutive Akt phosphorylation in H295R cells following a 1 
h pre-incubation with 0.1 µM wortmannin. In contrast to the effect on Akt 
phosphorylation, the same concentration of wortmannin did not modulate Erk1/2 
activation induced by ACTH treatment (Fig. 4.8B) suggesting that the PI3-
Kinase/Akt pathway does not act upstream of Erk1/2 activation in this case. 
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Fig. 4.8 Akt phosphorylation is not a pre-requisite for Erk1/2 activation. A, H295R cells were treated 
with 0.1 µM Wortmannin or SFM for 1 h and lysates analysed for levels of phospho Akt and total 
Erk1/2. B, H295R cells were pre-treated for 1 h with 10
-7 M Wortmannin or SFM prior to adding 
ACTH to a final concentration of 10-7 M ACTH or SFM for 5 mins. Lysates were analysed for 
phospho and total Erk1/2.  
 
4.3.7  Involvement of Internalisation in signalling to Erk1/2 
 
Although there are various approaches to modulating internalisation including the 
use of dominant negative expression of dynamin, GRKs and β-arrestin, we first 
used inhibitors of clathrin-mediated internalisation to investigate the effects on 
ACTH induced Erk1/2 activation. Fig. 4.9 demonstrates the effects of pre-treatment 
with two widely used inhibitors of clathrin-mediated internalisation, sucrose (Fig. 
4.9B) and dansylcadaverine (Fig. 4.9A), on ACTH stimulated Erk1/2 activation 
compared to vehicle alone.   
 
Fig. 4.9A shows a normal time-course of Erk1/2 activation, peaking at 5 mins 
following ACTH treatment and reducing back to basal levels by 60 mins when cells 
were treated with vehicle alone. However, in the presence of 0.3 mM 
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dansylcadaverine, the potent Erk1/2 activation at 5 mins is completely abolished. In 
contrast H295R cells treated with 10% FBS for showed potent Erk1/2 activation 
after 5 mins that was unaffected by pre-treatment for 1 hour with dansylcadaverine.  
 
On the other hand, cells pre-treated for 1 h with 0.45 M sucrose, showed a large in 
increase in Erk1/2 activation before stimulation with ACTH compared to vehicle 
alone (Fig. 4.9B). This would suggest a very non-specific effect that is presumably 
the result of osmotic shock induced by such a high concentration of sucrose. 
Treatment with ACTH caused no further increase in Erk1/2 phosphorylation, 
however it cannot be suggested that this was due to inhibition of internalisation of 
the MC2R because the system was saturated.  
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Fig. 4.9 H295R cells were serum starved overnight then treated with either vehicle alone or 0.3 mM 
dansylcadaverine (A,) or vehicle alone or 0.45 M sucrose (B) for 1 h prior to the addition of 10-7 M 
ACTH for the indicated times (A) or for 5 mins (B). Cell lysates were analysed for phospho and total 
Erk levels. Densitometry of results from 3 independent experiments was performed. Error bars represent 
SEM. The * denotes a significant difference between the two ACTH treatments where p<0.05. 
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4.4  DISCUSSION 
 
4.4.1  The role of the MC2R 
 
This chapter aimed to elucidate some of the mechanisms involved in the activation 
of the Erk1/2 cascade by ACTH. The response would be presumed to be mediated 
though the binding of ACTH to the MC2R as the highest affinity receptor and as 
the mediator of steroid synthesis in the adrenal. However, since binding data in the 
previous chapter demonstrated a low affinity interaction of ACTH with the H295R 
cell surface, it was therefore necessary to investigate whether the Erk1/2 response 
was being mediated by an alternative melanocortin receptor. NDP-MSH provided a 
useful tool since it acts as a potent agonist at melanocortin receptors other than the 
MC2R, for which it has no affinity. This peptide however had no stimulatory effect 
of the Erk1/2 cascade in contrast to ACTH (Fig. 4.2) suggesting therefore that 
ACTH is unlikely to bind to another melanocortin receptor to bring about this 
response. Attempts to further investigate the central role of the MC2R in mediating 
the ACTH induced Erk1/2 response were hampered by a lack of availability of an 
effective MC2R receptor antagonist. An N-terminally truncated fragment of ACTH 
(11-24) has been previously shown to act as an antagonist at the MC2R where 
cAMP production was abrogated (Seelig et al., 1971). However, when H295R cells 
were pre-incubated with this peptide prior to ACTH stimulation, no inhibitory 
effect was seen (data not shown). However, this is not surprising since others have 
reported a steroidogenic effect of this peptide and further, one study showed an 
additive effect on a maximal dose of ACTH (1-39) (Szalay et al., 1989). 
 
These findings therefore do provide evidence to support a role for the MC2R in 
mediating the Erk1/2 response to ACTH in these cells, but further highlights the 
difficulties in studying responses through this receptor. 
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4.4.2  Role of Gi proteins 
 
A review by Rashid et al (Rashid et al., 2004) discussed the complexity of GPCR 
signalling and highlighted the promiscuity of many GPCRs which couple to 
alternative G-proteins. In view of this and the fact that several GPCRs have been 
shown to induce Erk1/2 activation through alternative G-protein coupling (Daaka et 
al., 1997), it was decided to investigate whether this could occur in response to 
ACTH in H295R cells. Coupling of the MC2R to a Gi protein may have explained 
the dampened cAMP response to ACTH in these cells. Results from a single 
experiment however (triplicate wells), showed an additive effect of ACTH and 
forskolin on cAMP production suggesting that ACTH does not couple to Gi to 
inhibit this response (data not shown). However, better evidence is the lack of 
effect of PTX on ACTH induced Erk1/2. For many receptors, alternative coupling 
to different G proteins most likely occurs due to different functional roles in 
heterologous cell types (Wu et al., 1997, Holst et al., 2001). Given that the main site 
of expression of MC2R is the adrenal gland, it would be surprising to find 
alternative coupling in adrenal cells such as H295Rs. 
 
4.4.3  Involvement of Gs coupling and the cAMP/PKA pathway 
 
Previous studies of Gs coupled receptors have demonstrated a direct role of the αs 
subunit in mediating Erk1/2 responses through the direct binding to Src as in the 
case of the β-adrenergic receptor (Ma and Huang, 2002). In addition, many other 
Gs coupled GPCRs also involve Gαs in the activation of Erk1/2 where the increase 
in cytosolic cAMP and/or the activation of PKA results in the activation of an 
upstream kinase of Erk1/2 (Norum et al., 2003, Klinger et al., 2002).  
 
Attempts at RNAi mediated knock down of the Gαs gene were unsuccessful due to 
low transfection efficiency seen in these cells and therefore a role for the αs subunit 
acting as a direct effector upstream of Erk1/2 activation cannot be ruled out. In the 
future, use of a stably transfected RNAi hairpin may over come this problem. 
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Alternatively, one study outlined a method for elucidating the role of Gs in Erk1/2 
signalling where expression of an 83 amino acid polypeptide derived from the c-
terminus of Gαs disrupted cAMP signalling of the dopamine 1A receptor and the 
β2 AR (Feldman et al., 2002).  
 
ACTH is only a weak activator of cAMP accumulation in H295R cells, however, 
interestingly, using a submaximal dose of forskolin to mimic the level of cAMP 
production to that of 10-7 M ACTH lead to very similar Erk1/2 responses. This is 
highly suggestive of a common mechanism of Erk1/2 activation by ACTH and 
forskolin by a cAMP/PKA mediated mechanism. However, in contrast to this were 
three further pieces of information. Firstly, when added in combination, ACTH and 
forskolin produced an additive Erk1/2 induction implying that alternative pathways 
are utilised. Secondly, the PKA inhibitor, H89, was effective (albeit not completely) 
at reducing forskolin mediated Erk1/2 activation, however it had little or no effect 
on the ACTH induced effect. Thirdly, the adenylate cyclase inhibitor SQ22536 had 
no effect on ACTH induced Erk1/2 activity further suggesting that a cAMP/EPAC 
mediated mechanism is unlikely to be important in this response. We therefore 
conclude that whilst cAMP production and activation of PKA, and possibly EPAC, 
is the probable mechanism of forskolin induced Erk1/2 activation, ACTH action 
largely by-passes this mechanism. This is consistent with results seen in PKA-
deficient Y1 cells (Le and Schimmer, 2001, Lotfi et al., 1997). 
 
An interesting further experiment would be to look at the effect of H89 on ACTH 
induced Erk1/2 activation over a time-course of ACTH treatment. It has been 
suggested previously that PKA can exert a negative feedback on Erk1/2 activity 
through the phosphorylation of src (Schmitt and Stork, 2002) and indeed it was 
previously shown in Y1 cells that the anti-mitogenic effect of ACTH was mediated 
through a mechanism dependent on the cAMP/PKA pathway (Lotfi et al., 1997) 
therefore it would be interesting to see whether Erk1/2 activity would be prolonged 
in H295R cells in the presence of H89.  
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4.4.4  Involvement of Gq/PKC pathway 
 
A number of Gs coupled GPCRs have been shown to couple to both Gs and Gq 
proteins, one example of which is the glucagon-like peptide-1 receptor in CHO 
cells (Montrose-Rafizadeh et al., 1999). In addition, constituents of Gq coupled 
pathways may also be activated by alternative means other than through Gq 
coupling itself. Activation of Ca2+ channels within the plasma membrane can allow 
an influx of Ca2+ and result in the activation of PKC. There is evidence, largely 
from primary cultures of adrenal cells, that ACTH can induce Ca2+ influx via the 
opening of plasma membrane Ca2+ channels (Enyeart, 2005) which might in turn 
activate PKC and subsequently the Erk1/2 pathway. Indeed, studies in Y1 cells 
would support the involvement of PKC in ACTH induced Erk1/2 activation where 
PMA treatment mimicked that of ACTH in activating Erk1/2 (Lotfi et al., 1997). 
Our results also confirmed that PMA mimics ACTH treatment in H295R cells, 
however, the use of inhibitors of PKC activity did not show that PKC acts 
upstream of Erk1/2 activation. The use of two PKC inhibitors ensured coverage of a 
broad range of isoforms as these inhibitors have different mechanisms of actions 
(Salamanca and Khalil, 2005) and neither had any effect on the level of Erk1/2 
activation induced by ACTH. Therefore it can be concluded that these signalling 
molecules are unlikely to be involved in this response.  
 
Neither Ca2+ influx nor release from intracellular stores was also shown to be likely 
to play a role in Erk1/2 activation since neither the Ca2+ channel blocker (nifedipine) 
nor the Ca2+ chelator (BAPTA-AM) had any effect on Erk1/2 activation in response 
to ACTH.  
 
4.4.5 Growth factor transactivation and src 
 
The transactivation of EGF receptors is a common feature in the transduction of 
mitogenic signalling pathways initiated in response to GPCR agonists. Inhibition of 
EGF receptor activity using the EGF specific inhibitor AG1478, has been shown to 
abolish downstream Erk1/2 activation and proliferation in response to EGF and 
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GPCR agonists (Yin et al., 2003, Shah and Catt, 2002). A time course of EGF 
treatment showed potent stimulation of Erk1/2 activation in a manner similar to 
ACTH (data not shown). Although a similar pattern of activation was seen, the 
EGF induced response did not reduce back to basal over the 1 hour investigated. 
However, since there was a similarity in the time-course, transactivation of the EGF 
receptor was thought to be a good candidate for mediating the ACTH response, 
albeit a weaker activation. However, even though results from this chapter have 
demonstrated the complete abolition of EGF induced Erk1/2 activity by AG1478, 
this inhibitor had no effect on ACTH induced Erk1/2 activity. It appears, therefore, 
that this common mechanism of activation of Erk1/2 by GPCRs is not involved 
with this particular response.  
 
Many of the studies implicating a role for growth factor transactivation by GPCRs 
have demonstrated the autophosphorylation of the EGF receptor, however, other 
tyrosine kinase receptors such as the PDGF receptor have also been implicated 
(Wang et al., 2005). Furthermore, one study has described the transactivation of the 
fibroblast growth factor (FGF) receptor-1 with agonist stimulation of the µ opioid 
receptor in rat C6 glioma cells (Belcheva et al., 2002). They demonstrated that a 
dominant negative FGF receptor-1 attenuated µ opioid receptor induced Erk1/2 
activation and found the response to be mediated through Gβγ, Ca2+, PKC and 
matrix metalloprotease (MMP) dependent release of FGF from glioma cells. FGF 
has also been shown to stimulate potent proliferation of Y1 cells suggesting that 
this receptor could be a candidate for transactivation by ACTH. However, this is 
unlikely for two reasons. Firstly, the use of genistein, a non-specific tyrosine kinase 
inhibitor, abrogated EGF induced Erk1/2 activation and, although not tested, would 
be expected to have the same effect with FGF; Secondly, studies in Y1 cells suggest 
that ACTH antagonises the proliferative effect of FGF through a process 
dependent on cAMP/PKA and the inactivation of PI3-K which results in 
destabilisation of c-Myc rather than transactivating this receptor (Lepique et al., 
2004).  
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Investigation into the role of the non-receptor tyrosine kinase src showed that this 
protein was unlikely to be involved in ACTH induced Erk1/2 activation. As 
previously mentioned, genistein had no effect on Erk1/2 activity following ACTH 
treatment and this inhibitor would be expected to inhibit src activity. In addition, the 
specific src inhibitors PP2 and SU6656 had no effect on ACTH induced Erk1/2 
activation and further, src was not phosphorylated on Tyr 416 to its active form 
following ACTH treatment (Fig. 4.8). The phospho src antibody cross reacts with 
various members of the src family kinases including Lyn, Fyn, Yes, Lck and Hck, 
thus it seems that no other family member was substituting for src in this pathway. 
In these experiments the phosphorylation of the tyrosine 527 residue was not 
investigated. Dephosphorylation of this residue leads to an increase in src activity 
and therefore this could lead to an increase in its activity in H295R cells (Roskoski, 
2005). However, this seems unlikely since total levels of src were almost 
undetectable. The fact that src has been shown to be involved in GPCR signalling to 
Erk1/2 for such a wide range of GPCRs, and via a number of different pathways, 
raises the possibility that other, as yet unidentified, proteins may play similar roles in 
the Erk1/2 response to ACTH. 
 
4.4.6 PI3-K/Akt pathway 
 
The observation in Y1 cells that Akt is dephosphorylated by 5 mins following 
ACTH treatment and that the upstream activator of Akt, PI3-K, is often involved 
in GPCR mediated activation of Erk1/2 lead us to look at the involvement of the 
PI3-K/Akt pathway in ACTH induced Erk1/2 activation in H295R cells. Results 
from the previous chapter showed high constitutive activation of Akt in H295R 
cells similar to that seen in Y1 cells (Forti et al., 2002). However, the activity of Akt 
generally remained unchanged following ACTH treatment. It was therefore 
hypothesised that inhibition of the PI3-K/Akt pathway would have no effect on 
ACTH induced Erk1/2 activation and, indeed, this was the case where wortmannin 
predictably abolished constitutive Akt phosphorylation but had no effect on ACTH 
induced Erk1/2 activation (Fig. 4.10). This difference between cell lines may be due 
to the weak cAMP response to ACTH in H295R cells. The dephosphoylation of 
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Akt seen in Y1 cells was thought to be mediated through a cAMP/PKA dependent 
mechanism since the effect could not be seen in a PKA defective derivative cell line 
(Forti and Armelin, 2000). Therefore, it is possible that in an adrenal cell in which 
ACTH is able to bring about both cAMP accumulation and Erk1/2 activation, that 
dephosphorylation of Akt via a cAMP dependent mechanism serves to regulate the 
activity of the Erk1/2 pathway. 
 
4.4.7  Receptor internalisation 
 
Finally, we have identified clathrin-mediated endocytosis as a possible pre-requisite 
for ACTH induced Erk1/2 activation using chemical inhibition of this process. 
MDC is thought to function by preventing clathrin coated pit formation (Davies et 
al., 1984). This inhibitor reduced the 5 min stimulation of Erk1/2 activity 
reproducibly back to basal levels (Fig. 4.11A) suggesting that either the recruitment 
of signalling components into the coated pit is necessary for Erk1/2 signalling 
and/or internalisation of the receptor is necessary to bring about the activation of 
this pathway. Conversely, pre-treatment with hypertonic sucrose caused a potent 
activation of the Erk1/2 cascade, presumably due to an osmotic shock effect, and 
therefore the effects of ACTH could not be analysed. The sucrose effect has been 
seen before in a previous study looking at the mechanisms of Ang II internalisation 
(Olivares-Reyes et al., 2005). Internalisation has been shown to be a pre-requisite 
for GPCR mediated Erk1/2 activation in many previous studies, however, in some 
cases, the effects were thought to be due to internalisation of a down-stream 
effector such as the EGF receptor (Vieira et al., 1996). In the case of the ACTH 
response, however, we have shown that internalisation of a growth factor tyrosine 
kinase is unlikely due to a lack of sensitivity of the Erk1/2 response to tyrosine 
kinase inhibitors.  
 
In view of this data and given previous findings from our laboratory that 
demonstrate the internalisation of the ACTH receptor, the following chapter 
investigates in greater detail the role of internalisation of the MC2R in mediating the 
Erk1/2 response.  
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5 THE ROLE OF INTERNALISATION OF THE MC2R 
IN SIGNALLING TO ERK 
 
5.1  INTRODUCTION 
 
Having demonstrated in the previous chapter a potential requirement for receptor 
internalisation in the mediation of the Erk1/2 signal by ACTH, further investigation 
was necessary to confirm this finding. Internalisation of ACTH in H295R cells has 
not been previously investigated however, in Y1 cells, acid wash techniques have 
shown specific internalisation of I125 ACTH which could be inhibited by sucrose 
(Baig et al., 2002). It was therefore intended to investigate the ability of H295R cells 
to internalise ACTH and, if so, to attempt to modulate this effect with sucrose (as a 
positive control) and MDC. This evidence will ascertain whether or not the 
inhibition of Erk1/2 signalling by MDC is through specific inhibition of receptor 
internalisation or a non-specific effect of the chemical. 
 
Receptor internalisation is measured most commonly using the acid wash technique 
(Hunyady et al., 1994), which was the primary method used in this chapter. An 
additional biotin method of visualising internalisation was used to confirm some of 
the results (see chapter 2.16 for a description of this technique). 
 
A further aim of the chapter is to investigate the role of the 
desensitisation/internalisation machinery in the mediation of the Erk1/2 response. 
Many studies have used stable and transiently transfected cell lines expressing 
dominant negative dynamin, GRK2 and ß-Arrestin (Ferguson et al., 1995, Damke 
et al., 1994, Ferguson et al., 1996a). However, more recently the use of RNAi has 
allowed the study of the role of such proteins. 
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5.2  METHODS 
 
The production of stable cell lines was chosen over transient transfection of the 
constructs as H295R cells have low transfection efficiency. In addition, by 
producing monoclonal lines, those lines showing the highest expression of 
dominant negatives could be selected for further experiments. 
 
All plasmids were kind gifts from Laszlo Hunyadi. The GRK2 (K220M) has a 
mutation in the kinase domain leaving the protein kinase inactive (Ferguson et al., 
1995). By competing with wild type GRK for receptors it exerts its dominant 
negative effect. The dominant negative dynamin plasmid (K44A) has a defect in 
GTP binding and hydrolysis and thus inhibits the budding of clathrin coated 
vesicles (Damke et al., 1994). Dominant negative ß-Arrestin 1 (V53D) binds well to 
clathrin but weakly to phosphorylated agonist-activated GPCRs thus mediating its 
dominant negative effect by competing with endogenous ß-Arrestin for clathrin. 
(Ferguson et al., 1996b, Krupnick et al., 1997, Orsini and Benovic, 1998). 
 
5.3  RESULTS 
5.3.1  Internalisation of the MC2R 
 
Having seen the effect of MDC on ACTH induced Erk1/2 activation, it was first 
necessary to confirm that the MC2R does internalise in response to ACTH 
treatment in H295R cells. Fig. 5.1 demonstrates specific internalisation of ACTH 
over 60 mins with around 16 % of cell surface ACTH receptors internalising over 
this period. Having demonstrated that the MC2R does internalise, a similar 
experiment was performed to determine whether this could be abrogated by 
treatment with MDC and also sucrose since this has been previously been shown to 
inhibit internalisation of the MC2R in Y1 cells. Fig. 5.2 demonstrates the results of 
these experiments.  
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Fig. 5.1 Internalisation of I125 ACTH in H295R cells.  I125 ACTH was added and incubated for the 
indicated times. Internalisation was measured using the acid wash technique. Samples were analysed in 
duplicate in 5 independent experiments. Error bars represent SEM. 
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Fig. 5.2 Effect of inhibitors on internalisation of MC2R. Cells were pretreated for 1 hour with either 
SFM, 0.4 M Sucrose or 0.3 mM MDC (DC) I125 ACTH was added and incubated for the indicated 
times and the amount of internalised ACTH analysed using the acid wash technique. Samples were 
analysed in duplicate in 3 independent experiments. Error bars represent SEM. 
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Although it appears that sucrose effectively inhibited internalisation, no significant 
difference was found between that of untreated and MDC treated cells. The acid 
wash technique however caused significant variance between experiments thus 
making it difficult to see small differences between treatments. It was therefore 
decided to use an alternative approach to confirm the effect of MDC, that of the 
biotin method of internalisation. In essence, the protocol firstly labels surface 
proteins with biotin. Cells are then treated with either SFM or MDC followed by 
ACTH accordingly. Cells are then treated with a non-cell-permeable reducing agent 
which removes all surface biotin. Subsequent immunoprecipitation with an 
antibody to the desired protein and immunoblotting with an anti-bitotin antibody 
allows detection of internalised proteins. Although this is not a quantitative method, 
a difference in intensities of the bands could be visualised (Fig. 5.3).  
 
 
 
Fig. 5.3 Effect of MDC on MC2R internalisation. H295R cells were treated with 10-7 M ACTH for 
the indicated times with or without MDC pretreatment. Internalisation was visualized using the Biotin 
method. This is representative of two independent experiments. 
 
This experiment demonstrates internalisation of the MC2R over 1 hr as shown with 
the acid wash technique. In addition it demonstrates the blocking of internalisation 
with MDC treatment over the full 1 hr period. 
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5.3.2  Effects of dominant negative dynamin, GRK2 and ß-Arrestin on 
Erk1/2 activation 
5.3.2.1 Expression of GRKs, dynamins and ß-Arrestins in H295R cells 
 
Using RT-PCR for the different isoforms, H295R cells were analysed for GRK, 
Dynamin and ß-Arrestin expression (Fig. 5.4). These results demonsrate that 
H295R cells express only GRK 2 and 3, Dynamin 1 and 2 and ß-Arrestin 1 and 2. 
 
 
 
Fig. 5.4 Expression of GRK, Dynamin and ß-Arrestin. PCRs were performed on H295R cDNA for 
30 cycles. Markers are shown in base pairs (bp). A, GRK2 (407 bp), GRK3 (401 bp), GRK4 (310 
bp), GRK5 (667 bp), GRK6 (547 bp). B, Dyn 1 (589 bp), Dyn 2 (635 bp). C, HeLa cDNA was 
used as a positive control for expression of ß-Arrestins. ß-Arrestin 1 (286 bp), ß-Arrestin 2 (193 bp), 
GAPDH (198 bp). 
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5.3.2.2  GRK2 dominant negative 
 
Monoclonal cell lines were produced using the method described in chapter 2.3.2. 
Fig. 5.5 shows the expression of the construct in G418 selected cells lines in clone 
1, 5 and 6 (A). These lines were therefore used to look at the effect of dominant 
negative inhibition of GRK on Erk1/2 activation by ACTH compared to cells 
expressing vector alone (B). It can be seen that the Erk1/2 response to ACTH is 
maintained in all three clones however it may be slightly enhanced compared vector 
alone.  
 
 
 
Fig. 5.5  GRK dominant negative expression. A, Several monoclonal cell lines were selected in media 
containing G418 and screened by RT-PCR (30 cycles) for expression of the plasmid. Lanes 1 and 2 in 
each case are controls for genomic DNA contamination and GAPDH respectively. Lane 3 for each clone 
represents expression of GRK dominant negative (GRKDN, 362 bp). + represents a positive control for 
the GRK PCR (plasmid DNA). B, Immunoblot for phospho Erk1/2 and total Erk on GRK clones (or 
vector alone clone) after treatment for 5 minutes with 10-7 M ACTH or SFM alone. This is representative 
of two experiments. 
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5.3.2.3  Dynamin dominant negative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.6  Dynamin dominant negative. A, Several monoclonal cell lines were selected in media containing 
G418 and screened by RT-PCR (30 cycles) for expression of the plasmid. Lanes 1 and 2 in each case are 
controls for genomic DNA contamination and GAPDH respectively. Lane 3 for each clone represents 
expression of Dynamin dominant negative (400 bp). + represents a positive control for the Dynamin PCR 
(plasmid DNA). B, Monoclonal wild type and dominant negative dynamin clonal cells were treated with 
either SFM (-) or ACTH (+) for 5 mins and immunoblotted for phospho Erk1/2 and total Erk1/2. C, 
Dynamin polyclonal cells were treated with ACTH or SFM (zero point) for the indicated times and 
immunoblotted for phospho Erk1/2 and total Erk1/2. Densitometry was performed on the resulting blot as 
a ratio of phopsho:total Erk1/2 . Responses were normalised to % of unstimulated cells. This data is from 
two experiments. 
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Monoclonal cell lines containing either wild type or dominant negative dynamin 
were produced and expression confirmed by RT-PCR (Fig.5.6A). Those cell lines 
with highest expression of the plasmids were analysed as above for their effect on 
ACTH induced activation of Erk1/2. Fig. 5.6B shows the results from two 
experiments.  
 
From this it can be seen that there is no significant difference between wild type 
and dominant negative clones. A time-course of ACTH treatment on polyclonal 
wild type and dominant negative dynamin expressing cells was also undertaken. 
Densitometry of the resulting blots was performed since there were differences in 
total Erk1/2 (Fig. 5.6C). This again demonstrated no significant differences between 
wild type and dominant negative dynamin cells, indicating that dynamin is unlikely 
to be involved in the ACTH induced activation of Erk1/2. 
 
5.3.2.4  ß-Arrestin dominant negative 
 
Finally, monoclonal H295R cell lines expressing wild type or dominant negative ß-
Arrestin were produced (Fig. 5.7A). Wild type clone 2 and dominant negative clone 
2 were compared for their ability to stimulate Erk1/2 in response to ACTH (B). No 
significant difference was found between the two. Additionally, polyclonal cell lines 
expressing each of the plasmids were treated similarly. Again, no differences could 
be seen in the size of the Erk1/2 response. Taken together, these results suggest no 
involvement of ß-Arrestins in the Erk1/2 response to ACTH.  
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Fig. 5.7 Dominant negative ß-Arrestin. A, Several monoclonal cell lines were selected in media 
containing G418 and screened by RT-PCR (30 cycles) for expression of GAPDH (198 bp) and the ß-
Arrestin (482 bp) plasmids. + represents a positive control for the ß-Arrestin PCR (plasmid DNA). B, 
ß-Arrestin clones (WT 2 and DN 2) were treated with ACTH (+) or SFM (-) for the 5 mins and 
immunoblotted for phospho Erk1/2 and total Erk1/2. C, ß-Arrestin (βA) polyclonal cells were treated 
with ACTH (+) or SFM (-) for 5 mins and immunoblotted for phospho Erk1/2 and total Erk1/2. This 
is representative of two experiments. 
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5.4  DISCUSSION 
 
In the previous chapter it was demonstrated that Erk1/2 activation induced by 
ACTH in H295R cells could be inhibited by MDC. MDC was first shown to inhibit 
internalisation of I125-EGF in acid wash internalisation studies (Haigler et al., 1980). 
Although the exact mechanism of interference in endocytosis is not known, it is 
thought to be due to its covalent coupling to cellular membranes mediated by the 
enzyme transglutaminase (Davies et al., 1984). This coupling appears to prevent 
clathrin mediated internalisation of a host of receptors in a number of cell types. 
Despite its wide use in similar studies, we wanted to confirm that MDC was 
mediating its Erk1/2 inhibitory effect through the modulation of internalisation of 
the MC2R. Therefore in this chapter we have verified through use of the biotin 
assay that MDC prevents internalisation of the MC2R over 1 hour implying that it 
is through such a mechanism that ACTH mediates Erk1/2 activation. It is difficult 
to quantify the amount of internalisation that has taken place in the first 5 minutes 
when the Erk1/2 response is at its strongest, however, results from the acid wash 
method (Fig. 5.1) would suggest that only around 4% of MC2-receptors have 
internalised at this point, suggesting that few receptors are required to cause this 
rapid response.  
 
These data are not comparable with those from any other GPCR since most 
internalisation dependent Erk1/2 activation mechanisms are seen with receptors 
which rapidly endocytose and have been discovered to be dependent on the 
internalisation of a transactivated growth factor receptor rather than the GPCR 
itself (Pierce et al., 2000). Given that the MC2R is demonstrated to internalise over 
1 hour in contrast to the 5 minute activation of Erk1/2, it suggests that there are 
regulatory mechanisms in place which quickly modulate the Erk1/2 response to 
allow only transient activity of this pathway. MAPKs are negatively regulated by 
MKPs and previous studies in H295R cells have demonstrated that stimulation of 
cells with dibutyryl-cAMP induces MKP-1 mRNA (within 30 minutes) and protein 
(within 1 hr). It also promoted increased 32P associated with MKP-1 (Sewer and 
Waterman, 2003). Thus the Erk1/2 response may be regulated through a cAMP 
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mechanism allowing only transient activation of this pathway. Although it was not 
done in this investigation, an interesting experiment would be to look at the effect 
of H89 on the timecourse of Erk1/2 activation to investigate whether Erk1/2 
activation was prolonged in the absence of cAMP regulation.  
 
5.4.1  Dominant negative Dynamin  
 
The fact that expression of a dominant negative dynamin in H295R cells did not 
effect Erk1/2 activation was surprising. Dynamin is directly required for the budding 
of clathrin coated vesicles and thus internalisation and since MDC was able to block 
this response, dominant negative dynamin would also be thought to have the same 
effect. Although the expression of the construct was confirmed by PCR analysis, 
protein expression was not determined thus we cannot rule out that the protein was 
functionally inactive. Due to time constraints, establishment of the effect of 
dominant negative dynamin expression on MC2R internalisation using the biotin 
method was not performed. Experiments using the acid wash technique however 
were not conclusive (data not shown). 
 
Alternatively, the lack of effect may be explained by the differing actions of MDC 
and the dominant negative dynamin. MDC is thought to prevent the formation of 
clathrin coated pits by covalent coupling to the membrane whereas the dominant 
negative dynamin blocks vesicle budding due to a defect in GTP binding and 
hydrolysis (Davies et al., 1984, Damke et al., 1994). It is possible therefore, that the 
formation of a vesicle is enough to allow recruitment of the necessary components 
to enable the activation of the Erk1/2 pathway. 
 
5.4.2 Dominant negative GRK and ß-arrestin 
 
Previous studies in our laboratory have demonstrated a possible role for GRKs in 
the desensitisation of the MC2R since the cAMP response induced by ACTH in Y1 
cells could not be desensitised by either forskolin or isoproterenol, and more 
importantly that expression of a dominant negative GRK inhibited internalisation 
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of the MC2R in Y1 cells (Baig et al., 2002). Y1 cells express both GRK2 and 5. 
Since H295R cells also expressed only two of the GRKs (2 and 3) it was thought 
that a dominant negative GRK2 would be sufficient to block the activity of both 
endogenous enzymes. The fact that the GRK mutant had no effect on Erk1/2 
activation was therefore surprising since it was assumed that GRK is involved in 
internalisation of the MC2R in H295R cells as it is in Y1 cells. This would seem 
reasonable as internalisation dynamics appear to be similar in both cell types, 
occurring over 1 hour with around 20% total internalisation in Y1 cells and 16% in 
H295R cells. Again, due to time constraints, it was not possible to analyse the effect 
of the mutant on ACTH internalisation by the biotin method, and therefore we 
cannot rule out the possibility that the dominant negative protein was not having its 
desired effect. 
 
Alternatively, GRK may mediate its effect by a mechanism independent of its 
kinase activity. The dominant negative mutant is still capable of binding to an 
activated receptor however, it is not able to phosphorylate it and recruit ß-arrestin. 
Therefore it is possible that GRK functions by recruiting Erk1/2 to receptor-GRK 
complexes within clathrin coated pits independently of receptor phosphorylation. 
This would concur with the apparent lack of effect of ß-arrestin mutants on Erk1/2 
activation in H295R cells. 
  
The GRK expression pattern in H295R cells is interesting in that studies utilising 
RNAi knock down of GRK isoforms have shown GRK 5 and 6 to be important in 
ß-arrestin 2 mediated Erk1/2 signalling for both the Angiotensin 1A receptor and 
the V2 Vasopressin receptor whereas GRK2 and 3 were not capable of mediating 
the response (Kim et al., 2005, Ren et al., 2005). Only GRK2 and 3 are present in 
H295R cells suggesting that the ACTH induced Erk1/2 response may be unlikely to 
occur via a ß-arrestin mediated mechanism. This is supported by the fact that those 
Erk1/2 responses mediated through ß-arrestin are usually prolonged in contrast to 
the transient response seen with ACTH treatment (Murphy and Blenis, 2006). 
These observations may explain why the expression of the ß-arrestin dominant 
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negative construct also appeared to have no effect on ACTH induced Erk1/2 
activation. 
 
Although this preliminary data using dominant negative forms of dynamin, GRK 
and ß-arrestin indicate no involvement of either internalisation or GRK/ß-arrestin 
mediated signalling, these mechanisms cannot be ruled out. In each case the 
dominant negative used is for one isoform whereas H295R cells express at least one 
other isoform. For this reason the dominant negative proteins may be insufficient 
to compete with all of the relevant proteins present.  For example it has been 
shown for the m3 muscarinic acetylcholine receptor that, out of dominant negative 
mutants to isoforms 2, 3, 5 and 6, only 6 was effective at blocking desensitisation 
(Willets et al., 2003). In addition, catalytically inactive GRK mutants impaired 
phosphorylation and internalisation of m2 mAChR in COS 7 cells but had no effect 
in BHK-1 or HEK 293 cells (Tsuga et al., 1994, Pals-Rylaarsdam et al., 1995). It was 
subsequently found that varied levels of GRK2 existed in the different cell types 
therefore the effectiveness of the dominant negative may be dependent on levels of 
GRK expressed in the cell line (Aramori et al., 1997). 
 
A study comparing the effectiveness of ß-arrestin dominant negative V53D and 
319-418, found that the V53D mutant was only modestly effective at inhibiting 
ß2AR internalisation in COS-1 cells since it still has some ability to bind to 
phosphorylated GPCRs (Krupnick et al., 1997). The 319-418 mutant, on the other 
hand, was more effective since it completely lacked the ability to bind to receptors 
but still had a high affinity to clathrin. If there were small differences in the Erk1/2 
response to ACTH using the V53D mutant, an immunoblot may not have been 
able to demonstrate this effectively due to a lack of sensitivity. Future studies to 
investigate the role of these mechanisms further could make use of RNAi to knock 
down the relevant proteins and again use the phospho Erk1/2 immunoblot to 
determine the effect. Successful RNAi knockdowns within the H295R cell line have 
since been carried out in our laboratory for other genes using stable expression 
systems. 
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Finally, a requirement for endocytosis in the Erk1/2 response to ACTH may be a 
mechanism through which signal specificity is conferred. This model fits with the 
suggestion that multiple mechanisms exist to spatially regulate the MAPK signalling 
pathways (Murphy and Blenis, 2006).   
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FINAL DISCUSSION 
 
In summary, this thesis has investigated, in a cell line not previously used for such 
studies, the potential mitogenic signalling mechanisms arising from the action of 
ACTH on adrenal cells. The H295R model has been shown to express a functional 
MC2R, expressed at low levels, evidenced by a weak but nonetheless significant 
cAMP response to ACTH. Furthermore, it has shown a strong and reproducible 
Erk1/2 activation in a manner similar to that shown in certain Y1 cell strains. This 
cell line however, although originating from a carcinoma, does not contain the 
mutant Ras oncogene present in Y1 cells and thus enables a more effective look at 
the Erk1/2 pathway. In addition, because there is only a weak cAMP response, this 
has allowed us to dissect out the Erk1/2 pathway without the interference of a 
robust cAMP/PKA response.  
 
Using the H295R model we have established that Erk1/2 activation is transient, 
peaking at 5 minutes and returning to basal levels by around 15 minutes. Studies as 
to the mitogenic effect of this transient response have so far produced conflicting 
results. Although short treatments of ACTH have shown an increase in Elk-1 
transcriptional activity as measured by luciferase activity, as yet a proliferative 
response has yet to be shown in terms of increasing cell number, although there did 
appear to be a dose dependent effect of ACTH in the presence of serum. These 
studies however, were hampered because H295R cells have a low rate of division 
and could not be maintained in SFM for periods needed to register a measurable 
response. An alternative method would be to use 2% serum in the presence of 
ACTH in order to maintain basal metabolism of the cells. In addition, other 
markers of proliferation such as BrdU labelling could be used as an earlier marker. 
There has been no recent advancement in this field in terms of establishing whether 
or not ACTH is involved in maintenance of growth of the adrenal. Clinical and 
animal evidence is highly suggestive of a mitogenic role for ACTH, however, it is 
likely to be a complex process involving the interplay between a number of factors 
and signalling pathways.  
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Whilst a proliferative role for ACTH has not been established in these studies, an 
alternative role is perhaps the requirement of Erk1/2 activation for steroidogenesis. 
The main controlling step in steroid production is thought to be the cAMP-
dependent expression of the steroidogenic acute regulatory (StAR) protein, a 
mitochondrial protein essential for cholesterol transport to the inner mitochondrial 
membrane where it is converted to pregnenolone by the cytochrome P450 side 
chain cleavage complex (Stocco, 2000). Steroidogenic factor 1 (SF-1) is an orphan 
member of the nuclear receptor family and has been shown to contribute to the 
regulation of steroid synthesis by activating a variety of genes involved in steroid 
biosythesis (Lala et al., 1992). One study demonstrated that cAMP induced steroid 
synthesis is dependent on the phosphorylation of Erk1/2 and that Erk1/2 activation 
resulted in enhanced phosphorylation of SF-1 and a concomitant increase in steroid 
production through increased transcription of the StAR gene (Gyles et al., 2001).  
 
Having established the presence of an Erk1/2 response to ACTH, our attention 
focused on the mechanisms by which this signal is activated. In general, 
investigating signalling mechanisms involving the MC2R has been hampered due to 
a lack of an effective antibody to it and the difficulty in expressing functional 
receptor in non adrenal cell lines. Despite this, using the endogenously expressed 
MC2R in H295R cells, we have been able to investigate some of the mechanisms by 
which ACTH induces an Erk1/2 response. It appears that cAMP signalling may 
provide a partial explanation for the increase in Erk1/2 activity probably through the 
activation of PKA, however this does not account for the entire response. Thus it 
seems likely that another less well-recognised Erk1/2 signalling pathway, possibly 
dependent on an internalisation complex, is involved. That MDC reduces the Erk1/2 
response significantly (and the cell surface expression of MC2R) but had no effect 
on serum induced Erk1/2 activation implies the requirement for internalisation of 
the MC2R. This, however, has not been confirmed by the expression of dominant 
negative dynamin I. Furthermore, use of GRK2 and ß-arrestin dominant negatives 
also showed a lack of involvement of GRK and ß-arrestin which often accompany 
such mechanisms of Erk1/2 activation. However, this may be consistent with recent 
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studies demonstrating arrestin-independent but clathrin-dependent mechanisms of 
GPCR internalisation (Wolfe and Trejo, 2007).   
 
Consistent with these atypical features of the internalisation of the MC2R is the 
recent study from our laboratory that the MC2R within the H295R cell interacts 
with nucleoporin 50, one of a family of nuclear transport proteins, and translocates 
to the nucleus with a time course similar to that of receptor internalisation 
(Doufexis et al., 2007). The study of intracellular trafficking of the MC2R may 
therefore present a future avenue of investigation to fully understand the signalling 
pathways elicited by this receptor.  
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